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Background: Inherited retinal diseases (IRDs) constitute a group of clinically and 
genetically heterogeneous conditions which cause degeneration of retinal 
photoreceptor cells and result in visual impairment. Characterisation of the genetic 
basis of IRD is not only beneficial for the affected families, but also contributes 
towards understanding of the disease pathobiology. Investigations into the 
molecular basis of IRDs have been ongoing in South Africa (SA) for over 30 years, 
however the evaluation of reported genetic mutations has yielded low returns in 
certain populations. Indigenous southern Africans comprise a unique population 
group with distinct genetic diversity, providing a valuable resource for genetic 
discoveries; nonetheless, this population remains largely underrepresented in 
genomic studies. The aim of this investigation was to characterise the underlying 
genetic mutations in a cohort of indigenous African IRD patients.   
Methods: The IRD registry in the Division of Human Genetics (University of Cape 
Town) was reviewed for causative mutations. Subsequently, upon identifying a 
mutation underlying Usher Syndrome in two indigenous African patients, an assay 
was designed to screen for this mutation in probands with different IRDs (n=170) 
and controls (n=51), and haplotype analysis was performed on mutation-positive 
individuals. The registry review additionally served to identify a suitable cohort for 
the application of next generation sequencing (NGS) technology. Whole exome 
sequencing (WES) was performed on genomic DNA samples from 56 individuals 
from 16 families. The WES data analysis strategy involved prioritisation of variants 
in reported and candidate IRD genes. Rare, co-segregating, pathogenic, exonic or 
splice variants were validated by Sanger sequencing. Custom TaqMan assays were 
designed to screen seven mutations, identified by WES, in 193 unrelated 
indigenous African probands with IRDs.   
Results: A homozygous founder mutation, c.6377delC in MYO7A, was identified in 
43% of the indigenous African patients with Usher syndrome, which is the most 
common cause of deaf-blindness. Targeted WES data analysis of all known IRD 
genes resulted in identification of the underlying genetic defects in six distinct genes 
(RHO, PRPF3, PRPF31, ABCA4, CERKL, and PDE6B) in six families. Taqman 
screening revealed four additional probands with identical homozygous mutations in 
CERKL and PDE6B. An X-linked gene (RP2) mutation was subsequently identified 
in an affected family with semi-dominant retinitis pigmentosa. Supplementary 
analysis of the X-linked RPGR ORF15 mutation hotspot (not adequately covered by 





found in one family by analysis of 22 putative candidate genes. The large number of 
variants in the remainder of the indigenous African exomes presented considerable 
challenges for identification of additional novel genes.  
Discussion: The results of this project have important implications for IRD 
molecular diagnostic services in SA. Using WES, a genetic diagnosis was obtained 
for ~73% of the indigenous African cohort, and ~70% of the causative mutations 
identified were novel. This outcome emphasises the superiority of NGS-based 
approaches over genotyping-based microarrays which screen for IRD mutations 
previously reported in other (mainly European-derived) populations. The 
unexpected identification of mutations in known X-linked genes in four families 
highlighted key considerations for IRD WES analysis. Cascade screening of 
mutations identified in this study, across larger cohorts of unrelated probands, 
revealed the genetic cause of IRD in additional cases and the number of indigenous 
African families in the registry with a genetic diagnosis was effectively doubled. 
Members of these families can now opt for diagnostic, carrier, or predictive testing 
of familial mutations. Finally, the information obtained from this research contributes 








This thesis is comprised of six chapters. Two original publications have been 
included with the permission of the Doctoral Degrees Board of the University of 
Cape Town (Appendix 1).  
Chapter 1 is a general introduction of the topic, and presents the rationale and aims 
of this research project. Chapters 2–5 each contain brief introductions, methods, 
results and discussions.   
Chapter 2 describes the review of the inherited retinal diseases registry at the 
Division of Human Genetics, which was performed to identify (a) common mutations 
for further investigation, and (b) a suitable cohort for whole exome sequencing.  
Chapter 3 is a publication describing a founder mutation identified in (a) above.  
The whole exome sequencing portion of the research project is covered in Chapters 
4 and 5. Chapter 4 focuses on the analysis of variants in known inherited retinal 
disease genes, and is divided into three sections: 4.1 is a publication of the primary 
analysis; 4.2 and 4.3 present the findings from re-analysis of known genes. In 
Chapter 5, the variants in the remainder of the exome were interrogated, initially by 
prioritising a specific list of candidate genes (section 5.1). The additional strategies 
employed to identify causative mutations in the cohort, including supplementary 
screening, are described in section 5.2.    
Chapter 6 provides a general overview of the research findings, which are examined 
and discussed in terms of their implications.  
The American Journal of Human Genetics convention has been used for the 
reference list of this thesis. Mutation nomenclature is in accordance with the latest 
guidelines (Version 15.11) from the Human Genome Variation Society. However, 
the manuscript in Chapter 3 was published prior to version 2.120831 of these 
guidelines, which incorporated parentheses into protein variant descriptions lacking 






Chapter 1. Introduction 
 
An estimated 161–259 million people worldwide suffer from visual impairment1. The 
causes of visual impairment are diverse; however, several heritable forms are 
known and make up a significant proportion of the disease burden. Inherited retinal 
diseases (IRDs), as a group, are one of the most clinically and genetically 
heterogeneous disorders, which complicates both patient diagnosis and molecular 
genetic research endeavours.  
Notwithstanding the challenges, determining the molecular genetic basis of the 
various forms of IRD has been the focus of numerous investigations around the 
globe, with the ultimate goal being the development of therapeutic interventions. 
Consequently, the molecular basis of several inherited forms of visual impairment 
have been elucidated.  
Whilst investigations into IRDs have been ongoing globally, including in South Africa 
(SA) for more than 30 years, the genetic basis of this group of disorders in 
indigenous Africans remains unclear. This is partly due to underrepresentation of 
this population group in the patient sample archive, and to earlier screening 
approaches being based on results obtained in the rest of the world, mainly in 
Europeans and North Americans. Characterisation of the molecular basis of disease 
in indigenous Africans, who comprise a unique population group with distinct 
genetic diversity, would therefore improve the understanding of these disorders and 
provide novel insights to this field of study. 
In this introductory chapter the retinal architecture which underlies vision, the visual 
transduction process, the complex genetic landscape of IRDs (globally and in the 
context of SA), the research approaches used, as well as the evolution of African 







1.1 The retina and vision 
The retina is an intricate, laminated tissue lining the inside of the eye, which is 
essential for vision. The retina is considered to be part of the central nervous 
system (it develops from the embryonic forebrain2), and houses a complex neural 
network comprising 50–60 cell types3 including six major neuron types: horizontal, 
bipolar, amacrine and ganglion cells, and rod and cone photoreceptor cells4. The 
function of the retina is to convert light energy (photons) into electrochemical signals 
that are conveyed via the optic nerve to the brain, resulting in the process of vision.  
Light passes through the eye into the layers of the retina and excites the sensory 
photoreceptor cells, which are situated in the innermost layer of the retinal 
architecture (Figure 1.1). The phototransduction signalling cascade is initiated in 
these photoreceptors when light induces bleaching of the photopigment, a complex 
containing a chromophore derived from Vitamin A (11-cis-retinal) covalently bound 
to the protein opsin5.  Photoexcitation results in isomerisation of 11-cis-retinal to all-
trans-retinal, which then dissociates from opsin and triggers a series of biochemical 
events, causing closure of ion channels and ultimately resulting in hyperpolarisation 
of the cell2,6. Photoreceptors release the neurotransmitter glutamate in the dark; 
however, hyperpolarisation in response to light prevents this release2. The 
glutamate signal is processed by the bipolar, horizontal, and amacrine cells, and 
transmitted to the brain via the ganglion cells, the axons of which form the optic 
nerve4,7.  
Photoreceptors occur as two subtypes, the rods and the cones (described by their 
shapes). Rods mediate black-and-white vision and vision in low light conditions, 
whilst cones mediate perception of colour and high-resolution central vision (visual 
acuity). Rods outnumber cones 20:1 in the human retina4. While rods are evenly 
spread throughout the retina towards its periphery, cones are concentrated in the 
macula, an oval-shaped area at the centre of the retina. Human rods have the 
photopigment rhodopsin, whilst each cone expresses one of three cone opsins; S-
opsin, M-opsin and L-opsin, which are blue-, green- and red- sensitive, 
respectively4.  The photoreceptors therefore allow visual perception in all light 
conditions and trichromatic colour vision. Photoreceptor cells have an outer 
segment (OS) densely packed with membranous discs containing opsin, an inner 
segment (IS) which contains cellular metabolic components, and a cell body 
containing the nucleus4,7 (Figure 1.1).  Each IS and OS is joined by a narrow 





   
 
Figure 1.1 An illustration showing the layers of the retina involved in vision. 
Rod (R) and cone (C) photoreceptor outer segments (OS) are close to the retinal pigment 
epithelium (RPE). Light travels through the retinal layers (from the bottom of the image) to 
the OS where visual transduction is initiated in the membranous discs.  Photoreceptor inner 
segments (IS) connect to the cell bodies and nuclei, which are located in the outer nuclear 
layer (ONL). Photoreceptor axons terminate in the outer plexiform layer (OPL), and synapse 
with the neurons in the inner nuclear layer (INL), namely the horizontal (H), bipolar (Bi), and 
amacrine (A) cells. The Muller (M) glial cells provide support and protection of the neurons. 
The neurotransmitter signal is relayed through the synapses of the inner plexiform layer 
(IPL) to the ganglion (G) cells in the ganglion cell layer (GC), the axons of which (Ax) form 
the optic nerve.  The RPE contains melanin pigment and is separated from the choroidal 
capillaries of the eye by Bruch’s membrane (BM). Image by Peter Hartmann at de.wikipedia, 
edited by Marc Gabriel Schmid. Creating SVG version by Юкатан - Own work, CC BY-SA 
3.0, https://commons.wikimedia.org/w/index.php?curid=27237061 
 
Photoreceptors are supported and maintained in four important ways by the retinal 
pigment epithelium (RPE), a monolayer of cells containing melanin pigment 





photoreceptors with nutrients and oxygen8. Secondly, for the retina to remain 
receptive to light, the 11-cis-retinal that is isomerised as the first step of visual 
transduction (as described above), must constantly be regenerated and recycled. 
The recycling of these Vitamin A derivatives occurs through a series of reactions in 
the photoreceptors and the RPE, called the “visual cycle” or the “retinoid cycle”9. All-
trans-retinal is reduced to all-trans-retinol, which diffuses from the photoreceptors 
into the adjacent RPE. Esterification of the retinol with fatty acids occurs and (inside 
the RPE) the all-trans-retinal esters are converted, firstly into 11-cis-retinol and then 
11-cis-retinal. The 11-cis-retinal diffuses back to the photoreceptor OS, and binds to 
opsin, regenerating the photopigment9. Thirdly, the RPE allows renewal of the OS 
content, since photoreceptors are terminally differentiated post-mitotic cells and 
cannot divide or regenerate. The OS tips are shed and phagocytosed by the RPE in 
a circadian manner (whereas rod shedding peaks in the morning, cone shedding 
peaks at night). Approximately 10% of the rod membranous discs are replaced in 
this manner, daily9. Finally, the melanin granules of the RPE absorb stray photons 
of light, preventing blurred vision and light damage to the retina2.   
The RPE, photoreceptors and other neurons of the retina function interdependently, 
in a delicately balanced homeostasis with high metabolic demand. Meta-analysis of 
retinal datasets10 has yielded at least ~15,500 retinal and RPE genes (referred to as 
the ‘15K retinome’), of which ~13,000 have been confirmed in more than one study 
(i.e. the ‘13K retinome’). Whilst substantial overlap exists in gene expression 
between retina and other tissues, at least 5,000 genes were reportedly retina-
specific10.  Retinal tissue has been shown to have elevated splicing activity, 
expressing ~7-fold more major small nuclear RNAs (snRNA) and ~2-fold more 
minor snRNA, compared with other tissues (brain, heart, testis and skeletal 
muscle)11. The retina produced the greatest amount of constitutive, 
spliced/processed messenger RNA (mRNA) when 2,255 housekeeping gene 
transcripts were quantified across 31 human tissues11. RNA sequencing from three 
human retinas has revealed unprecedented transcript diversity12, detecting over 
80% of all exons in the human reference transcriptome, corresponding to 160,000 
unique transcripts. This study implies that novel splicing events are enriched in the 
retina, with almost 80,000 novel splicing events identified (including novel exons, 
alternative splice sites and exon skipping events), resulting in novel exons in genes 
known to cause retinal diseases, as well as 116 putative novel genes. Additional 
RNA sequencing from temporal, macular and nasal regions of the retina has shown 





retina and macula regions13. This is perhaps to be expected given the distribution of 
different cells, namely the rod and cone photoreceptors, across the retina, as 
previously described. More recently (in the past year), expression analysis of a 
larger dataset of 50 human retinal samples has allowed a more precise estimation 
of the retinal transcriptome14. Pinelli et al confirmed 65% of known protein coding 
genes are expressed in the retina, and detected transcripts from ~13,000 to 
~24,000 genes14. Notably, mitochondrial genes are amongst the most highly 
expressed genes in the retina12,14.   
The retina is thus a sophisticated, metabolically active tissue displaying cellular 
diversity and vast gene expression diversity, and as such is particularly susceptible 
to dysfunction.  
 
1.2 Inherited retinal diseases 
IRDs comprise of a large number of conditions causing progressive degeneration of 
the light-sensitive photoreceptor cells of the retina, which in turn leads to visual 
impairment (and can result in total blindness). IRDs are one of the most clinically 
and genetically heterogeneous groups of human disease.  
IRD phenotypes can be broadly categorised on the basis of the primary 
photoreceptor type affected. Patients with primary rod cell loss experience 
nightblindness and reduction of the visual fields i.e. the loss of peripheral vision, 
resulting in tunnel-like vision15–17. These diseases can be congenital or have a later 
onset, and are either stationary (e.g. Congenital stationary night blindness, CSNB), 
or progressive (e.g. Leber congenital amaurosis, LCA, or retinitis pigmentosa, RP). 
Conversely, patients with ‘macular dystrophy’ (MD), or a primary loss of cone cells, 
experience loss of their central vision which can occur at an early age (e.g. the 
juvenile-onset Stargardt macular dystrophy, STGD) or later (e.g. age-related 
macular degeneration, ARMD)15–17. Initial loss of one photoreceptor subtype may or 
may not lead to secondary loss of the other subtype, worsening the individual’s 
prognosis. On the other hand, reduced penetrance can occur resulting in intra-
familial disease variability16,18–20. Furthermore, whilst many IRDs are non-syndromic 
and limited to the loss of vision, they can also occur as part of a syndrome with 
multi-systemic dysfunction15–17,21. The phenotypic overlap between IRDs can 
impede a clinical diagnosis, and providing a patient prognosis can often be 





diagnosis can change, which can be frustrating and confusing for patients. A 
definitive molecular genetic diagnosis therefore can verify and clarify a clinical 
diagnosis22.   
IRDs can be inherited in an autosomal dominant (ad), autosomal recessive (ar) or 
X-linked (xl) manner, although sporadic or isolated cases are common15–17. Rarer, 
atypical inheritance patterns include mitochondrial, digenic, tri-allelic and uniparental 
disomy cases16,17. Although most IRDs are monogenic, more than 200 different 
genes have been identified23 (RetNet, https://sph.uth.edu/retnet/) and a significant 
overlap exists between the genes causing different IRDs (i.e. mutations in a single 
gene can result in different phenotypes)15. IRDs therefore demonstrate: (i) locus 
heterogeneity (a single phenotype, e.g. RP, can be caused by mutations in genes at 
different chromosomal loci, including dominant, recessive or X-linked loci), (ii) allelic 
heterogeneity (many different mutations can occur in each gene), (iii) genetic 
heterogeneity (the combination of locus and allelic heterogeneity), and (iv) clinical 
heterogeneity (a single gene or even a single mutation can result in different 
phenotypes in different individuals). A substantial amount of missing heritability 
further complicates the genetic diagnosis of IRDs. It is estimated that only 50–70% 
of cases (depending on geographical regions or populations) can be attributed to 
known genes24, indicating that a considerable number of genes remain to be 
identified.  
Identification of the specific mutation(s) causing an IRD affords several benefits to 
the patient. As described previously, due to the overlapping phenotypes of these 
diseases, a clear clinical (ophthalmological) diagnosis/prognosis may not always be 
possible. A genetic diagnosis on the other hand is of utility value and unequivocal, 
as diagnostic, predictive and carrier testing can be offered to family members. A 
genetic diagnosis, supporting a clinical one, may also influence the management of 
the disease/patient. Finally, improved molecular diagnosis in patients is important, 
given the number of clinical trials and treatments currently under investigation25 for 
this group of disorders (http://www.clinicaltrials.gov/). 
The degree of clinical and genetic heterogeneity of IRDs complicates not only the 
molecular diagnosis of patients, but also investigations of the pathogenic 
mechanisms of these disorders. For this reason, it is proposed that a candidate-free 
approach is required in order to better understand IRDs and characterise genes that 
are not yet identified. This is supported by the fact that, whilst many IRD genes are 
involved in phototransduction, the visual cycle, retinal metabolism or maintenance of 





function) at their time of discovery, instead encoding transcription factors4 or 
ubiquitously expressed components of the spliceosome11.  
 
1.3 Next generation sequencing approaches in 
retinal research 
Next generation sequencing (NGS) technologies are tools which allow the high-
throughput capture of vast amounts of sequence data to study the genome, 
transcriptome and epigenome27. NGS-based genome analysis is highly applicable in 
scientific investigations into heterogeneous Mendelian diseases such as IRDs28, as 
most (if not all) genes can be interrogated simultaneously. This hypothesis-free 
approach provides exceptional opportunity for gene discovery and identification of 
IRD mutations. 
To this end, genomic NGS approaches have been employed increasingly in IRD 
research since 2010, with many of the earlier studies using ‘targeted capture’ 
methodologies to investigate panels of reported IRD genes. For example, ultra-high 
throughput sequencing of a single gene has been performed to characterise the 
mutation spectrum and allelic heterogeneity when: (a) a single gene is thought to be 
responsible for the majority of cases of a certain disorder29; or, (b) a newly-identified 
gene is investigated to determine mutation allele frequencies and contribution to the 
disease burden30. Moreover, extensive NGS strategies have allowed molecular 
diagnosis through the screening of panels of relevant genes. This approach has 
involved, in increasing order of scale, the targeted enrichment and subsequent 
sequencing of either, (a) exons of the genes known to cause a specific form of IRD 
e.g. RP31–33 or LCA34 or, (b) exons of many identified IRD genes in panel-based 
tests23,35–43.   
Subsequently, the improved capacity of whole exome sequencing (WES), with the 
strategic analysis of known IRD genes has become more commonplace. With WES, 
the entire coding portion of the genome is sequenced, together with predetermined 
desirable 5’ and/or 3’ ends of genes, and introns. The targeted analysis of IRD 
genes in WES data resulted in detection of causative mutations in as much as 83% 
of European families interrogated44, with 50% of identified mutations being novel. 
Other population groups investigated in a comparable manner include Saudi 
Arabian45, Chinese46, Thai47, and Israeli48,49 with detection rates ranging from 49% to 





recently been suggested that panel-based diagnostic testing in IRDs is more 
effective than WES, due to better gene coverage50 and cost considerations51, the 
benefit of WES is that unresolved families can be re-analysed as novel IRD genes 
are reported, without re-designing gene panels and performing additional tests52. 
Moreover, WES has re-enforced the vast genetic (allelic) and clinical heterogeneity 
observed, as mutations in a gene previously thought to cause one specific IRD, are 
now reported for some cases of an entirely different IRD53–55, thereby expanding the 
phenotypic spectrum associated with certain genes56–58 and occasionally prompting  
clinical re-evaluation59,60.   
In addition to diagnostic applications, WES has facilitated huge strides in IRD 
research (unlike the initial targeted capture NGS panels), as a priori knowledge is 
not necessary to detect novel causative mutations. The approach has thus led to 
numerous gene discoveries and the elucidation of the roles these genes play in 
retinal functioning. More than 60 IRD genes have been identified via WES27. Many 
of these genes are involved in intraflagellar transport across photoreceptor cilia61 or 
have assorted ciliary functions62–68;  however, additional roles include photoreceptor 
differentiation and maintenance69,70, fatty-acid transport in the retina71, chaperone 
activity72, ubiquitination73, and protein glycosylation in neural development58.  
As anticipated, these large-scale NGS approaches generate “big data”, and the 
greatest challenge encountered with WES is therefore data analysis. The vast 
numbers of gene sequence variants obtained are thus interrogated via a series of 
prioritisation filters in order to distinguish pathogenic mutations from benign 
sequence alterations. The challenge of “big data” analysis is anticipated to be 
intensified when generated from older populations such as from Africa. 
Indigenous Africans are generally underrepresented in genomic studies, and those 
with IRDs have not been interrogated using NGS platforms. However, WES of RP 
families in the United States of America (USA) has yielded a greater number of 
novel variants (both single nucleotide variants and small indels) in families of African 
ancestry compared with families of European ancestry74.  In this study, the number 
of variants novel to the National Centre for Biotechnology Information (NCBI) Short 
Genetic Variations database (dbSNP) was reportedly >6-fold larger in a family of 
African American descent (n >2,500) than in Caucasian USA families (n ~400). 
Given that genome wide ancestry estimates show an average proportion of only 
~73% African ancestry in African Americans75 (who show substantial ancestry from 
west Africa76) , the exomes of indigenous Africans are expected to yield even more 





expected per individual, from which the causative pathogenic mutation must be 
identified. This is confounded by the fact that, on average, each individual carries 10 
to 20 heterozygous recessive alleles for Mendelian disorders, and that the carrier 
frequency for recessive IRD mutations may be as high as 1 in 224, indicating that 
many heterozygous mutations identified by NGS may occur by chance and not be 
relevant to the disease observed. Indeed, novel candidate genes have been 
proposed77 but later suggested to be false positives, prompting the recommendation 
of variant frequency thresholds in WES analysis for IRDs78.  
 
1.4 Inherited retinal diseases in South Africa  
The reported prevalence of IRDs is approximately 1 in 3,50024 in populations where 
some level of epidemiologic data is available. No data exists on the prevalence of 
this group of conditions anywhere in Africa. Nonetheless, using Statistics South 
Africa's 2011 population census i.e. ~51 million people in SA 
(http://www.statssa.gov.za/), one may extrapolate that  approximately 14,500 
individuals might be suffering from IRD-related visual impairment/blindness in SA, of 
which (taking population demographics into account) ~11,600 are estimated in the 
indigenous African population.  
Research into IRDs in SA was initiated in 1985, when a questionnaire-based survey 
was utilised to determine the scope of RP in the country79. This was a joint 
endeavour between the Division of Human Genetics at the University of Cape Town 
(UCT) and the patient support group (then called the ‘Retinitis Pigmentosa 
Foundation of South Africa’), and was prompted by the patients. It led to the 
identification of 63 families in SA containing 130 affected individuals of which ~36% 
were syndromic, whilst ~14%, 10% and 6% exhibited autosomal dominant (adRP), 
autosomal recessive (arRP) and X-linked (xlRP) inheritance patterns respectively. A 
large proportion (~27%) of cases were isolated, and the remaining ~8% had 
indeterminate inheritance patterns. It was determined that local families could 
benefit from the advances in genetic screening at the time, and that molecular 
diagnostic and carrier testing may be of some utility. The biological samples 
collected from these patients and their family members were thus stored in a 
biorepository with an associated electronic database or registry, generated in 1990–
199180. Within ten years, the registry had expanded to include other IRDs in addition 
to RP, namely MD (including STGD), LCA81 and syndromic forms of IRD, for 





After the first ten years of study, an underrepresentation of IRD patients from 
indigenous African ethnolinguistic groups82 (n=182) was noted and thought to be 
mainly due to a lack of access to resources (particularly in rural areas). Recruitment 
efforts in the last decade have therefore aimed to address the historical 
ascertainment bias so that the registry eventually reflects the population 
demographics of SA, however, this remains challenging. Patients from throughout 
SA are referred to the Division of Human Genetics via the support group, currently 
known as Retina South Africa, which also provides funding for research. Referrals 
are received from ophthalmologists and genetic counsellors, however these are in 
the minority despite attempts to raise awareness amongst professionals about the 
benefits of genetic testing for IRDs.    
The ultimate goal of the research in SA has been to identify the causative genetic 
mutation in each of the families registered in the UCT IRD registry, hence the 
research programme has a strong translational and service component83–88. 
Traditionally, mutation analysis of candidate genes in South African patients with 
IRDs was performed, whereby patients were selected from the registry according to 
their clinical diagnosis, and an appropriate candidate gene was selected for 
screening based on international reports of mutation frequencies. This approach 
was arduous and time consuming, and the majority of South African patients 
remained lacking a clear molecular diagnosis until technologies advanced89. With 
the advent of microarray technology, commercially available mutation microarrays 
from Asper Ophthalmics in Tartu, Estonia (http://www.asperbio.com/asper-
ophthalmics) have been employed since 2006. Currently, as part of the translational 
research programme, participants can opt for self-funded genetic screening with 
these microarrays which make use of arrayed primer extension (APEX90) 
technology to test specifically for previously reported mutations in candidate genes 
associated with specific IRDs91–93. The specific array used to screen each sample is 
selected based on the pedigree data and clinical diagnosis of that individual. 
Additionally, since November 2012, a limited number of samples have been 
subjected to NGS of a panel of 105 retinal candidate genes, by the Manchester 
Centre for Genomic Medicine, Central Manchester University Hospitals NHS 
Foundation Trust, in Manchester, in the United Kingdom (UK)36,39. It should be 
highlighted that both of the technologies, i.e. the microarray mutation panels and the 
NGS candidate IRD gene panels, are based on genetic findings from patients 





Previous research has shown that the most prevalent genetic defects causing IRDs 
in the USA, the UK and Europe, are present in the South African patient cohort at 
an almost insignificant incidence, possibly indicating a novel gene pool for this 
group of disorders locally94–97. This is the case even in the Europe- and UK- derived 
Caucasian immigrant populations screened thus far in SA; identification of two novel 
loci for dominant IRDs98–100, and the subsequent identification of the previously 
uncharacterised IRD-causing genes PRPF8101 and CA4102, in the South African 
Caucasian population, supported this notion. Furthermore, investigation of the 
indigenous African sub-cohort for the most common genes and mutations produced 
remarkably low returns103.  The use of the microarrays emphasised that the 
mutation spectrum for IRDs in South Africans is dissimilar to that elsewhere, with 
many samples having either no mutations or partial mutation complements identified 
(unpublished data). This implied that South African patients either harbour novel 
mutations in previously identified genes, which are not being tested for with the 
arrays, or that their causative genes are novel. This concept is strengthened by the 
fact that indigenous Africans in SA exhibit vast genomic diversity104,105.  
 
1.5 Indigenous southern African genomes 
Being the most ancient of all populations, Africans display vast genetic 
diversity104,105 as a result of historical migration, population admixture, response to 
environmental change, and/or exposure to a plethora of infectious agents106,107. The 
‘Great Expansion’ of humans out of Africa 45,000–60,000 years ago was 
accompanied by a loss of genetic diversity with linear correlation to the geographic 
distance from the origin in Africa108.  
The majority of sub-Saharan Africans speak ‘‘Bantu’’ languages, which are 
generally accepted to have originated from a core region in the north west of the 
African continent, specifically southern Nigeria and north-western Cameroon109. The 
term ‘‘Bantu expansion’’ refers to the movement of people approximately 5,600 
years ago, across (west to east) and down (north to south) the continent. Evidence 
suggests migration accelerated around 2,000 years ago in south-central Africa 
(Malawi, Mozambique, Zambia and Zimbabwe), however a static frontier occurred 
upon arrival in SA110 approximately 1,500 years ago109. The slower migration 
allowed interactions with (admixture with- and assimilation of-) the Khoisan hunter-
gatherers already present in the region110 who themselves are amongst the most 





hunter-gatherers migrated into the Bantu communities at a greater rate than their 
male counterparts110. Eventually, southern African Bantu-speakers have diverged 
further into separate cultural and ethnolinguistic groups such as Sotho-Tswana, 
Xhosa and Zulu110.  
Today, there are two main Bantu-speaking groups in southern Africa, the 
Southwestern (subgroups R and K) and Southeastern (subgroup S) linguistic 
groups109.  The R and K subgroups occupied the areas north of Namibia, whilst the 
S subgroup generally occupied the eastern part of present-day SA, Zimbabwe and 
Botswana, and are therefore most relevant to this study. The S subgroup of 
languages comprises the following ethnolinguistic groups: Sotho-Tswana, Venda 
and Nguni (which includes Xhosa and Zulu)105. Several languages in SA include the 
click sounds of Khoisan origin, which are absent in Bantu languages spoken nearby 
in Botswana, Mozambique and Zimbabwe110. Furthermore, the click sounds are 
restricted to certain ethnolinguistic groups within SA, namely Nguni and south-
Sotho, indicating differing strengths of interactions between certain Bantu speakers 
and hunter-gatherers.   
Two populations, the Luhya from east Africa (Kenya) and Yoruba from west Africa 
(Nigeria), were until recently the major African populations represented in the 1000 
Genomes project112. It has been shown that the Luhya and Yoruba population 
groups are genetically diverse from the Bantu-speaking South Africans105 and that 
the vast genetic diversity of African populations generally prevents them being used 
as proxies for one another in genetic studies113. This underscores the importance of 
the Southern African Human Genome Programme114 and the African Genome 
Variation Project (AGVP)115. Nonetheless, a recent study on the genomic structure 
of indigenous southern African populations shows that the divergence of the Sotho-
Tswana, Zulu, and Xhosa populations was relatively recent116, suggesting that these 
people may be grouped together within genomic studies, to a greater extent than 
with other African populations.  
Black South African individuals (referred to collectively hereafter as ‘indigenous 
Africans’), represent a derivation of the original Bantu expansion, and are the focus 
of this study as they provide a valuable resource to study genetic contributions to 







Placing the focus on indigenous Africans with IRDs was a novel approach in the 
study of this group of diseases. The description of IRD mutations in this population 
had the potential to identify ancient founder lineages, allow the development of 
novel diagnostic strategies, and impact on the clinical management of individuals 
suffering from previously unattributed IRDs.  
Ultimately, the identification of novel IRD-associated genes, and the examination of 
the roles these genes play in IRDs, may render a better understanding of this group 
of diseases, potentially leading to novel approaches to disease intervention.  
 
1.7 Aims and objectives 
The aims of this project were to: (1) determine the genetic causes of IRDs in a 
cohort of indigenous Africans in SA, (2) translate these findings into diagnostic 
assays for the families concerned, and (3) contribute to the understanding of the 
biology of this group of conditions.  
In order to achieve these aims, the objectives included: 
i) Reviewing the UCT registry for previous screening results of indigenous 
Africans with IRDs in order to identify: a) potential causative mutations 
that had not previously been investigated, and b) an appropriate 
discovery cohort for WES 
ii) Performing WES on indigenous African samples lacking reported 
mutations in genes known to be associated with their specific form of 
IRD, in order to identify the causative mutations. 
iii) Investigating mutations identified either through prior screening or WES, 
which may account for large proportions of certain sub-cohorts (defined 
by clinical phenotype). These investigations included in silico 
pathogenicity investigations, assay design, family co-segregation 
analysis, screening in appropriate controls, haplotype analysis to 
ascertain an ancient founder lineage, and genotype-phenotype 
correlations. This information would determine whether specific assays 
should be developed as local diagnostic tools, for mutations having clear 





iv) Researching putative novel genes, should they be identified, including: 
characterisation of the function of the gene(s), investigation of the 
biological pathway linking the gene to the IRD observed, and description 
of the associated phenotype (genotype/phenotype correlation).  
  
Any diagnostic results achieved through this research were confirmed according to 
an established protocol, and translated to patients and clinicians through meaningful 
reports via professional genetic counsellors.  
 
1.8 Ethics approval 
Informed consent was obtained for all participants in this project, according to the 
Declaration of Helsinki (2008). Ethics approval for these genetic studies as well as 
the patient registry has been granted by the UCT Faculty of Health Sciences Human 
Research Ethics Committee (HREC REF. 226/2010, 768/2013 and 312/2014). The 
approval encompassed the Molecular Request Forms, Informed Consent forms and 






Chapter 2. Review of the registry: 
elucidating IRD trends in indigenous 
populations 
 
At the start of this research project, the baseline status of genetic findings in the 
indigenous Africans with IRDs was established. This was achieved by reviewing the 
Division of Human Genetics IRD registry with regard to prior screening that had 
been performed in these individuals, and the results thereof. A list of mutations 
previously identified in this population group, that had not been fully investigated but 
which may represent common causes of disease, was compiled. The registry review 
also served to identify a cohort for WES, enriched for novel discovery.  
 
2.1 Infrastructure of the registry 
The biorepository and the associated electronic database or registry80 archives 
biological samples collected from IRD patients and their family members from 
throughout SA over the past 30 years.  
Biological specimens (venous blood or saliva, and/or genomic DNA) are 
accompanied by Molecular Request Forms including informed consent 
documentation (Appendix 2). The forms contain data such as date of birth, gender, 
ethnic origin/s, family history of disease, diagnosis and contact information. Ideally 
Confirmation of Diagnosis (COD) forms (Appendix 2) are completed by an 
ophthalmologist to provide detailed clinical information, and pedigrees are provided 
by skilled individuals, e.g. genetic counsellors or trained individuals from patient 
support group, Retina South Africa. Samples are de-identified using a unique code 
generated by the electronic database. The code is assigned as follows: the IRD 
abbreviation (listed below), space, family number (1 being the family number for the 
first proband recruited), period/full stop, individual number (assigned sequentially as 
new family members participate; 1 being the proband), and the first three letters of 
the person’s first name. An example would be RPL 171.3LOU: IRD type LCA; 171st 
family recruited; 3rd person in this family; LOU from the person’s first name. All 





but unique individual numbers and letters. Multiple biological sample aliquots from 
the same individual are coded alphabetically.  
The IRD abbreviations assigned in the database are as follows (these are the 
product of coding for this group of disorders starting more than 30 years ago, and 
might be different if initiated today): 
• RP (isolated or indeterminate inheritance): RP 
• adRP: RPD 
• arRP: RPR 
• xlRP: RPX 
• USH: RPU 
• Other syndromic IRD, e.g. Bardet Biedl syndrome: RPO 
• LCA: RPL 
• MD, e.g. Sorsby fundus dystrophy, Best vitelliform macular dystrophy 
(VMD): RPM 
• STGD: RPS 
• ARMD (recruited post 2013, with a specific COD form): RPA 
 
A map generated from the database (Figure 2.1) shows the widespread distribution 
across SA, of families with IRDs participating in the UCT research project.  
The database is comprised of several linked Microsoft Access tables (Appendix 3) 
connected to each other by different reference numbers (i.e. the record number, 
family code and individual code). Cross-tab queries can be designed to extract 
relevant information across multiple tables. The data can then be exported and 
sorted manually in Microsoft Excel spreadsheets. All available data are captured on 
the registry in relevant coded fields, including clinical information, genetic screening 
history, if mutations have been identified, and whether genetic counselling and 
delivery of molecular results has occurred. Hardcopy documents, including (genetic) 
pedigrees, are stored in patient files.  
When the causative mutation(s) are identified in a family, and validated according to 
a specific protocol86, the family mode field in the registry is set as “diagnostic”. If 
suspected causative mutations have been identified, but this has not been 
confirmed, the family mode is “potential diagnostic”. Prior to this, all families are in 







Figure 2.1 A map of South Africa illustrating the scope of individuals 
participating in the IRD research programme at UCT in 2017. Different IRDs are 
highlighted in different colours, as indicated on the bottom of the map. The autosomal 
dominant, autosomal recessive and X-linked labels refer to cases of retinitis pigmentosa. 
Credit: Sr. G. Benefeld, Division of Human Genetics, University of Cape Town. 
 
An important registry field, in the context of this project, was whether samples had 
been sent overseas for testing by a specialist or commercial laboratory. Both 
overseas testing options offered in the translational research programme86,87, 
namely participant-funded genetic screening using APEX90 microarrays91–93 or 
targeted capture NGS of retinal candidate genes36,39, allow for  rapid, more 
comprehensive tests than can be offered locally, as traditional screening of 
candidate genes is expensive, lengthy and arduous. The overseas testing field 
provided valuable information, both in cases where mutations are attributed (for 
translation into a diagnostic service and identification of founder mutations for future 
targeted screening) and where mutations were not identified (for highlighting those 






2.2 Analysis of potential common causative 
mutations in indigenous Africans 
 
2.2.1 Methods 
A cross-tab query was run to extract the following fields on the database (accessed 
10 July 2014): family code, surname, ethnic group, family gene and mutation 
information, overseas testing history and family mode of analysis. This information 
was exported into the Microsoft Excel software program and filtered, in order to: 
A) identify the indigenous African families with potential causative mutations 
(regardless of methodology used to identify the mutations) 
B) analyse these causative mutations in the indigenous African families, with 
respect to frequency, predicted pathogenicity and whether they had 
previously been screened in significant numbers of relevant cases. 
C) retrospectively evaluate the success rate of the Asper microarrays. For this, 
the filtering focused on all probands (regardless of ethnic group) screened 
using this particular methodology. All microarray testing performed from 
September 2005 to June 2014 was assessed to obtain: 
i) the number of families screened (counted as unrelated probands) using 
each of the different Asper panels (e.g. the adRP microarray, arRP 
microarray, etc.), and 
ii) the number of families subsequently diagnosed, using each microarray 
panel.  Probands were considered diagnosed if the families were listed 
as being in ‘diagnostic’ or ‘potential diagnostic’ mode. 
 
2.2.2 Results 
This interrogation of the IRD database revealed that 33 distinct variants, in 16 







Table 2.1 List of the gene variants identified in indigenous African families by 
prior screening. These variants were considered for further investigation of potential 
founder effects. Distinct variants are in bold font when listed for the first time. 














p.(Val643Met) identified in two 
families. p.(Leu1201Arg)  identified 




p.(Val931Met) &  
c.3899G>A; 
p.(Arg1300Gln)  
p.(Val931Met) identified in a single 
family. p.(Arg1300Gln) variant of 
unknown pathogenicity identified in 




p.(Gly991Arg) &  
c.3899G>A; 
p.(Arg1300Gln)  
p.(Gly991Arg) mutation is identified 
in a single family. p.(Arg1300Gln) is 
a variant of unknown pathogenicity 







p.(Leu1201Arg) mutation identified 
in seven families. p.(Val849Ala) is a 
variant of unknown pathogenicity, 







p.(Gln1513Profs*42) identified in a 
single family. p.(Arg2107His) 







p.(Ser206Arg) identified in three 










p.(Ser206Arg) is identified in three 
families. p.(Arg1300Gln) is 
homozygous in RPD493, and 
heterozygous in RPM1171 
(identified in four families in total, but 




























p.(Val643Met) mutation identified in 







Table 2.1 (continued) 






Both are variants of  unclear 















Homozygous mutation identified in 











p.(Thr1209Ala)   
Homozygous variant of unclear 












p.(Pro836Thr).  Other 
change unknown. 
Partial result. Heterozygous 







Variant of unknown pathogenicity 
identified in two families 
RP 
1333 
EYS c.3443+1G>T. Other 
change unknown. 













NR2E3 c.1095C>T; p.(Pro365=) 
(Splice?)  
Homozygous variant of unclear 












Homozygous mutation in RPU80 
and heterozygous in RPU868 (other 










Mutation identified in a single family. 
RPD 45 RHO c.1040C>T; 
p.(Pro347Leu)  
Mutation identified in a single family. 
RP 
1251 













Table 2.1 (continued) 
Family Gene Variant cDNA; Protein Comment 
RPD 41 TOPORS c.2556_2557delGA; 
p.(Glu852Aspfs*20) 








p.(Trp4149Arg)   











Homozygous Mutation identified in 




p.(Pro1978Ser).  Other 
change unknown. 
Partial result. Mutation identified in a 
single family 
 
Variants were not considered high priority for screening in additional probands, if the 
pathogenicity was unclear, or if they were identified in a single family. Furthermore, 
certain variants had already been screened in a large proportion of the relevant 
indigenous African sub-cohort, therefore further screening was not warranted. For 
example, to date ABCA4 is the only gene known to cause ar STGD (RetNet 
https://sph.uth.edu/retnet/, accessed 27 January 2016), and 40 indigenous African 
probands had already been screened using the ABCA4 array, including 16 of the 21 
patients clinically diagnosed with STGD. The ABCA4 mutations occurring in multiple 
families, namely p.(Val643Met) (n=2), p.(Leu1201Arg) (n=7), p.(Arg2107His) (n=3) 
and p.(Ser206Arg) (n=3), would thus have already been screened for in the majority 
(~76%) of indigenous Africans with STGD, via the process of array testing. 
Similarly, all samples from the IRD registry with a suspected diagnosis of Bardet 
Biedl syndrome (BBS, an ar syndrome with RP or rod-cone retinal dystrophy and 
other associated features such as obesity, polydactyly and/or developmental delay) 
are referred to the National Health Laboratory Service (NHLS) at Groote Schuur 
Hospital in Cape Town for diagnostic testing of the BBS10 founder 
p.(Lys243Ilefs*15) mutation, which is common in indigenous Africans with this 
clinical diagnosis118.   
Three mutations were identified in genes known to be associated with USH in 
multiple families, namely p.(Arg1502*) in CDH23, p.(Thr1867del) in PCDH15 and 
p.(Pro2126Leufs*5) in MYO7A. The CDH23 and PCDH15 mutations were included 
on the USH array since its initial use in the translational programme in 2010, and 





those mutations using the USH array. However, the MYO7A mutation was only 
added to the USH array in 2013, and all but two of the 17 samples had already been 
tested using the array by that time. The MYO7A mutation was identified in family 
RPU 1338 using the array, and in family RPU 564 using targeted capture NGS, in 
2013. A sample from family RPU 564 had been tested with the array in 2010, 
however the mutation was not detected as it was not included in the panel at that 
stage. The p.(Pro2126Leufs*5) mutation in MYO7A was thus determined to be the 
only variant warranting further investigation as a high priority (Chapter 3).  
The efficacy of microarray technology in identifying causative IRD mutations was 
evaluated and compared between different ethnic populations (Table 2.2). Samples 
from Caucasians outnumbered those from any other ethnic group, and different 
arrays were used a range of times (and with different success rates) in the various 
population groups, therefore no conclusions can be drawn from these data. 
However, by simply comparing the Caucasian vs. the indigenous African samples 
as a whole, 115 of 280 Caucasian patients (41.1%) were diagnosed through the use 
of microarray technology, compared to 14 of 109 Indigenous African patients (i.e. 
12.8%).  
 
Table 2.2 The success rate of various Asper microarrays in the diagnosis of 
IRD patients from different population groups. The percentage of probands 
diagnosed using the microarrays are presented, together with the total number of families 
(i.e. unrelated probands) tested.  
Array Caucasian  Indigenous 
African  
Mixed 
ancestry   










































Best VMD 66% 
(n=5) 

















2.3 Selection of a discovery cohort for whole 
exome sequencing  
 
2.3.1 Methods 
A cross-tab query of the database (accessed 4 June 2014) was run to extract the 
individual code, ethnic group, diagnosis code (i.e. affected, at risk, carrier, parent, 
spouse, unaffected or query), family code, family mutation, overseas testing history, 
and family mode of analysis. The data was exported into the Microsoft Excel 
software program. Duplicate family numbers were removed, so that a single 
individual was included per family. Individuals were then stratified based on ethnic 
group (Caucasian, Indigenous African, Indian, Mixed Ancestry and Other), and 
subsequent systematic selections were performed exclusively on the indigenous 
African sub-cohort. 
Only samples with comprehensive prior screening and no mutation identified were 
considered for WES, in order to increase the likelihood of novel findings. 
Comprehensive screening was considered to be either: i) microarray analysis, or ii) 
targeted capture NGS. The indigenous African cohort was therefore examined 
regarding the type of screening performed and the current analysis mode (i.e. 
‘research’, ‘potential diagnostic’ or ‘diagnostic’). Only families in research mode 
were selected. Those families were then examined (using the database and paper-
based patient records) to determine: 1) how many individuals per family had 
submitted biological material for analysis, 2) the location of these individuals in the 
structure of the family pedigree, and (3) any supporting clinical information. 
DNA samples from all family members were retrieved from the biorepository, and 
sample integrity was confirmed by agarose gel electrophoresis. DNA was visualised 
using 1–2% weight/volume (w/v) agarose gels containing 0.5–1g agarose 
(SeaKem® LE, Lonza, Switzerland), 50mL of 1X Tris Borate EDTA (TBE) buffer and 
5µL SYBR® Safe DNA Gel Stain (ThermoFisher Scientific, MA, USA). A 
GeneRuler™ 100bp DNA Ladder Plus (ThermoFisher Scientific, MA, USA) was 
included on each gel for comparison purposes.  
DNA extractions were performed on additional archived blood samples if necessary, 
using a salting-out method119. Intact DNA was quantified using the Nanodrop ND-





Families were only included in the discovery cohort for WES if sufficient DNA was 
available for at least three family members. It was anticipated that a large number of 
sequence variants would be identified through WES; hence, careful selection of the 
individuals designated for WES within each family would improve the data analysis 
and elimination of benign variants. Variants co-segregating with disease in a family 
could be prioritised for validation, therefore, where possible, the most distantly-
related individuals (who would share fewer variants) within each family were 
selected, in order to facilitate the prioritisation of candidate variants. A minimum of 
three samples per family were thus selected for WES, and remaining samples from 




At the time this research project was initiated, a total of 3,215 individuals in 1,416 
families had agreed to participate in the IRD research programme. The cohort for 
WES was selected following the stratification of 271 indigenous (Black) South 
African families who had biological material as well as demographic and clinical 
data stored in the registry (Figure 2.2). Four probands were excluded from the 
cohort as their visual problems were not due to a definitive IRD, but possibly due to 
another cause, for example physical damage or infection. Of the 267 probands 
remaining, 226 (85%) were still in research mode, 28 (10%) were in diagnostic 
mode and 13 (5%) were in potential diagnostic mode. The probands in diagnostic 
mode and potential diagnostic mode were excluded from the WES cohort, as their 
causative mutations were already known, or at least suspected.   
The majority (76%, n=172) of the 226 probands in research mode had a diagnosis 
of RP; 128 were simplex cases, 25 had adRP, 15 had arRP and four had xlRP.  A 
further 42 probands (19%) had some form of MD: 27 had a diagnosis simply of MD, 
14 had STGD, and one had age-related MD. A small proportion (4%, n=10) of the 







Figure 2.2 A diagram showing the criteria applied for selection of the 
discovery cohort, and the numbers of indigenous African IRD families at each 
phase of stratification.  
 
The prior screening performed on samples from the 226 probands in research mode 
was assessed. In total, 65 comprehensive screens had been performed on 61 
probands (four samples had more than one type of screen performed, due to a 
change of clinical diagnosis with progression of the disease and/or unclear 
Mendelian pattern of disease inheritance). The vast majority of the screening tests 
(97%; n=63) were microarrays, with only two samples screened by NGS.  
The 61 probands remaining were evaluated regarding the biological material 
available from additional family members, both affected with IRD and unaffected. 
Genomic DNA samples, extracted from blood or saliva, were ultimately available 







Table 2.3 Summary of the information pertaining to the 16 families selected 


















18 total  
adRP RP. Age of onset 16–40 yrs. ad 
RPD 94 
(ZULU) 
9 affected/  
12 total adRP 
RP. Age of onset 10–52 
years. Some relatives 












RP. Age of onset 2–8 
years. 









4 total adRP 
Diffuse RP. Severe 
progression and 













4 total adRP 








4 total adRP 
RP. Age of onset 14 






9 total adRP 
Diffuse RP, Cataracts a 
common feature. Age of 





3 total adRP 
Diffuse RP, Age of onset 








2007 diagnosis: MD, 
2012 diagnosis: cone-
rod dystrophy, possible 






3 total arRP 
Diffuse RP. Very early 









RP. One relative had 
age of onset 6 years, 
rapid progression till 18 
years, then disease 

























3 or 4 
affected/ 4 
total 





6 total arRP 
RP. Age of onset 40 









RP. Age of onset 3–59 
years. Some have 
diffuse RP. One relative 






3 total ABCA4 
STGD, Age of onset 14–
18 years. ar 
 
The ethnolinguistic breakdown of these families was as follows: five Xhosa, three 
Zulu, two Tswana, one Shangaan, one Venda, one Tsonga/Ndebele, one 
Xhosa/Sotho, and two unknown. Two of the 16 families had been clinically 
diagnosed with ar MD (one had a subsequent diagnosis of cone-rod dystrophy or 
LCA, the other family had STGD) and the remaining 14 families had RP. Of the 109 
individual samples available, 56 were selected for WES, with the remainder to be 
used for subsequent validation of the WES results.   
 
2.4 Discussion 
Review of the registry confirmed the premise of this research project; indigenous 
Africans were underrepresented in the South African IRD cohort and remained 
largely undiagnosed. Although a total of 1,416 families had agreed to participate in 
the UCT IRD research programme at the start of this investigation, only ~19% of 
them (n=271 families) were of indigenous African ethnicity. In 2003, a review 
following the first 10 years of the programme reported 182 indigenous African 
families82, and despite an effort to make the programme more inclusive, the 
subsequent decade of recruitment resulted in only 89 additional families joining the 
IRD project at UCT by 2014. This indicated that many South African IRD patients do 
not benefit from a molecular diagnosis, which could be advantageous to their 
healthcare. Furthermore, the broader implication is that the true burden of disease 





of SA is ~80% indigenous African (http://www.statssa.gov.za/). Awareness must 
continue to be raised among healthcare professionals, particularly those in rural 
areas and urban medical centres which serve a large proportion of the local 
indigenous population. The special schools for the visually impaired could provide 
an additional source of families, however several ethical considerations exist for this 
approach (mainly surrounding the recruitment of children). Nonetheless, it should be 
noted that in the two years since this particular investigation was initiated (from June 
2014 to June 2016), 68 new cases joined the research programme of which 40 
(58.8%) were indigenous African, showing progress in the effort to reduce bias.  
The first goal in reviewing the registry was to ascertain whether any potential 
founder effects existed for IRD in the group of interest. A founder effect is the loss 
of genetic variation occurring when a new population is established by a small 
number of individuals (i.e. the ‘founding individuals’) from a larger population120. SA 
has local and immigrant populations, some of which exhibit significant admixture121–
123 and others which remain largely endogamous124–126. It can be postulated that 
founder mutations arose in indigenous black South Africans during the Bantu 
expansion109,116. Founder effects have been reported in indigenous South Africans 
with other disorders127,128, including BBS118,  so it was prudent to investigate this 
population group with respect to founder mutations causing IRD.  
The registry review indicated that 33 distinct variants in 16 different genes had been 
identified in the indigenous African sub-cohort. However, the majority of variants 
occurred in single families, had uncertain pathogenicity, or had already been 
screened in the majority of relevant cases and, thus, did not warrant further 
investigation in the context of this project. Although ad founder mutations have been 
reported129, including for IRDs130, none of the mutations identified in genes causing 
ad IRD (namely RHO and TOPORS) occurred in more than a single indigenous 
African family, each. These mutations could be screened in a larger ethnically-
matched cohort in the future, to ascertain allele frequency, however this would be 
unlikely to deliver large returns, given the vast genetic diversity reported in this 
population group104,105,116. A more successful approach may be screening of the 
homozygous mutations identified in single families. Of these, the CRB1 
p.(Thr745Met) mutation would be of greater interest than the homozygous 
mutations in the USH and BBS genes as these have already been interrogated 
appropriately. However, ultimately a single variant, p.(Pro2126Leufs*5) in MYO7A, 
was identified in the homozygous state in two unrelated families but had not been 





founder mutation in this population group and warranted further investigation as a 
high priority (Chapter 3).  
The efficacy of microarray technology was problematic to evaluate, as the majority 
of samples in the biorepository (and therefore screened using the arrays) are from 
Caucasian patients.  Furthermore, different panels have been used to different 
extents, and with different success rates, in the various population groups. For 
example, the ABCA4 panel is the most frequently used array; driven by the 
translational diagnostic service aspect of the programme87,88,131. No definitive 
conclusions can thus be drawn from these data. However, since the microarrays 
test for reported mutations identified predominantly in patients of 
European/Caucasian origin, it was perhaps unsurprising that a trend was observed 
that indigenous African patients are not diagnosed as frequently as Caucasian 
South African patients using this methodology.   
The second goal in reviewing the registry was to select an appropriate cohort for 
WES. Sixteen families met the established criteria, namely no mutation had been 
identified following comprehensive screening, and sufficient intact DNA samples 
were available from at least three family members. This cohort was thus selected to 
be enriched for novel variant discovery in reported IRD genes (Chapter 4), and was 






Chapter 3. A founder mutation in 
MYO7A underlies a significant 
proportion of Usher syndrome in 
indigenous South Africans: 
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PURPOSE. Research over the past 25 years at the University of Cape Town has led to the
identification of causative mutations in 17% of the 1416 families in the Retinal Degenerative
Diseases (RDD) biorepository in South Africa. A low rate of mutation detection has been
observed in patients of indigenous African origin, hinting at novel genes and mutations in this
population. Recently, however, data from our translational research program showed two
unrelated indigenous African families with Usher syndrome (USH), with the same
homozygous MYO7A mutation. Therefore, the extent to which this mutation contributes
toward the disease burden in South Africa was investigated.
METHODS. Cohorts of unrelated indigenous South African probands with different RDD
diagnoses were tested for the MYO7A c.6377delC mutation. Familial cosegregation analysis
was performed for homozygous probands, clinical data were evaluated, and SNP haplotypes
were analyzed.
RESULTS. This homozygous MYO7A mutation underlies a remarkable 43% of indigenous African
USH cases investigated in this study, the majority of which (60%) were diagnosed clinically
with Type 2 USH. All homozygotes shared a common haplotype. This mutation does not
appear to cause nonsyndromic vision loss.
CONCLUSIONS. Of interest is the origin of this common mutation relevant to the Bantu
population migration into southern Africa. Further investigation of the phenotype may
elucidate the disease biology, and perhaps reveal a larger cohort with the same mutation, with
which to assess the impact of environmental and genetic modifiers and evaluate therapeutic
trials.
Keywords: Usher syndrome, African, founder mutation, MYO7A
Usher syndrome (USH) is characterized by vision andhearing loss, and is the most common cause of deaf-
blindness.1,2 It is an autosomal recessively inherited group of
disorders, divided into three major clinical subtypes that are
differentiated by the severity of hearing loss and the presence
of vestibular dysfunction. Vision loss due to retinitis pigmentosa
(RP) is a hallmark of all three USH subtypes. In addition to
clinical heterogeneity, Usher syndrome displays genetic hetero-
geneity, with 12 causative genes identified to date.3
Usher syndrome type 1 is the most severe form, exhibiting
profound congenital hearing loss and vestibular dysfunction,
and prepubertal onset of progressive RP. To date, six genes have
been associated with USH type 1, namely CDH23, CIB2,
MYO7A, PCDH15, USH1C, and USH1G.4 Usher syndrome type
2 is less severe, characterized by congenital hearing loss that is
moderate to severe, with normal vestibular functioning and a
later RP onset. Mutations in three genes, namely DFNB31,
GRP98, and USH2A, cause type 2 USH.1,2 Type 3 USH is
characterized by variable onset of RP and hearing loss, as well
as varying degree of vestibular dysfunction. Two genes are
associated with USH type 3, namely CLRN12 and HARS,5 with a
third gene (ABHD12) being associated with a variant of this
subtype.6
A number of USH protein interactions (or interactomes)
have been reported,4,7 which function in the development and
maintenance of stereocilia hair bundles of the inner ear and
which also colocalize in the synaptic layer, connecting cilium
and the calyceal processes of the photoreceptors of the retina.
The exact function of these protein interactomes is not known,
as mouse models (of mutated USH genes) have little or no
retinal phenotype, but they may have a role in protein
trafficking between the inner and outer segments of the
photoreceptors, as well as synaptic function of these sensory
neurons.4
Due to the genetic and clinical heterogeneity, the large size
of the genes, and multiple isoforms underlying the syndrome,
identifying the molecular basis of USH in affected South African
families using traditional candidate gene screening methods has
been challenging. Technologic advances, such as the develop-
ment of microarrays and next generation sequencing, have
significantly improved the turnaround time and success rates of
genetic mutation screening for inherited retinal degenerative
diseases. As part of our translational research program in South
Africa.8,9 families can opt for genetic screening using micro-
arrays (Asper Biotech Ltd., Tartu, Estonia)10 or for whole exome
sequencing of 105 retinal candidate genes (through the
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Manchester Centre for Genomic Medicine, Central Manchester
University Hospitals NHS Foundation Trust, Manchester, UK).11
A review of data obtained from the Asper USH array and whole
exome analyses revealed two unrelated indigenous (Black)
South African USH probands with a homozygous c.6377delC
(p.Pro2126Leufs*5) mutation in MYO7A, which subsequently
was confirmed by cycle sequencing. This mutation has been
reported previously only recently (to the best of our
knowledge) in the compound heterozygous state, together
with p.Arg1240Trp, in a single Caucasian individual from the
United Kingdom with USH type 1.12 The mutation subsequent-
ly was added to the panel of mutations on the Asper Usher
Microarray; however, many South African samples had been
tested by that time and, therefore, it was deemed necessary to
rescreen appropriate samples for this mutation. The
p.Pro2126Leufs*5 mutation is predicted to truncate the 2215
amino acid MYO7A protein by 86 amino acids (3.88%).
The gene MYO7A was the first USH gene identified13 and
has since been recognized as the most frequent cause of USH
type 1, which is the most severe form of USH.14,15 The protein
MYO7A is an unconventional myosin expressed in multiple
epithelial cell types,16 including the RPE, where it functions in
the light-dependent localization of the visual cycle enzyme,
RPE65.17 It is also expressed in the photoreceptor calyceal
processes and cilia, and the stereocilia, together with other
USH proteins.
The identification of two unrelated indigenous South
African patients (and their respective families) with the same
homozygous MYO7A mutation warranted further investigation
in this population, particularly with respect to a potential
founder effect and the clinical manifestation of c.6377delC.
Phenotypic variation has been reported previously in USH,
with mutations in USH2A causing nonsyndromic RP18,19 and
MYO7A mutations causing nonsyndromic20 deafness. Founder
mutations have been reported previously in indigenous South
Africans,21,22 and determining whether this USH mutation
occurs on the same haplotype in all affected individuals would




Affected individuals and their family members were recruited
from throughout South Africa as part of a Retinal Degenerative
Disorders (RDD) research project, established in the Division
of Human Genetics at the University of Cape Town in 1990.
Biological material (genomic DNA extracted from venous
blood) is archived in the RDD registry, together with
demographic and clinical information. Informed consent is
obtained from all RDD research participants according to the
tenets of the Declaration of Helsinki (2013), and ethics
approval for this specific study was obtained from the
institutional Human Research Ethics committee (HREC/REF:
312/2014).
A cohort of 12 unrelated indigenous South African probands
with confirmed clinical diagnoses of USH (regardless of the
clinical subtype), but no genetic diagnoses, were tested for the
c.6377delC mutation. A further six indigenous South African
probands with RDD and some hearing loss, but no clinical
confirmation of USH, also were tested and considered to be a
‘‘query USH cohort.’’ Testing also was performed on samples
from three probands of Mixed Ancestry with confirmed clinical
diagnoses of USH (who likely share similar ancestry with the
indigenous South African individuals, as Bantu-speaking
Africans are a major ancestral contributor to this admixed
population23).
Familial cosegregation analysis was performed where
possible for probands carrying the homozygous c.6377delC
mutation, to ensure that the mutation cosegregated with
disease within the families. A total of 51 indigenous South
African population controls, who had not specifically been
assessed for the absence of RDD, also was screened for the
mutation. No detailed population data were available for these
controls, other than that they are of indigenous South African
origin. To investigate possible phenotypic variation, a cohort of
10 indigenous South African probands with nonsyndromic
autosomal recessive RP (arRP) and 107 indigenous South
African simplex RP cases also were tested.
c.6377del C Assay Design
The MYO7A Transcript variant 1 NCBI (NM_000260, accessed
November 2013) and Ensembl (ENSG00000137474,
ENST00000409709, accessed November 2013) sequences
were used to compare the region containing exon 47 and to
ensure that the entire exon was included in the assay.
Transcript variant 1 was selected as it encodes the longest
isoform. Primers were designed to span exon 47 and at least 50
bp of intronic sequence flanking the exon. The primers used
were Forward 50 GCAACAGGAGAGGCTGACTTTATC 30, Re-
verse 50 GTGGCTAGGAGGGCTTGTG 30.
The primers were used to amplify a 287 bp fragment under
standard 25-lL PCR conditions: 100 ng genomic DNA, 0.4 lM
forward and reverse primer, 200 lM dNTPS, 1X Colourless
GoTaq Reaction Buffer, and 0.5U GoTaq DNA Polymerase
(Promega, Madison, WI, USA). Cycling conditions were as
follows: 958C – 5 minutes, 30 cycles of (948C – 30 seconds,
618C – 30 seconds, 728C – 40 seconds), 728C – 7 minutes.
The c.6377delC mutation creates an Hpy188III restriction
enzyme recognition site 131 bp into the amplicon, resulting in
156 bp and 131 bp fragments in samples with the homozygous
mutation, and 287, 156, and 131 bp fragments in samples with
the heterozygous mutation. Restriction digests with Hpy188III
were performed as follows: a standard 20-lL reaction
containing 10 lL PCR product, 1X NEB CutSmart Buffer, and
5U NEB Hpy188III enzyme (New England Biolabs, Ipswich,
MA, USA) was incubated at 378C for 3 hours. The digest
products were subjected to electrophoresis on a 3% agarose gel
containing SYBR Safe DNA Gel Stain (Applied Biosystems by
Life Technologies, Woolston, Warrington, UK) and visualized
under UV light using a UVIpro Gold transilluminator (UVItec,
Cambridge, UK). A heterozygous and homozygous sample
(confirmed by cycle sequencing) were included as controls.
Haplotype Analysis
To examine the possibility of a founder effect in the indigenous
South African population (which would have diagnostic
implications), it was necessary to determine whether the
mutation exists on a common haplotype in the cases.
Additionally, haplotyping of African controls could determine
the origin of the mutation in South Africa, and the potential
contribution to USH disease burden in other African countries.
The mutation of interest is located at position 76924019 on
chromosome 11 (human genome build GRCh37.p13/hg19).
More than 1 Mb of the sequence flanking the mutation (584
709bp 50 and 502 265bp 30) was interrogated for informative
SNPs with minor allele frequencies > 20% in the Luhya and
Yoruba 1000 Genomes dataset.24 Three single nucleotide
polymorphisms (SNPs) were selected for haplotyping analysis
in mutation-positive families: rs6592706, rs948972, and
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rs11237122. All selected SNPS are 50 of the mutation; no
suitable SNPs were identified 30 of the mutation (Fig. 1).
Primers were designed to amplify a 250, 210, and 247 bp
fragment spanning rs6592706, rs948972, and rs11237122,
respectively. Polymerase chain reactions (PCR) were per-
formed in a 25-lL volume under standard PCR conditions:
100 ng genomic DNA, 0.4 lM forward and reverse primer, 200
lM dNTPS, 1X Colourless GoTaq Reaction Buffer and 0.5U
GoTaq DNA Polymerase (Promega). Cycling conditions were as
follows: 958C – 5 minutes, 30 cycles of (948C – 30 seconds,
annealing temperatures (Ta) – 30 seconds, 728C – 40 seconds),
728C – 7 minutes. Primer sequences, annealing temperatures,
and assay information are listed in Table 1.
The G allele of rs6592706 creates a BsrBI restriction
enzyme recognition site, generating fragments of the following
sizes for the various genotypes: A/A, 250 bp; A/G, 250, 159,
and 91 bp; G/G, 159 and 91 bp. Restriction digests were
performed as follows: a standard 20 lL reaction containing 10
lL PCR product, 1X Tango Buffer, and 2U BsrBI enzyme
(ThermoScientific, Waltham, MA, USA) was incubated at 378C
for 3 hours. The digest products were subjected to electro-
phoresis on a 3% agarose gel containing SYBR Safe DNA Gel
Stain (Applied Biosystems by Life Technologies) and visualized
under UV light.
The C and G alleles of rs948972 were distinguished by cycle
sequencing following purification of PCR products; 8.9 lL PCR
products were purified by 1U FastAP Shrimp Alkaline
Phosphatase (ThermoScientific) and 2U Exonuclease I (Ther-
moScientific) in a 10-lL reaction that was incubated as follows:
378C – 60 minutes, 758C – 15 minutes, 958C – 5 minutes. Cycle
sequencing was performed in a 20-lL reaction containing the
10 lL purified PCR products, 1 lM reverse primer, 1X
Sequencing Buffer, and 1X BigDye Terminator v3.1 Reaction
Mix (Applied Biosystems by Life Technologies). Cycling
conditions were: 968C – 5 minutes, 30 cycles of (968C – 30
seconds, 508C – 15 seconds, 608C – 4 minutes). Sequencing
products were purified by ethanol precipitation and resus-
pended in 10 lL Sabax water (Adcock Ingram, Johannesburg,
South Africa), after which 5 lL sequencing reaction was
loaded, together with 8 lL Hi-Di Formamide (Applied
Biosystems by Life Technologies), onto a 3130xl Genetic
Analyser (Applied Biosystems by Life Technologies).
The T allele of rs11237122 creates a PflMI restriction
enzyme recognition site, generating fragments of the following
sizes for the various genotypes: C/C, 247 bp; C/T, 247, 138, and
109 bp; T/T, 138 and 109 bp. Restriction digest were performed
as follows: a standard 20-lL reaction containing 10 lL PCR
product, 1X Buffer R and 2U PflMI enzyme (ThermoScientific)
was incubated at 378C for 3 hours. The digest products were
subjected to electrophoresis on a 3% agarose gel containing
SYBR Safe DNA Gel Stain (Applied Biosystems by Life
Technologies) and visualized under UV light.
Haplotypes of affected individuals with the homozygous
c.6377delC mutation were constructed manually based on
segregation within the families, and then compared between
families, and compared to control data; individual genotypes
for the 3 SNPs were obtained from 97 Luhya and 88 Yoruba
individuals in the 1000 Genomes dataset.24 Linkage disequilib-
rium testing and haplotype analysis was performed subse-
quently, and v2 and Pearson’s P values were calculated, using
the SHEsis online program (available in the public domain at
http://analysis.bio-x.cn/myAnalysis.php).25,26
RESULTS
Frequency of c.6377del C
After the initial identification of two unrelated indigenous USH
probands homozygous for c.6377delC, another four unrelated
homozygotes were identified by screening 12 additional
probands. Thus, a total of six homozygotes was identified in
the total cohort of 14 confirmed indigenous South African USH
cases (42.86%).
No mutation-positive individuals were identified in the
additional cohorts screened (Table 2). Furthermore, the
mutation was not present in the Luhya or Yoruba individuals
in the 1000 Genomes dataset,24 nor was it present in 200
chromosomes from Zulu individuals sequenced as part of the
African Genome Variation Project (AGVP).27
USH Mutation-Positive Families: Cosegregation and
Haplotyping Analysis
The six identified families came from the following ethno-
linguistic groups: one Sotho, two Zulu, two Xhosa, and one
unknown indigenous South Africans. The families live in two
large, geographically distinct provinces in South Africa, and
each family lives in a different town, indicating that consan-
guinity was unlikely. Familial DNA was available for three of the
six probands, and familial cosegregation analysis confirmed
that the mutation cosegregated with disease within these
families (Fig. 2). Genotyping of 3 SNPs (>83kB from
c.6377delC) in all available familial DNA samples also showed
the total of 10 homozygotes all shared a common haplotype
(Fig. 2). The clinical and demographic information pertaining
to the affected individuals is presented in Table 3.
FIGURE 1. Diagrammatic representation of the >1 Mb region of
chromosome 11 (between [A] and [B]) interrogated for informative
SNPS, and the three SNPs selected for genotyping (SNP1¼ rs6592706,
SNP2 ¼ rs948972, and SNP3 ¼ rs11237122). The mutation location is
shown as a bold vertical arrow. The numbers below the horizontal
solid line indicate the position (bp) on the chromosome, the numbers
above the horizontal arrows show the distance between adjacent
SNPS, and numbers above the dashed line show the distance between
each SNP and c.6377delC. The MYO7A gene is represented as a gray
box (located from 76839310–76926284 bp).
TABLE 1. Primer Sequences, PCR Annealing Temperatures (Ta), and Assay Information for the Genotyping of Three SNPs in Families Carrying the
c.6377delC Mutation
SNP Fwd Primer, 5030 Rev Primer, 5030 Ta, 8C Assay
rs6592706 cttgaaggtggtctagttctca atgtggattcaacagggcca 60 þ BsrBI
rs948972 agtccaagctcacagaggag acactcctgtctgcctgatc 60 Cycle sequencing
rs11237122 tgctgtactttggccctgaa gcagaatctcgaagtcagagg 58 þ PflMI
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The SHEsis Linkage Disequilibrium test was used to
calculate Lewontin’s D’ and r2 between each pair of the 3
SNPs in the 1000 Genomes control data from 97 Luhya and 88
Yoruba individuals. The results indicated that there is no
linkage disequilibrium among the three SNPs in the separate
control populations or when they are combined, and,
therefore, this is not a block of low haplotype diversity in
these African population groups.
We performed v2 calculations for genotype frequencies
(Table 4) of the 3 SNPs in the 185 African controls and 6
unrelated, c.6377delC homozygous probands affected with
USH. These statistical tests showed that the cases, separate
control groups, and combined controls showed no deviation
from Hardy Weinberg Equilibrium. The v2 analysis showed a
significant difference between the Luyha and Yoruba controls
in the frequency of rs6592706 (Pearson’s P ¼ 0.017293);
however, this was no longer significant when the critical value
was set to P < 0.01666 (Bonferroni correction for testing of 3
SNPs). There was no significant difference in the frequencies of
rs948972 and rs11237122 between the Luhya and Yoruba
controls (Pearson’s P ¼ 0.122203 and 0.527811, respectively)
and, therefore, these control groups were combined for
subsequent comparison with the cases. The results showed
that for rs6592706 and rs11237122 there are significant
differences in the genotype frequencies between the cases
and controls, which remained significant after Bonferonni
correction (P < 0.01666).
Subsequently, haplotypes were reconstructed and haplo-
type frequencies compared between the 6 unrelated cases and
185 controls (Table 5). The SHEsis analysis of 370 control and
12 case haplotypes gave a Global v2 of 77.993309, while df¼6,
and a Pearson’s P value was 9.27e-015. Haplotypes occurring
with a frequency less than 0.05 were excluded. The results
indicated a significant difference in the frequency of the ACT
haplotype in the African controls compared to the six
probands with Usher syndrome.
DISCUSSION
Our experience has shown that testing for known candidate
genes and mutations for RDDs (as configured through the
Asper Biotech Ltd. Arrays28) has a good yield with our
subcohort of Caucasian subjects, with 115 of 280 patients
(41.1%) having their mutation(s) identified through the use of
various Asper arrays, but a rather low return in our indigenous
African patients, in whom only 14 of 109 patients (i.e., 12.8%)
have a genetic diagnosis after microarray screening (results not
shown). This is understandable, since most of the testing arrays
are based on mutations generally identified in cohorts of
patients of European/Caucasian origin. Our identification of a
homozygous MYO7A mutation in two USH patients of
indigenous African origin was initially surprising, but its
emergence as the cause of a large proportion (42.86%) of
TABLE 2. Results of Mutation Screening in South African Case and Control Cohorts
Cohort Screened No. Individuals No. Chromosomes
No. Chromosomes
With c.6377delC
Indigenous South African USH 14 28 12
Indigenous South African query USH 6 12 0
Mixed Ancestry USH 3 6 0
Indigenous South African arRP 10 20 0
Indigenous South African simplex RP 107 214 0
Indigenous South African controls 51 102 0
South African Zulu control AGVP data* 100 200 0
Luhya control 1000 Genomes data* 97 194 0
Yoruba control 1000 Genomes data* 88 176 0
* Control data from publically available datasets.
TABLE 3. Clinical and Demographic Data From 10 Affected c.6377delC Homozygous Individuals in 6 Families
DNA Code Ethnic Group Age of Onset, y Clinical Diagnosis and Information
RPU 318.1UNA Unknown 1 USH Type 2
RPU 340.3JEA* Xhosa Congenital USH Type 2; VA: L ¼ 6/60; R ¼ 6/12 at age 43. Congenital hearing
loss.
RPU 340.4PAT* Xhosa Congenital USH Type 2; VA: L ¼ 6/48; R ¼ 6/48 at age 40. Congenital hearing
loss.
RPU 340.5PET* Xhosa Congenital USH Type 2; VA: L ¼ 6/24; R ¼ 6/60 at age 37. Congenital hearing
loss.
RPU 340.8SIG* Xhosa Congenital Congenital hearing loss, developed RP.
RPU 564.1FRA Zulu 11 USH Type 2
RPU 954.1ELI Xhosa 6/7 USH Type 2
RPU 1136.1MAN* Zulu Congenital USH Type 1. Congenital hearing loss, RP developed at 6–8 y,
progressive loss of day and night vision.
RPU 1136.2LIN* Zulu Congenital USH Type 1. Congenital hearing loss, RP developed at 6–8 y,
progressive loss of particularly night vision.
RPU 1338.1ISI Sotho Congenital USH Type 1. VA: L ¼ 6/18; R ¼ 6/12 at age 30. Night blindness
onset at 21 y. Slow disease progression, pigment, attenuation, pale
discs.
VA, visual acuity; L, left eye; R, right eye.
* Multiple members of Family RPU 340 and Family RPU 1136.
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FIGURE 2. (A–F) Pedigrees of six c.6377delC mutation–positive individuals and their family members. Squares represent males and circles
represent females, with shaded symbols indicating individuals affected by USH. All individuals from whom DNA was available are indicated by a
DNA code. Key: The 3 SNPs and c.6377delC mutation are indicated in the order shown, with the founder haplotype shaded.
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unselected USH cases from this population group was
remarkable. Several possibilities could explain the existence
of this relatively frequent mutation underlying USH in this part
of Africa, including a mutational hotspot at this nucleotide
position of the MYO7A gene, evolutionary advantage con-
ferred, or genetic drift. The c.6377delC mutation has been
reported only once previously (in the compound heterozygous
state, in a Caucasian individual from the United Kingdom with
type I USH),12 and the mutation has not been detected in the
1000 Genomes dataset, indicating that this codon is not
particularly susceptible to mutagenesis. It is unlikely that the
mutation confers an advantage to carriers, as heterozygous
mutations in MYO7A can cause autosomal dominant hearing
loss.29,30 Furthermore, in the present study, USH patients from
different ethnolinguistic subgroups, namely Xhosa, Zulu, and
Sotho, were identified with this homozygous mutation,
negating genetic drift as a cause of the mutation.
The majority of sub-Saharan Africans speak ‘‘Bantu’’ languag-
es, which are believed to originate from a core region in the
north west of the African continent, specifically Nigeria and
western Cameroon.31 The ‘‘Bantu expansion’’ refers to the
movement of people approximately 5600 years ago, across and
down Africa. Bantu speakers arrived in South Africa approxi-
mately 1500 years ago, where they diverged further. Today, there
are two main Bantu-speaking groups in South Africa, the
Southeastern (subgroup S) and Southwestern (subgroups R
and K) groups. The S subgroup of languages comprises the
following ethnolinguistic groups: Sotho-Tswana, Venda and
Nguni (which includes Xhosa and Zulu).32 The different
ethnolinguistic groups described in this affected cohort,
therefore, represent a derivation of the original Bantu expan-
sion. All mutation-positive patients in the present study, whether
Xhosa, Zulu, or Sotho, shared a common haplotype spanning
>83kB of sequence which is 50 of the mutation. This denotes
that c.6377delC is a founder mutation that arose in speakers of
the S-subgroup of Bantu languages before their divergence.
The haplotype is imputed to be present in the 1000
Genomes data at a frequency of 10%, although the mutation is
not present on this haplotype in the African populations in east
Africa, that is, the Luhya of Kenya and in west Africa, that is,
the Yoruba of Nigeria. Furthermore, there is no linkage
disequilibrium of the three SNPs in these two populations,
implying that the c.6377delC mutation arose on the haplotype
after the Bantu speakers expanded southwards in Africa. A
limitation of this study is the sole use of the Yoruba and Luhya
data as proxy control populations, with which to investigate
the haplotype frequency. It has been shown that these
populations are genetically diverse from the Bantu-speaking
South Africans,32 and that proxy populations may not be
applicable due to the vast genetic diversity of African
populations.33 This study highlights the paucity of genetic
data from indigenous South Africans, as no local population
frequency data were available for the SNPs of interest in this
study in the SNP dataset recently made publically available by
Ramsay et al.32 This underscores the importance of the
Southern African Human Genome Programme (SAHGP)34 and
the Africa Genome Variation Project.27 Nevertheless, the use of
the Yoruba and Luyha datasets was valuable in showing that
this founder mutation arose as a more recent event: post-Bantu
expansion but predivergence into the different ethnolinguistic
groups of South Africa.
The 51 indigenous South African population controls used
in this study to establish the frequency of the mutation
comprises individuals speaking the S-group of Bantu languages
(including Xhosa, Zulu, and Sotho), although a complete and
defined ethnolinguistic breakdown of these samples is
unavailable. Nonetheless, a recent study on the genomic
structure of indigenous southern African populations shows
the relatively recent divergence of the Sotho-Tswana, Zulu, and
Xhosa populations, suggesting that these may serve as proxies
for one another, to a greater extent than the Luhya and/or
Yoruba.35 Thus, this cohort was appropriate to compare the
frequency of the mutation between cases and controls,
especially when supplemented by the 200 Zulu chromosomes
of the AGVP data.
Interestingly, 6 of the 10 homozygous mutation–positive
patients had been clinically diagnosed with type 2 USH, whereas
MYO7A mutations previously generally have been associated
with the more severe type 1 USH. This is not the first report of
MYO7A mutations causing type 2 USH,14 but the observation is
rare. The milder phenotype diagnosed could be due to the fact
that the mutation affects the C-terminal FERM domain, and less
than 4% of the protein is predicted to be truncated. A mouse
study of a different MYO7A mutation (albeit a splice variant),
affecting the same C-terminal FERM domain, showed tissue-
dependent mRNA instability36; truncated mRNA in the ear
appears to be degraded by nonsense-mediated decay, whereas
mRNA expressed in the retina is not. The majority of our




Frequency A/A (freq) A/G (freq) G/G (freq) C/C (freq) C/G (freq) G/G (freq) C/C (freq) C/T (freq) T/T (freq)
Case, n ¼ 6 6 (1.000) 0 (0.000) 0 (0.000) 6 (1.000) 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 6 (1.000)
Luyha control, n ¼ 97 14 (0.144) 45 (0.464) 38 (0.392) 46 (0.474) 44 (0.454) 7 (0.072) 28 (0.289) 49 (0.505) 20 (0.206)
Yoruba control, n ¼ 88 23 (0.261) 46 (0.523) 19 (0.216) 53 (0.602) 27 (0.307) 8 (0.091) 20 (0.227) 45 (0.511) 23 (0.261)
Total control, n ¼ 185 37 (0.200) 91 (0.492) 57 (0.308) 99 (0.535) 71 (0.384) 15 (0.081) 48 (0.259) 94 (0.508) 43 (0.232)
v2/df 21.320929/2 5.073668/2 17.951681/
df ¼ 2
Pearson’s P 2.35e-005* 0.079116 0.000126*
* P  0.001.
TABLE 5. Haplotype Reconstruction and Frequencies for rs6592706,
rs948972, rs11237122 in 6 USH Cases and 185 African Controls
Haplotype Case (freq) Control (freq) v2 Pearson’s P
A C C 0.00 (0.000) 70.59 (0.191) 2.947 0.086060
A C T 12.00 (1.000) 38.47 (0.104) 77.993 1.09e-018*†
A G C 0.00 (0.000) 35.20 (0.095) 1.313 0.251864
A G T 0.00 (0.000) 20.74 (0.056) 0.742 0.389170
G C C 0.00 (0.000) 53.38 (0.144) 2.106 0.146678
G C T 0.00 (0.000) 106.56 (0.288) 5.060 0.024500
G G C 0.00 (0.000) 30.83 (0.083) 1.135 0.286700
* The haplotype associated with c.6377delC.
† P  0.001.
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homozygous cohort reported congenital onset of USH, yet the
clinical diagnosis of USH type 2 indicated no vestibular
dysfunction is present and RP onset is later.
Mutations in MYO7A are associated with nonsyndromic
hearing loss20 and it would be interesting to evaluate whether
this particular founder mutation contributes to the burden of
hearing loss in indigenous South Africans and other African
populations. Our screening indicates that this mutation is not
associated with nonsyndromic RP, which is not surprising
given the lack of prior reports correlating MYO7A mutations
with RP, and the tissue-specific protein effects reported.36
Providing a genetic diagnosis to a family means that
individuals within that family can elect to have diagnostic,
carrier, or predictive testing. Genetic testing, therefore,
provides patients and their relatives with more accurate risks
of developing disease, upon which they can base their
informed life decisions and reproductive choices. The
identification of this founder mutation will allow targeted
genetic testing, based on clinical diagnosis and patient
ethnicity, which will reduce the costs of genetic testing and
facilitate a rapid test turnaround time. Although the
c.6377delC mutation was not present in 51 indigenous South
African controls, screening larger numbers of unaffected
controls from Xhosa, Zulu, and Sotho populations, and
combining these results with data from the AGVP27 and
SAHGP,34 will provide mutation carrier frequency information
that could be useful for genetic counseling purposes and risk
calculations. Further screening in larger cohorts of Mixed
Ancestry USH patients and nonsyndromic deafness patients is
warranted as these patients likely share some ancestry with
indigenous South Africans. Furthermore, there is potential for
identifying a large number of individuals with the same
pathogenic mutation, which could facilitate detailed genotype-
phenotype investigations37 and studies of phenotypic modifi-
ers. Finally, identification of these indigenous South African
patients with a MYO7A mutation is important given the
development of UshStat, the MYO7A gene replacement
therapy38 currently in trials (https://clinicaltrials.gov/ identi-
fiers NCT01505062 and NCT02065011).
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Lisa Roberts,1 Rinki Ratnapriya,2 Morné du Plessis,1 Vijender Chaitankar,2 Raj S. Ramesar,1 and
Anand Swaroop2
1University of Cape Town/MRC Human Genetics Research Unit, Division of Human Genetics, Department of Pathology, Institute of
Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
2Neurobiology, Neurodegeneration & Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland,
United States
Correspondence: Anand Swaroop, N-
NRL, National Eye Institute,
MSC0610, 6 Center Street, Bethesda,
MD 20892, USA;
swaroopa@nei.nih.gov.
Lisa Roberts, Room N3.14, Level 3,
Wernher and Beit North Building,
Institute of Infectious Disease and
Molecular Medicine, University of
Cape Town Faculty of Health Sci-
ences, Anzio Road, Observatory,
7925, Cape Town, Western Cape,
South Africa;
lisa.roberts@uct.ac.za.
LR and RR contributed equally to the
work presented here and should
therefore be regarded as equivalent
authors.
Submitted: April 21, 2016
Accepted: October 18, 2016
Citation: Roberts L, Ratnapriya R, du
Plessis M, Chaitankar V, Ramesar RS,
Swaroop A. Molecular diagnosis of
inherited retinal diseases in indige-
nous African populations by whole-
exome sequencing. Invest Ophthal-
mol Vis Sci. 2016;57:6374–6381. DOI:
10.1167/iovs.16-19785
PURPOSE. A majority of genes associated with inherited retinal diseases (IRDs) have been
identified in patients of European origin. Indigenous African populations exhibit rich genomic
diversity, and evaluation of reported genetic mutations has yielded low returns so far. Our goal
was to perform whole-exome sequencing (WES) to examine variants in known IRD genes in
underrepresented African cohorts.
METHODS. Whole-exome sequencing was performed on 56 samples from 16 families with
diverse IRD phenotypes that had remained undiagnosed after screening for known mutations
using genotyping-based microarrays (Asper Ophthalmics). Variants in reported IRD genes
were identified using WES and validated by Sanger sequencing. Custom TaqMan assays were
used to screen for identified mutations in 193 unrelated indigenous Africans with IRDs.
RESULTS. A total of 3494 variants were identified in 217 known IRD genes, leading to the
identification of seven different mutations (including six novel) in six genes (RHO, PRPF3,
PRPF31, ABCA4, CERKL, and PDE6B) in six distinct families. TaqMan screening in additional
probands revealed identical homozygous CERKL and PDE6B variants in four more patients.
CONCLUSIONS. This is the first report of WES of patients with IRDs in indigenous African
populations. Our study identified genetic defects in almost 40% of the families analyzed,
significantly enhancing the molecular diagnosis of IRD in South Africa. Thus, WES of
understudied cohorts seems to present an effective strategy for determining novel mutations
in heterogeneous retinal diseases.
Keywords: next generation sequencing, genetic testing, photoreceptor dysfunction, South
Africa, vision loss, inherited blindness, retinal degeneration, clinical genetics
Indigenous African populations are underrepresented ininternational genetic/genomic studies. The African continent
includes 55 countries (https://africacheck.org/reports/how-
many-countries-in-africa-how-hard-can-the-question-be/), with
over 2000 distinct ethnolinguistic groups.1 Being the most
ancient of all populations, Africans display vast genetic
diversity2,3 as a result of historical migration, population
admixture, response to environmental change, and/or expo-
sure to a plethora of infectious agents.1 Indigenous Bantu
language–speaking individuals arrived in South Africa approx-
imately 1500 years ago as a result of the movement of people,
known as the ‘‘Bantu expansion,’’ across (west to east) and
down (north to south) Africa.4,5 Subsequent divergence of
Bantu speakers in South Africa occurred relatively recently into
separate ethnolinguistic groups such as Sotho-Tswana, Xhosa,
and Zulu. These black South African individuals, referred to
collectively hereafter as indigenous Africans, are the focus of
this study as they provide a valuable resource to detect genetic
defects in heterogeneous Mendelian diseases including inher-
ited retinal diseases (IRDs).
Inherited retinal diseases encompass a genetically and
clinically heterogeneous group of blinding diseases, with a
common phenotype of dysfunction and/or degeneration of the
light-sensitive photoreceptor cells (rods and cones) in the
retina.6,7 Patients with gene defects causing a primary disease
of rod photoreceptors, for example, retinitis pigmentosa (RP),
initially experience night blindness and loss of peripheral
vision. In contrast, IRDs showing initially the loss of cone
photoreceptors, for example, macular degeneration (MD) and
Stargardt disease (STGD), manifest with a loss of central vision.
Inherited retinal diseases can exhibit autosomal dominant,
autosomal recessive, or an X-linked pattern of inheritance and
demonstrate progressive or stationary and syndromic or non-
syndromic clinical phenotypes.6,7 Over 240 genes have been
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identified for IRDs (https://sph.uth.edu/Retnet/sum-dis.htm; in
the public domain). Recent studies using animal models have
finally begun to uncover some of the underlying disease
mechanisms and pathways that affect photoreceptor develop-
ment or function.7–9 Furthermore, it is estimated that only 50%
to 70% of the cases with RP (depending on geographical
regions or populations) can be attributed to the known
genes,10–12 indicating that a considerable number of as yet
unknown mutations and genes remain to be identified. Such a
vast clinical and genetic heterogeneity displayed by IRDs
confounds molecular diagnosis and investigation of the
pathogenic mechanisms.
Identification of the specific genetic defect in a patient with
IRD affords several potential benefits. First, overlapping
phenotypes and clinical variability of IRDs do not always
permit a clear clinical (ophthalmologic) diagnosis/prognosis.
Genetic analysis is unequivocal and provides clinical utility as
diagnostic, predictive, and carrier testing can be offered to
family members. Second, genetic tests may also influence the
clinical management of the disease. The IRD research program
in South Africa (SA), initiated in 1990,13 has a strong
translational and service component.14 Lastly, the knowledge
of precise genetic defects can allow development of gene-
based therapies for treatment of IRDs.15
The reported prevalence of IRDs is approximately 1 in
350011 in populations where epidemiologic data are available.
No data exist on the prevalence of IRDs in Africa. Nonetheless,
using SA’s 2011 population census (http://www.statssa.gov.za/;
in the public domain), one may extrapolate that approximately
14,500 individuals suffer from IRD-related visual impairment/
blindness in SA; of these (taking population demographics into
account), as many as 11,600 are expected in the indigenous
African population. However, a high frequency of unaffected
carriers of IRD gene mutations could exist because of local
founder effects and further elevate the potential burden of
disease.11
Demographic information, biological material, clinical
details, and diagnoses have been archived for 3237 individuals
in 1430 SA families with distinct IRDs in the University of Cape
Town (UCT) registry, which contains information and biolog-
ical material primarily from individuals of Caucasian origin;
indigenous Africans currently comprise only 19% of the
collection (n ¼ 275 families). Understandably, this does not
reflect the population demographics of SA and is due to
ascertainment bias and the lack of resources in rural areas
where a large proportion of the indigenous populations reside.
To date, 249 families (249/1430¼ 17%), mostly Caucasian (n¼
204/249; 82%), are in diagnostic mode, with clear pathogenic
mutations having been identified using a variety of methods.16
The most prevalent reported genetic defects in IRDs exhibit an
almost insignificant incidence in the SA patient cohort.17–20
Investigation of the indigenous African subcohort for reported
mutations through the use of Asper Ophthalmics microarrays
(http://www.asperbio.com/asper-ophthalmics; in the public
domain) has produced lower returns in the indigenous African
IRD subcohort than in the Caucasian subcohort. Approximate-
ly 41.2% of Caucasian samples (n¼ 279) have been diagnosed
by microarray screening as opposed to only 12.8% of
indigenous African samples (n ¼ 109) because each Asper
Ophthalmics microarray specifically tests for reported muta-
tions that have been identified predominantly in patients of
European/Caucasian origin. Novel mutations are detected only
if they occur at a nucleotide position(s) where a mutation has
already been reported, as only select nucleotides are assayed.
Thus, either SA indigenous IRD patients harbor novel
mutations in known genes that are not included in the Asper
arrays or causative genes are novel.
The advent of next-generation sequencing technologies has
revolutionized the speed and cost at which disease mutations
can be identified. An increased number of mutations are now
being identified in different populations using high-throughput
methods such as whole-exome sequencing (WES).21,22 Im-
proved molecular diagnosis in patients is important, given the
number of clinical trials and treatments currently under
investigation for this group of disorders.23 We therefore
resorted to a comprehensive WES approach, followed by
targeted analysis of all reported IRD genes, toward understand-




Informed consent was obtained according to the 2008
Declaration of Helsinki for all members from whom samples
have been archived in the UCT IRD registry. Ethics approval
was granted by the Human Research Ethics Committee of the
UCT Faculty of Health Sciences (Rec Ref. 226/2010 and 768/
2013). Samples from indigenous African families were selected
from the registry if DNA was available from at least three family
members and if a proband had been screened using the
appropriate microarray but no molecular diagnosis had been
obtained. A total of 16 families met the selection criteria,
comprising 109 individuals; of these, 56 were chosen for WES.
The selected 16 families originated from diverse, self-identified,
indigenous African ethnolinguistic groups: 5 Xhosa, 3 Zulu, 2
Tswana, 1 Shangaan, 1 Venda, 1 Tsonga/Ndebele, 1 Xhosa/
Sotho, and 2 Unknown. Two of the 16 families had been
clinically diagnosed with autosomal recessive MD (one of
whom had a subsequent diagnosis of Leber congenital
amaurosis) and 14 with RP.
Whole-Exome Sequencing
Genomic DNA samples were quantified using the QuantiFluor
dsDNA system (Promega, Madison, WI, USA), according to
manufacturer’s instructions. Whole-exome capture was per-
formed on 50 ng DNA using the Nextera Rapid Capture
Expanded Exome kit (Illumina, San Diego, CA, USA), and 125-
bp paired-end sequences were obtained on a HiSeq2500
platform (Illumina), according to manufacturer’s instructions.
Details of WES analysis are described elsewhere.24 FastQC
(available at http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/; in the public domain) was used to confirm
quality of sequencing, after which adapter indexes were
removed using Trimmomatic.25 Reads were mapped to the
human reference sequence (hg19, GRCH37) using BWA,26 and
GATK27,28 was used for variant calling, local realignment, base
quality recalibration, and variant recalibration. Annotation of
variants was performed with ANNOVAR.29
Variant Prioritization and Validation
Sequence variants present in genes (Supplementary Table S1)
listed on the RetNet database (https://sph.uth.edu/Retnet/sum-
dis.htm; in the public domain; accessed 12 November 2014)
were extracted for further analysis. Variants with a minor allele
frequency (MAF) of <0.1 in the 1000 Genomes Project30
(October 2014 annotation) were prioritized, as were exonic or
splicing variants. The variants were subsequently selected
based on cosegregation with the disease phenotype within
each family. For nonsynonymous variants, a minimum thresh-
old of three pathogenic predictions was applied to the
dbNSFP31 annotation of ANNOVAR, for either of the following
Whole Exome Analysis of South African IRD Families IOVS j November 2016 j Vol. 57 j No. 14 j 6375
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935850/ on 11/30/2016
predictor subsets: (SIFT, PolyPhen2-HDIV, PolyPhen2-HVAR,
LRT, MutationTaster, MutationAssessor, FATHMM, MetaSVM,
and MetaLR), or (VEST3 CADD-raw, CADD-phred, GERPþþ,
phyloP46way-placental, phyloP100way-vertebrate and SiPhy-
29way-logOdds). Variants were then assessed for their pres-
ence in the remainder of the cohort. High-priority candidate
variants were finally evaluated by examining RetNet and
Ensembl release 832 with particular emphasis on population
data for 1000 Genomes African subpopulations and NHLBI
Exome Sequencing data (http://evs.gs.washington.edu/EVS/;
in the public domain) in African Americans, as well as reported
phenotypes associated with the genes.
Wherever possible, additional familial samples not subject-
ed to WES were included for validation of candidate variants by
Sanger Sequencing on a 3130xl Genetic Analyzer (Applied
Biosystems, ThermoFisher Scientific, Waltham, MA, USA).
Finally, validated variants were checked for MAF in the African
Genomes Variation Project33 data, which include low-coverage
whole-genome sequences from 100 Bagandan of Uganda, 100
Zulu of SA, and 120 Ethiopian individuals.
Screening of SA Cohort
Custom TaqMan assays (primer and reporter sequences in
Supplementary Table S2) were designed to determine the allele
frequency of seven variants identified by WES, in a larger
cohort of 193 unrelated indigenous African probands with
IRDs but no known causative mutation. In order to determine
the optimal template concentration, two control samples were
screened for each assay (including a positive control for each),
at 8, 6, 4, 3, 2, and 1.5 ng/lL. It was empirically determined
that 2 ng/lL was optimal, allowing for effective allele
discrimination for each assay.
The final volume in each assay reaction was 5 lL, composed
of 2.5 lL TaqMan GT mastermix (23) (Applied Biosystems),
0.25 lL assay mix (203), 2.25 lL DNA (at 2 ng/lL, that is, total
input of 4.5-ng template). Each assay included at least two no-
template controls and two positive controls. Thermal cycling
was performed using the ABI 7900HT instrument (Applied
Biosystems) and the following conditions: 958C, 10 minutes;
(958C, 15 seconds; 608C, 1 minute) 3 40 cycles. If fluorescence
values dictated after this cycling, a second cycling of 103
(958C, 15 seconds; 608C, 1 minute) cycles and subsequent
postread analysis were performed. Sanger sequencing was used
to validate all candidate variants.
RESULTS
Whole-exome sequencing was performed for 56 samples that
included at least three individuals from each of the 16 families.
On average, 92% of the exome was captured at 253 coverage,
and a total of 1,816,031 variants were identified. We excluded
intergenic (n ¼ 759,459), intronic (n ¼ 710,303), and
synonymous (n ¼ 59,723) variants from further analysis and
identified 3494 candidate variants in 217 reported IRD genes.
We then filtered out variants that were present upstream or
downstream (n ¼ 298) of the coding exons, in the 50 or 30
untranslated region (n ¼ 1813), or in the noncoding RNA
(ncRNA) regions (n¼ 96). Of the remaining IRD variants (1266
exonic and 21 splice site), 561 variants were potentially
pathogenic (Supplementary Table S3). At least three prediction
algorithms identified 498 variants as pathogenic, and 63
variants were deletions, insertions, gain/loss of stop codons,
or variants of unknown effect. The candidate variants
remaining after each filtering step are shown in Table 1.
We identified seven different likely mutations in six IRD
families; of these, six had not been reported previously (Table
2; Fig. 1). Four of the variants are missense, one is predicted to
affect splicing, and two are predicted to result in frameshift
and protein truncation. None of the variants has been reported
in the whole-genome sequence data of 100 Zulu, 100
Bagandan, or 120 Ethiopian individuals in the AGVP study.33
Additionally, these variants are not detected in 97 Luyha or 88
Yoruba individuals in the 1000 Genomes data.30 Therefore, the
seven variants identified in IRD families are not present in 505
control African individuals (1010 chromosomes), providing
additional evidence in support of their pathogenicity. The
previously reported autosomal recessive RP (arRP) mutation
p.(His620GlnfsTer23) in PDE6B was present only once in 4266
alleles in the NHLBI WES dataset (ESP) of African Americans
(rs769671323, as of 27 October 2015); this frameshift mutation
is predicted to generate a truncated protein lacking over 200 C-
terminal amino acids.34 The second frameshift mutation
identified in ABCA4 is predicted to truncate the protein by
612 C-terminal amino acids. The c.698-1G>A variant in the
acceptor splice site of exon 8 of PRPF31, interrogated by
Human Splicing Finder 3.0,35 is predicted to activate an
intronic cryptic acceptor site while simultaneously disrupting
an exon splicing silencer site and creating an exon splicing
enhancer site. Therefore, all seven variants were computation-
ally predicted to be pathogenic, cosegregated with disease in
TABLE 1. Candidate Variants in Each of the 16 Families After Prioritization Filters
Family ID
No. of IRD







RPD 55 1351 749 280 17 7 0
RP 583 1431 796 302 8 8 0
RPD 94 1181 599 198 10 1 0
RP 391 1224 607 209 25 13 PRPF3
RPD 401 1183 619 234 30 11 0
RPD 799 1309 686 259 15 5 0
RPD 1001 1416 805 316 8 4 0
RPD 1005 1285 679 223 5 3 0
RPD 1010 1217 628 234 5 3 RHO
RPD 1339 1153 579 194 21 10 PRPF31
RPM 537 1130 550 191 9 5 ABCA4 (x2)
RPM 1167 1086 552 198 2 0 0
RPR 397 1063 525 199 19 3 PDE6B
RPR 624 1200 620 217 3 0 0
RPR 917 1154 574 203 4 1 CERKL
RPX 54 1432 760 259 1 1 0
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the respective families, verified by Sanger sequencing, and
exhibited conservation across vertebrates (Fig. 2). According
to ACMG guidelines for the interpretation of sequence
variants,36 the frameshift truncations identified in this study
have sufficient evidence to classify them as ‘‘pathogenic,’’
while each of the splice site or missense variants meets the
criteria of ‘‘likely pathogenic’’ variants in the absence of
functional studies.
We then performed TaqMan assays for these seven
pathogenic or likely pathogenic variants, identified here, in
an additional 193 indigenous Africans with IRDs. Five of these
variants were not detected in this cohort. The PDE6B
c.1860delC mutation was identified in a homozygous state in
one additional individual (diagnosed with arRP, from infancy)
and in a heterozygous state in four individuals (two sporadic
RP, one arRP, and one with an apparent dominant family
history). In addition, we identified the homozygous CERKL
c.365T>G variant in three patients with different IRD
phenotypes: one each of sporadic RP, sporadic STGD, and
arRP. This c.365T>G variant was also identified in the
heterozygous state in one RP proband.
DISCUSSION
The use of indigenous SA populations, combined with next-
generation sequencing platforms, provides an enriched re-
source for discovering novel IRD genes and mutations. Due to
the vast clinical and genetic heterogeneity, traditional candi-
date gene-based approaches have been less effective for the
molecular diagnosis of IRDs. Targeted capture of specific IRD
genes, associated with particular retinal phenotypes, is a
strategy being used for molecular diagnosis with increasing
frequency.37–41 Both targeted capture and WES allow for the
detection of novel mutations in genes (in contrast to micro-
arrays). Recently targeted capture of known IRD genes in
panel-based testing was reportedly more successful than
WES,42 probably due to better coverage of the genes of
interest. We believe that panel-based testing is especially not
suitable for the research on understudied populations, like the
indigenous Africans, where WES with targeted bioinformatic
analysis could enhance molecular diagnosis and even lead to
novel gene discovery. Collaborative and combined analysis of
WES data from different groups can yield genetic evidence for
novel IRD genes. In addition, WES data from unresolved
families can be reanalyzed when novel IRD genes are reported
without redesigning diagnostic gene panels and performing
new experiments. The latter is an important consideration
when providing a molecular diagnosis for patients in resource-
limited settings.
Our targeted analysis approach was successful in assigning
molecular diagnosis in 38% of the indigenous African families, a
clear improvement on the 13% detection rate using the
commercially available arrays that test for specific reported
variants. Six of seven (85%) variants discovered were novel,
supporting the high genetic heterogeneity in IRDs as well as
genetic diversity among indigenous Africans. Analysis of a
larger cohort of unrelated indigenous African probands
revealed that five out of seven variants were rare and detected
in a single family each, further advocating the use of WES-based
diagnosis instead of the genotyping-based microarrays used
previously to screen this population group. Nonetheless, the
detection rate is still much lower than the reported 83% of
European families interrogated using a similar approach.43
Other population groups investigated in a comparable manner
include Saudi Arabian,44 Chinese,45 Thai,46 and Israeli,22,47
with detection rates ranging from 49% to 83% and the number
of analyzed genes ranging from 60 to 226.
The relatively low detection of causal mutations in the SA
cohort of IRD families can be attributed to multiple factors.
Whole-exome sequencing is a capture-based method with
genomic regions of low coverage and poor detection of large
genomic alterations. Additionally, WES will not detect less
obvious pathogenic variants, such as ncRNA or regulatory
variants and those present in the untranslated regions or
introns. The clinical complexity of IRDs, that is, nonpene-
trance, frequent manifestation in carriers of X-linked disorders,
and variable expressivity within families, could result in an
incorrect inheritance pattern being assumed and hence
incorrect variant filtering during cosegregation analysis. This
problem is exacerbated in SA, where frequently sparse clinical
information accompanies the samples particularly from the
more rural areas of the country, and where language barriers
can often result in misinformation. However, it is also plausible
that causative mutations in many families reside in an as yet
TABLE 2. Potential Causative Mutations in Indigenous African Families With IRDs
Family Disorder Ethnicity Gene Variant: cDNA; Protein Comment
Pathogenicity,
ACMG Category36 Reported/Novel








RPD 1339 adRP Zulu PRPF31 c.698-1G>A; p.(?) Heterozygous Likely pathogenic Novel













RPR 397 arRP Shangaan PDE6B c.1860delC; p.(His620GlnfsTer23) Homozygous Pathogenic Reported,
Danciger et al.34




adRP, autosomal dominant RP; arRP, autosomal recessive RP; arSTGD, autosomal recessive STGD.
Whole Exome Analysis of South African IRD Families IOVS j November 2016 j Vol. 57 j No. 14 j 6377
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935850/ on 11/30/2016
unreported IRD gene. We believe that the use of previously
understudied populations is a sensible approach for ascertain-
ing missing heritability in genetically heterogeneous diseases
such as IRDs.
PDE6B mutations have been associated with autosomal
dominant congenital stationary night blindness (adCSNB) and
arRP.48 In our patient samples, two probands with arRP carried
the homozygous c.1860delC mutation of PDE6B. In addition,
we identified four IRD patients (two sporadic RP, one arRP, and
one with an apparent autosomal dominant [adRP] family
history) with a heterozygous PDE6B c.1860delC allele. The
relatively high frequency of this allele (1.9%; n¼ 8/418 alleles)
in the SA IRD cohort could imply compound heterozygosity for
PDE6B, digenic inheritance, or enhanced genetic burden. The
individual RPR 397.1 (in the WES cohort) had been tested
previously by the arRP microarray; however, this array platform
was designed to detect the c.1857_1858delC PDE6B variant
and not c.1860. We also noted the relatively frequent
occurrence of the CERKL c.365T>G variant in SA IRD patients
(n¼ 9/418 alleles; 2.2%). The four homozygous cases with this
mutation displayed varying phenotypes: two arRP, one
sporadic RP, and one sporadic STGD. CERKL mutations are
shown to result in autosomal recessive forms of cone
dystrophy, cone–rod dystrophy and RP (RetNet). In our study,
an identical CERKL mutation is associated with distinct IRD
phenotypes, implying the existence of modifier variants or the
impact of vastly different environmental and epigenetic
landscape in this genetically diverse cohort compared to the
reported Caucasian patients. Given the existence of the large
number of sequence variants in native Africans,2,3 it would be
prudent to perform WES on carriers of PDE6B and CERKL
variants to identify causal IRD mutation(s).
FIGURE 1. Pedigrees of IRD families showing cosegregation of the variants identified by WES. Squares represent males, and circles, females. Shaded
symbols indicate individuals with IRD. Identifier codes show individuals from whom biological material is available, and those selected for whole-
exome sequencing are noted with an asterisk. Segregation of mutation(s) in the families is indicated asþ/þ, homozygous for wild-type allele; M/þ,
heterozygous; M/M, homozygous for mutation. Clinical information is presented in Supplementary Table S4.
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Our study shows that genetic investigations of the SA
indigenous population present considerable challenges and
unique opportunities in human disease gene discovery.49
Africans have smaller haplotype blocks and low levels of
linkage disequilibrium compared to non-African populations,
as well as evidence of genetic admixture, leading to unique
diversity.3,4 Whole-exome sequencing of RP families in the
United States has yielded a greater number of novel variants
(both single nucleotide variants and small indels) in the
families of African ancestry compared with families of
European ancestry.50 In this study, the number of variants
novel to the National Center for Biotechnology Information
Short Genetic Variations database (dbSNP) was reportedly >6-
fold larger in a family of African American descent (n > 2500)
than in Caucasian U.S. families (n ~400). Given that genome-
wide ancestry estimates show an average proportion of only
~73% African ancestry in African Americans,51 the exomes of
indigenous Africans are expected to yield even more novel
variants. Therefore, inclusion of African populations in
genomics research should facilitate the discovery of genetic
defects associated with human disease.52
This study employs the first next generation sequencing
(NGS)-based approach in an indigenous SA cohort as an
opportunity for improved understanding of the genetic
architecture of IRDs. We have shown that success of diagnosis
is enhanced considerably using WES, and have identified
important genes and novel variants for genetic counseling for
IRD patients. Our study provides valuable insight into the
etiology of IRD in SA, and contributes toward more compre-
hensive understanding of this heterogeneous group of disor-
ders by cataloguing novel causative variants.
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4.2 Extended WES analysis of known IRD 
genes and the identification of a novel X-linked 
mutation  
 
The analysis of all known candidate genes gave a relatively low yield of causal 
mutations (Chapter 4.1). Given the pace at which IRD genes are currently being 
identified, it was considered prudent to re-analyse the WES data with an updated 
list of IRD genes. Furthermore, accurate clinical information such as individual 
disease status, phenotypes and mode of inheritance within a family remain crucial 
for WES, as per traditional genetic approaches, with errors in clinical data impeding 
downstream analysis and variant prioritisation for mutation identification. As 
described previously, it is impossible to predict the causative IRD gene based solely 
on phenotype and inheritance pattern. This is particularly true for RP, and 
specifically xlRP.  Consequently, an incorrect assumption of inheritance modes in 
the previous analysis required consideration.  
RP is the most common IRD, with an estimated prevalence of about 1 in 3,500–
4,000 individuals15,17 . Approximately 15–25% of cases are adRP, 35–50% arRP, 
and 7–15% xlRP17. Simplex or isolated cases are also common17,132. RP is usually 
monogenic, yet an expansive list of genes has been associated with the disease. 
There are currently 22, 36 and two genes identified as causing adRP, arRP and 
xlRP respectively (RetNet https://sph.uth.edu/retnet/, accessed 18 May 2016). 
However, several genes have been associated with multiple inheritance patterns, 
e.g. RHO, NRL, and RP1 have each been associated with both adRP and 
arRP26,133.  
Although phenotypic variability occurs, it can be generalised that xlRP cases display 
a severe RP phenotype, with early age of onset (childhood to late teen years) and 
rapid disease progression132,134. The two causative genes, RP2 and RPGR, account 
for 10–20% and 50–90% of xlRP cases, respectively132,134,135. In contrast with many 
other xl recessive Mendelian disorders where males are exclusively affected, female 
carriers of mutations in the xlRP genes can manifest with disease, resulting in a 
pedigree which displays an apparent ad trait17,136. It has been reported that  ~9% of 
families with a provisional diagnosis of adRP actually have xlRP137, and 15% of 





There is a spectrum of disease severity in female carriers of xlRP134,138–141; they 
often display some degree of fundus changes despite having normal visual acuity, 
however 10–30% of carriers show no fundus abnormalities142. Moreover, families 
with semi-dominant xlRP have been reported in whom several heterozygous 
females have a highly penetrant phenotype136,143–145 whilst remaining more mildly 
affected than hemizygous males. Furthermore, intrafamilial clinical heterogeneity 
has been reported amongst obligate carriers143. This variable disease expression in 
xlRP carrier females is often attributed to lyonisation (random inactivation of most 
genes on either the maternal or paternal X chromosome, occurring early in female 
embryo development). If the wild type allele is inactivated in retinal tissues, and 





4.2.1.1 Patient cohort and WES 
The 10 families (of the original cohort of 16 families) in whom no causative 
mutations had been detected through the preceding WES analysis were 
interrogated further. Pedigrees with an absence of male-to-male transmission of 
disease were identified as possible cases of xlRP.  
WES methodology has been described (Chapter 4.1). Briefly, exome capture was 
performed using the Nextera Rapid Capture Expanded Exome kit (Illumina, San 
Diego, CA, USA) on 50ng DNA, and sequencing was performed on a HiSeq2500 
platform (Illumina, San Diego, CA, USA), according to manufacturer’s instructions. 
Reads were mapped to the human reference sequence (hg19, GRCH37) and 
software versions for exome analysis were as follows:  Fastqc v.0.11.4 (available at 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) , Trimmomatic v.0.33146, 
BWA v.0.7.12147, GATK v.3.4-46148,149, Samtools v.1.2150, and ANNOVAR 
2014Nov12151. This WES analysis utilised computational resources of the high 
performance computing Biowulf cluster (https://hpc.nih.gov) at the National 






4.2.1.2 Exclusion of intergenic, intronic and synonymous WES variants 
Intergenic, intronic and synonymous variants were excluded sequentially using an 
inverse (-v) ‘grep’ command on a PC running the UBUNTU LINUX operating 
system. Quality control (QC) was performed by viewing the outputs of the various 
grep commands (using the ‘whole’ flag -w), with ‘intergenic’, ‘intronic’ and 
‘synonymous’ keywords, and ensuring the variant totals in the output files added up 
correctly (Appendix 4). Examples of the commands used are below:  
> grep –w “intergenic” DATA.csv > intergenicDATA.csv 
> grep –v –w “synonymous” NOintergenic_or_intronicDATA.csv > 
NOintergenic_intronic_OR_synonymousDATA .csv 
 
4.2.1.3 Extraction of IRD variants from WES data  
An updated list of 714 gene symbols was obtained from the RetNet database 
(https://sph.uth.edu/retnet/, accessed 27 January 2016), which included the original 
217 analysed genes (Chapter 4.1). The 714 gene names comprised NCBI gene 
symbols for genes associated with all IRD phenotypes, including non-Mendelian 
diseases and syndromic IRDs, as well as gene aliases, therefore this count has 
redundancy. It also included four genes not yet listed on the database (personal 
communication with Prof. S. Daiger, The University of Texas HSC at Houston). 
Nonetheless, the revised list now contained 240 identified IRD genes, including 22 
adRP, 34 arRP and two xlRP genes (Table 4.2.1).  
The list of 714 gene symbols was extracted using the file ‘grep’ command, and QC 
was performed again by viewing the output file and ensuring the variant totals 
added up correctly. Examples of commands used are: 
> grep –w –f Full714IRDlist20160127.csv DATA.csv > 
ALL714RETNETcandidatesDATA.csv 
> grep –w –f Full714IRDlist20160127.csv 







Table 4.2.1 Summary of all Mendelian IRD phenotypes, with the number of 









Bardet-Biedl syndrome, autosomal recessive 17 17 
Chorioretinal atrophy or degeneration, autosomal dominant 1 1 
Cone or cone-rod dystrophy, autosomal dominant 9 5 
Cone or cone-rod dystrophy, autosomal recessive 15 14 
Cone or cone-rod dystrophy, X-linked 1 0 
Congenital stationary night blindness, autosomal dominant 1 1 
Congenital stationary night blindness, autosomal recessive 9 9 
Congenital stationary night blindness, X-linked 2 2 
Leber congenital amaurosis, autosomal dominant 1 1 
Leber congenital amaurosis, autosomal recessive 11 11 
Macular degeneration, autosomal dominant 14 9 
Macular degeneration, autosomal recessive 3 3 
Ocular-retinal developmental disease, autosomal dominant 1 1 
Optic atrophy, autosomal dominant 6 3 
Optic atrophy, autosomal recessive 2 1 
Optic atrophy, X-linked 1 0 
Retinitis pigmentosa, autosomal dominant 23 22 
Retinitis pigmentosa, autosomal recessive 37 34 
Retinitis pigmentosa, X-linked 5 2 
Syndromic/systemic diseases with retinopathy, autosomal 
dominant 9 8 
Syndromic/systemic diseases with retinopathy, autosomal 
recessive 49 45 
Syndromic/systemic diseases with retinopathy, X-linked 3 2 
Usher syndrome, autosomal recessive 16 13 
Other retinopathy, autosomal dominant 13 9 
Other retinopathy, autosomal recessive 15 13 
Other retinopathy, mitochondrial 7 7 
Other retinopathy, X-linked 8 7 






The data at this stage represented the sum of variants across all 56 individuals, and 
not necessarily those occurring in each distinct family. Thus, data were separated 
into the ten families of interest in Microsoft Excel, and all subsequent analyses were 
executed separately for each family.  
A perl script, dotzero.pl (written by Dr. G. Rebello) was used to detect variants 
without alternative genotypes, i.e. a wild type genotype (0/0) or gaps (./.). The script 
detected variants if their occurrence within a family was only with a 0/0 genotype or 
gaps, or a combination of the two, across all individuals in that family. The option 
“keep” would extract these rows, whilst the option “throw” would extract the inverse, 
for example:  
> perl dotzero.pl Fam55ALL2016RETNETDATA.csv keep > FAM55dotzeros.csv  
> perl dotzero.pl Fam55ALL2016RETNETDATA.csv throw > FAM55nodotzeros.csv  
QC was performed by manually viewing the “keep” output file to ensure the correct 
rows were extracted, and also ensuring the variant totals added up correctly 
between the “keep” and “throw” output files.  
 
4.2.1.4 Variant prioritisation 
Variants with a minor allele frequency (MAF) of <0.1, in the 1000 Genome Project112 
(Oct 2014 annotation) were prioritized, as were exonic or splicing variants. These 
variants were extracted in Microsoft Excel, by filtering for variants with no MAF 
information and MAF <0.1. Subsequently, downstream, upstream, 3’ untranslated 
region (UTR), 5’ UTR, and non-coding RNA (ncRNA) variants were removed by 
filtering in Microsoft Excel.  
Family pedigrees were assessed for male-to-male transmission, and apparent mode 
of inheritance. A perl script, coseg.pl, was written in collaboration with Dr. G. 
Rebello, to apply rules for Mendelian inheritance (ad, ar and xl patterns) to each 
family. A text file, cosegfamily.txt which included identifier, column number, affection 
status and gender information for each sample in the cohort, was employed by the 
script. The coseg.pl script executed allele co-segregation analysis of each family, 
retaining variants which segregated appropriately within the family based on a 
specified inheritance model, e.g. 
> perl cosegv03.pl FAM55ExonicSplice.csv cosegfamily.txt D > FAM55cosegD.csv 





The above commands would retain variants co-segregating with disease in a family, 
based on an ad and xl inheritance model, respectively. The script was used to 
analyse each family for each potential mode of inheritance, hence some families 
were analysed for two different modes if male-to-male transmission was absent. All 
segregating variants per family were then incorporated into a single input file for 
downstream analyses.  
During coseg.pl script design, QC was performed by ensuring that output variants 
matched those that would have been correctly selected manually. This confirmed 
that conservative results were obtained using the script which could be refined 
manually. This was preferable to a less conservative script incorrectly filtering out 
variants that should be retained.  
Another perl script, scorep.pl (written by Dr. G. Rebello), was used to select 
pathogenic variants from the segregating variants extracted above. This script 
requires a text document, svalues.txt, containing user-established thresholds for the 
different prediction tools present in the Database for nonsynonymous SNPs’ 
functional predictions (dbNSFP)152,153 , annotated by ANNOVAR151. Two types of 
pathogenicity predictions, termed Predictions (P, where the prediction tool gives a 
decision) and Matrix (M, where the prediction tool gives a score but no decision) 
were used (Table 4.2.2). Low- and high- thresholds were established, based on the 
literature154. Scores below the low threshold, between the low threshold and high 
threshold, and above the high threshold, were scored 0, 1 and 2 respectively. 







Table 4.2.2 Summary of 16 pathogenicity prediction tools and the score 








SIFT_pred Protein sequence conservation among 
homologs155. 
P T = 0, D = 2 
Polyphen2_HDIV 
_pred 
Several sequence, phylogenetic and 
structure based features, (default 
HumDiv-trained predictor)156. 
P B = 0, P = 1, 
D = 2 
Polyphen2_HVAR 
_pred 
Several sequence, phylogenetic and 
structure based features, (HVAR 
distinguishes drastic effects and is better 
for Mendelian disease diagnostics)156. 
P B = 0, P = 1, 
D = 2 
LRT_pred DNA sequence homology, evolutionary 
model using 32 vertebrate species (≥ 10 
eutherian mammals)152,154,157. 




Functional prediction using DNA 
sequence conservation, splice site 
prediction, mRNA stability prediction, and  
protein feature annotations154,158. 




Sequence homology of protein families 
within and between species154,159. 
P L/N = 0, M = 
1, H = 2 
FATHMM_pred Sequence conservation160. P T = 0, D = 2 
RadialSVM_pred Ensembl score to aggregate individual 
prediction scores and MAF (Support 
Vector Machine approach)154. 
P T = 0, D = 2 
LR_pred Ensembl score to aggregate individual 
prediction scores and MAF (Logistic 
regression approach)154. 
P T = 0, D = 2 
VEST3_score Identifies causal variants based on 
enrichment for functional changes in 
across disease exomes161. 
M <0.5 = 0, 
≥0.5 and 
<0.75 = 1, 
≥0.75 = 2 
CADD_raw Contrasts variants surviving natural 
selection (comparison between human  
and chimpanzee) with simulated 
mutations162. The raw score is effectively 
arbitrary.  
M <5 = 0, ≥5 = 
2 
CADD_phred Contrasts variants surviving natural 
selection (comparison between human  
and chimpanzee) with simulated 
mutations162. The phred score is a scaled-
C score that ranks variants relative to the 
most deleterious substitutions.  
M <10 = 0, ≥10 
and <20 = 1, 
≥20 = 2 
GERP++_RS Identifies slowly evolving regions 
(constrained elements) and measures 
functional constraint163–165. 
M <4.4 = 0, 
≥4.4 = 2 
phyloP46way 
_placental 
Measures conservation in terms of 
faster/slower evolution than expected166. 
The dataset used is 46 placental 
mammals.   
M <1.6 = 0, 





Table 4.2.2 (continued) 
 
The scorep.pl script scored each prediction as 0, 1 or 2 and totalled the sum of the 
16 prediction scores. QC was performed by manually confirming scoring and the 
expected sum totals in the output file. Since frameshifts and truncation mutations 
would be excluded from analysis by many of the prediction tools (i.e. no prediction 
would be assigned), the script also totalled the number of missing predictions. QC 
was performed by manually confirming the total number of missing predictions. The 
command could be flagged to output all variants, or only variants scoring above a 
minimum baseline for pathogenicity as follows: 
> perl scorep7.pl FAM55tracking.csv svalues.txt P,0,M,0,A,0,AND > 
Fam55P0M0A0ANDout.csv 
> perl scorep7.pl FAM55tracking.csv svalues.txt P,6,M,6,A,0,OR > 
Fam55P6M6A0ORout.csv 
The first command would output all variants with their overall score and number of 
gaps. The second command would output only those variants with a pathogenic 
total score of 6 for either the P or M predictors. A minimum baseline of 6 was 
selected as it would include either: a) 3 predictions with a score of 2 each (3X2); or 
b) 4 predictions of which half had a score of 2, and half had a score of 1. 
Both commands were run for each family, thereafter the output was combined to 
include all variants with an overall pathogenicity sum total of 6 or more and all 
variants without pathogenicity predictions due to the nature of the variants. 
Heterozygous variants in recessive families were discarded at this stage if a second 
mutation was absent in the same gene.  
Remaining variants were then analysed using the scanfexome.pl script (written by 
Dr. G. Rebello) to ascertain the frequency of each variant within the cohort of 56 
individuals subjected to WES. This script would search for each variant (by amino 
acid effect and gene information) in the larger variant call format (vcf) file for the 
whole cohort, and extract the genotype occurrences in the larger dataset. A text file, 
Pathogenicity 
prediction tool 






Measures conservation in terms of 
faster/slower evolution than expected166. 
The dataset used is 100 vertebrates.   
M <1.6 = 0, 
≥1.6 = 2 
SiPhy_29way 
_logOdds 
Estimates likely substitution patterns, as 
well as accelerated/decelerated mutation 
rates of bases, by examining patterns of 
base subsitutions167.  
M <12.7 = 0, 





fexomefamline.txt, was used by the script, and contained relevant pedigree and 
disease information for each individual, to be presented with the output. In order for 
the script to function, the column containing the amino acid effect and gene 
information (referred to as ‘column 9’) required indexing to ensure no duplicates, 
and ‘fixing’ to replace missing column 9 data with unique chromosome coordinates. 
Both correctional steps were performed for the larger cohort vcf file and the 
individual family input files:  
> perl fixcolumn9.pl FAM583pathogenic.csv comma > FAM583pathFIXED.csv 
> perl indexcolumn9v3.pl FAM583pathFIXED.csv comma 
> perl "scanfexome1(3).pl" FAM583pathFIXED.csv fexomefamline.txt > 
FAM583OUT.csv 
Manual confirmation was used as QC for this script. The output of scanfexome.pl 
was manually interrogated to remove variants which occurred frequently and 
randomly (i.e. without appropriate co-segregation with disease) in other individuals 
and families in the larger cohort. Variants with a single spurious occurrence were, 
however, retained in a conservative approach to allow for a potential false positive 
variant call.  
Variants remaining after the analysis pipeline were considered as potential 
candidates for manual appraisal. Reads and coverage were viewed using 
Integrative Genomics Viewer (https://www.broadinstitute.org/igv/). Each variant was 
evaluated with respect to the gene, phenotype and mode of inheritance listed in 
RetNet (https://sph.uth.edu/retnet/). Variants were then checked in the Leiden Open 
variation database (LOVD www.lovd.nl/)168 and the Human Gene Mutation Database 
(HGMD) (www.hgmd.cf.ac.uk/). Variant MAF’s were examined using Ensembl 
release 8 (http://www.ensembl.org/)169 with particular emphasis on African 
subpopulations in the 1000 Genomes Data112, and African American exome 
sequencing data from the National Heart, Lung, and Blood Institute (NHLBI)170. 
Furthermore, the MAF’s were compared in >60,000 exomes of the Exome 
Aggregation Consortium (ExAC) Browser171, and 640 control African chromosomes 
in the AGVP115. The AGVP data includes low coverage whole genome sequences 
from 100 Bagandan, 100 Zulu and 120 Ethiopian individuals (from Uganda, SA and 
Ethiopia, respectively). It has recently been suggested that the frequency-centred 
threshold should not exceed 1:100 000 for an ad IRD gene78, which was considered 






4.2.1.5 Validation by cycle sequencing 
In order to verify candidate variants, primers were designed flanking the mutation(s) 
of interest, using Primer3 Plus (available at http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) and Oligoanalyzer 3.1 (available at 
https://www.idtdna.com/calc/analyzer). General rules for primer design were: (1) the 
primer pair should amplify the entire exon if possible, including 10–20bp of intronic 
flanking sequence, however the amplicon product should not exceed 600bp; (2) 
forward and reverse primers should have similar melting temperature, in the range 
of 55–65°C and similar GC content, of approximately 45–50% (3) Hairpin structures 
should not involve the 3’ end of the oligonucleotide, and should melt at 
temperatures lower than 40°C; (4) Homo- and hetero- dimers ideally have a 
maximum delta G of -5 kcal/mole, involve no more than 3bp and should not include 
the 3’ end of the oligonucleotides; (5) Primer specificity should be confirmed using 
the NCBI Primer-blast tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) against the 
Refseq representative genomes database for Homo Sapiens, and the UCSC In-
Silico Polymerase Chain Reaction (PCR) tool (http://genome.ucsc.edu/) against the 
GRCh37/hg19 reference genome assembly.  
Primers designed for validation in this particular study amplified a 359bp portion of 
exon 2 [F: 5' GATGCAGGGCTAAGTATCTTC 3'; R: 5' 
AATGGAAGTACTCCAGAGTGG 3’] of the RP2 mRNA NCBI Reference Sequence, 
NM_006915. PCR was performed under standard conditions in a 25µL reaction 
containing 200ng DNA, 10pmols each primer, 200µM dNTPs (Bioline, MA, USA), 1X 
GoTaq® Colourless buffer (Promega, WI, USA) and 0.5U GoTaq® G2 DNA 
Polymerase (Promega, WI, USA). The final volume was made up with SABAX 
distilled water (Adcock Ingram, Johannesburg, SA). The cycling conditions were as 
follows: 94°C – 3 minutes, 30 cycles of {94°C – 30 seconds, 58°C – 30 seconds,  
72°C – 40 seconds}, 72°C – 7 minutes, on a Multigene thermocycler (Labnet 
International Inc., NJ, USA). A volume of 5µL PCR products was visualised using 
2% weight/volume (w/v) agarose gels containing 1g agarose (SeaKem® LE, Lonza, 
Switzerland), 50mL of 1X TBE buffer and 5µL SYBR® Safe DNA Gel Stain 
(ThermoFisher Scientific, MA, USA). Size estimation of products was performed by 
comparison against a GeneRuler™ 100bp DNA Ladder Plus (ThermoFisher 
Scientific, MA, USA).  
PCR products were subjected to enzymatic Shrimp Alkaline Phosphatase and 
Exonuclease I (SAP/Exo) purification as follows: 8.9µL PCR products, 1U FastAP™ 





Exonuclease І (ThermoFisher Scientific, MA, USA) were incubated in a 10µL final 
volume on a 2720 thermal cycler (Applied Biosystems by ThermoFisher Scientific, 
MA, USA) as follows: 37°C – 60 minutes, followed by 75°C – 15 minutes, and a final 
hold of 95°C – 5 minutes.  
Cycle sequencing was performed in a 20µL reaction containing 4–7µL purified PCR 
product, 20pmols reverse primer, 1X BigDye® Terminator v3.1 Ready Reaction Mix 
(Applied Biosystems by ThermoFisher Scientific, MA, USA), 1X BigDye® 
sequencing buffer (Applied Biosystems by ThermoFisher Scientific, MA, USA), and 
the final volume was made up with SABAX distilled water (Adcock Ingram, 
Johannesburg, SA). Sequencing reaction cycling was performed on a 2720 thermal 
cycler (Applied Biosystems by ThermoFisher Scientific, MA, USA) as follows: 96°C 
– 5 minutes, {96°C – 30 seconds, 50°C – 15 seconds,  60°C – 4 minutes} X 30 
cycles.  
Cycle sequencing products were purified by ethanol precipitation: samples were 
mixed with 50μL absolute ethanol (Merck Chemicals, Gauteng, SA) and 2μL sodium 
acetate (3mM, pH5.5), and incubated overnight at -20°C. Samples were centrifuged 
at 10,000 revolutions per minute (rpm) for 10 minutes using the Microcentrifuge 
5415D (Eppendorf, NY, USA). The supernatant was removed, after which samples 
were washed in 50μL of 70% ethanol. A repeat centrifugation at 10,000 rpm for 10 
minutes was followed by the removal of supernatant, upon which samples were air 
dried for 60 minutes. A volume of 5µL purified sequencing reaction was added to 
8µL Hi-Di™ Formamide (Applied Biosystems by ThermoFisher Scientific, MA, USA) 
and capillary electrophoresis was performed on an ABI Prism 3130xl Genetic 
Analyser (Applied Biosystems by ThermoFisher Scientific, MA, USA). Sequences 
were aligned to the reference sequence (NM_006915) using Bioedit Sequence 
Alignment editor v.7.1.3.0172. 
 
4.2.1.6 Clinical examination 
In order to review the phenotype of a semi-dominant xlRP family diagnosed in this 
investigation, and to compare it with published findings, some participants were re-
evaluated. Dilated retinal examinations were performed by the same 
ophthalmologist on multiple family members (n=11) and their visual acuity was 
tested. Other clinical information was available from a previous clinical examination 
(n=1), or family history taken during counselling sessions and recruitment. 





unavailable in the Eastern Cape Province where the family resides, at the time of 
the clinical examination.  
 
4.2.2 Results 
Approximately 12 million reads (n=12,610,197) were captured per sample, and ~1.8 
million variants identified in the 16 indigenous African families. However, 34,579 
variants were identified in the updated list of RetNet genes, and 4,866 of these were 
retained after eliminating intergenic, intronic and synonymous variants (Appendix 4). 
Four of the ten families showed male-to-male transmission of the disease. The 
remaining six families comprised four apparent adRP and two arRP pedigrees, each 
thus had potential for actually having xlRP, and were analysed accordingly.  
On average ~2,140 IRD variants were identified in each of the 10 families (Range: 
1,881–2,329), of which ~1,355 had a low MAF (Range: 1,168–1,502) and ~288 
(Range: 232–359) resided in exonic or splicing locations. On average, ~12 variants 
per family co-segregated appropriately with disease (Range: 2–36), and ~5 of these 
were predicted to be pathogenic (Range: 0–13), however most variants were 
subsequently eliminated based on their frequency in the larger cohort and/or 
publically available control data.  
Ultimately all but two variants were excluded via the analysis pipeline and 
subsequent manual appraisal, namely c.1144G>A; p.(Val382Ile) in exon 9 of 
AFG3L2 (Chapter 4.3), and an xl mutation in a pedigree with an apparent ad 
inheritance pattern of disease. This c.704C>A; p.(S235*) mutation in exon 2 of RP2 
(NM_006915) was identified in a large Xhosa family with an initial diagnosis of 
adRP. This mutation was predicted (using Mutalyzer v.2.0.21173)  to truncate 116 C-
terminal amino acids from the wild type 350 amino acid protein (Figure 4.2.1). Whilst 
the X chromosome was not included in the AGVP data, the c.704C>A variant was 
not listed in Ensembl, nor was it reported in the ExAC Browser, LOVD or HGMD 






  1  MGCFFSKRRK ADKESRPENE EERPKQYSWD QREKVDPKDY MFSGLKDETV GRLPGTVAGQ 
 61  QFLIQDCENC NIYIFDHSAT VTIDDCTNCI IFLGPVKGSV FFRNCRDCKC TLACQQFRVR 
121  DCRKLEVFLC CATQPIIESS SNIKFGCFQW YYPELAFQFK DAGLSIFNNT WSNIHDFTPV 
181  SGELNWSLLP EDAVVQDYVP IPTTEELKAV RVSTEANRSI VPISRGQRQK SSDESCLVVL 
241  FAGDYTIANA RKLIDEMVGK GFFLVQTKEV SMKAEDAQRV FREKAPDFLP LLNKGPVIAL 
301  EFNGDGAVEV CQLIVNEIFN GTKMFVSESK ETASGDVDSF YNFADIQMGI * 
Figure 4.2.1 Predicted truncation of the RP2 protein sequence by the 
c.704C>A mutation. The sequence highlighted in red is absent when the protein is 
truncated, resulting in a predicted loss of 116 amino acids.   
 
The presence of the mutation was confirmed by cycle sequencing in the four 
relatives originally selected for WES. Furthermore, cycle sequencing of samples 
from all family members in the extended pedigree (n=18) established that the 
variant co-segregated with disease (Figure 4.2.2, Figure 4.2.3). According to 
recently published guidelines for the interpretation of sequence variants174 this 
variant meets the specified combination of criteria that classify it as pathogenic, 
namely it is a nonsense mutation (very strong evidence) that is absent from controls 
(moderate evidence) and co-segregates with disease (supporting evidence). 
 
 
Figure 4.2.2 Sequencing electropherograms showing the wild type RP2 
sequence (top), and heterozygous (middle) and hemizygous (bottom) 






Figure 4.2.3 Pedigree of family RP 583, demonstrating co-segregation of the RP2 c.704C>A mutation with disease.  
Squares represent males, and circles, females. Shaded symbols indicate individuals affected with IRD. Identifier codes show individuals from whom biological 
material was available, and those selected for whole exome sequencing are noted with an arrow. Segregation of the mutation in the families is indicated as: M 
(hemizygous mutation); +/M (heterozygous mutation); +/+ and + are wild type alleles in females and males, respectively.  





Table 4.2.3 Clinical information for the members of family RP 583. Females 





DNA identifier Clinical description 
II 5, (M) RP 583.3WIL AOO 16 years  
II 8, (F) RP 583.4ELS AOO 18 years, no typical RP features, atypical 
macular changes, bilateral pigment clumping 
and atrophy in macula, bilateral tessellated 
fundus, slowly progressive, bilateral cataracts 
at age 82.* 
II 10, (F) RP 583.5NON AOO 15 years, diffuse RP (grade 3 with 
macular involvement), slowly progressive, 
cataracts.* 
II 12, (M) N/A Onset childhood, no typical RP features, atypical 
macular dystrophy, bilateral geographic macular 
atrophy, slow progression.* 
III 4, (M) RP 583.6ZAL Onset early childhood, diffuse RP with macular 
involvement, slow progression.*  
III 5, (F) RP 583.8CEL No nyctalopia, no visual complaints, no reduction 
to visual fields, however both retinas have a 
diffuse mottled, granular appearance. No 
refractive error.*  
III 8, (M) RP 583.7MGC AOO 16 years 
III 10 (M) N/A AOO 20 years, Diffuse RP, slowly progressive * 
III 19 (M) RP 
583.11GEO 
AOO 6 years, original diagnosis was STGD, 
diffuse RP with macular involvement, slow 
progression, early cataracts, high myopia.*  
III 22 (M) RP 583.16RIE AOO 10 years, diffuse RP with macular 
involvement, slow progression, cataracts.* 
III 24 (M) RP 
583.13MZO 
AOO 12 years 
III 29, (F) N/A AOO 30 years, both retinas have a diffuse 
mottled, granular appearance, but no bone 
spicule pigmentation. Slowly progressive.* 
IV 1, (M) RP 583.14ZOL AOO 11 years, diffuse RP with macular 
involvement, slow progression, epiretinal 
membranes, Pseudopapilloedema.* 
IV 6, (M) RP 
583.17LWA 
AOO 3 years. 
IV 7, (M) N/A Normal retinal examination* 
IV 13, (F) N/A Onset early childhood, diffuse 
mottling/granularity of the RPE and macular 
area, severe refractive error with 
anisometropia.*  







Missing heritability is an issue in the investigations of IRD, with known disease 
genes accounting for only 50% of the cases17. It has been estimated that 20–30% of 
arRP cases, 60–70% of adRP cases and 80–85% of xlRP cases can be diagnosed 
using a combination of Sanger Sequencing and targeted capture NGS175. WES with 
targeted analysis of candidate genes for IRD detects 49–83% cases in different 
population groups44–49 and ~38% of the indigenous South African cohort was 
diagnosed using this approach (Chapter 4.1). However one large Xhosa family was 
subsequently identified as carrying a causative pathogenic mutation in an xlRP 
gene, that had been overlooked previously when the family was analysed using an 
ad model. Incorrect assumption of the Mendelian inheritance pattern had produced 
a false negative result, emphasising that all pedigrees lacking male-to-male 
transmission of IRD should be considered for mutations in xlRP genes. It has 
recently been suggested that targeted capture of the X chromosome, or ‘X-exome 
sequencing’ may be useful in identifying causal variants176, yet this only applies in 
cases where the xl inheritance pattern is obvious. Additionally, whilst it is clear that 
approaches such as WES and targeted capture NGS are preferable to traditional 
screening methods,  it must be considered that the mutation hotspot in exon ORF15 
of RPGR is repetitive and purine rich177 and may not be captured adequately by 
these technologies (Chapter 5.2.2).  
A majority of mutations in RPGR and RP2 are predicted to result in a truncated 
protein, implying the loss of gene function causes xlRP132,135,137,178. N-terminal RP2 
has homology to the tubulin-specific chaperone cofactor C and forms a complex 
with the small G-protein Arl3, suggesting that RP2 is a GTP’ase activating protein 
for Arl3179. In photoreceptor cells, Arl3 is localised in the microtubule-rich connecting 
cilium (which forms a bridge between the IS and OS), and RP2 is localised to the 
photoreceptor plasma membrane, suggesting they function in the ciliary transport 
and distribution of proteins like rhodopsin. Photoreceptors are neurons which are 
exceptionally metabolically active, demanding accurate protein synthesis, sorting 
and trafficking. 
The C-terminus of RP2 (predicted to be abolished by c.704C>A), has similar 
structure to nucleoside diphosphate (NDP) kinase, which catalyses the 
phosphorylation of nucleoside diphosphates to triphosphates, but there are 
significant differences around the active site180 between these two proteins, hence 





identified in the present study falls within the ferredoxin-like fold of the C-terminal 
α/β domain and should cause a loss of function similar to other reported RP2 
truncation mutations.  
The clinical expression of the c.704C>A mutation in this large Xhosa family is that of 
diffuse RP with an early age of onset in males ranging from 3 to 16 years. The 
disease is characterised by slow progression in many individuals. Interestingly, four 
individuals had cataracts. Eight of the 15 affected individuals with clinical 
information had macular involvement, including one with an initial diagnosis of 
STGD. This is in accordance with the recognisable RP2 phenotype (early onset 
macular atrophy, high myopia and reduced visual acuity)181, although only one 
individual was reported with myopia in this family. Of the five affected females 
examined, one (RP 593.5NON) was classified as Grade 3, according to the Grover 
et al classification for manifesting female carriers140. The remaining females did not 
match the classification system, as they had reduced vision with either: (1) Pigment 
clumping in the macula but without typical RP features (RP 584.4ELS); or (2) a 
diffuse mottled, granular appearance of the retina but without bone-spicule 
pigmentation (III 29 and IV 13).  
Individual RP 583.8CEL presented an interesting case, as she did not carry the 
mutation but had abnormal fundus photographs indicating some regions with 
pigment clumping and the diffuse mottled granular appearance referred to as ‘salt-
and-pepper fundus’. However, this patient, unlike the other females examined, did 
not experience nyctalopia, visual complaints or visual field reduction. Multiple 
archived blood samples were tested for this case, eliminating the possibility of a 
sample substitution error. There are thus two explanations for this scenario, either: 
(1) the observed clinical abnormalities are not due to the mutation, but instead are 
as a result of congenital infection or chronic medication; or (2) genetic mosaicism 
has occurred, and although the mutation is not present in the blood it may be 
present in her other tissues, including the retina. Intriguingly, a germ-line mosaic for 
an RP2 mutation has already been reported in SA previously, albeit for a different 
mutation and in a Caucasian family182.  
There is intrafamilial clinical heterogeneity observed amongst the females, still the 
large number of women manifesting with visual complaints is interesting. Whilst 
many semi-dominant families with RPGR mutations have been reported, to our 
knowledge this is only the second such family to be described with an RP2 
mutation. In 2009, Pomares et al143 described a large Spanish pedigree with a wide 





that ‘RP2 joins RPGR as the cause for semi-dominant xlRP’. The c.1073-9T>A 
mutation reported in that study resulted in exon skipping and protein truncation, 
however the aberrant protein escaped nonsense-mediated decay, making it difficult 
to establish whether the mutation caused a gain or loss of function. In that family, 
affected males expressed 95% of the aberrant and 5% of the wild type product 
respectively, whereas carrier females expressed a range (8–90%) of aberrant 
transcript levels, leading the authors to suggest skewed X-inactivation as the cause 
of the phenotypic range observed in females.  
X-inactivation status, however, cannot be measured directly in the retina139, and 
indirect measurements (in lymphocytes) show random X-inactivation in the majority 
of female carriers regardless of their affection status144,183. Recently, adaptive optics 
with scanning laser ophthalmoscopy has allowed non-invasive study of individual 
cone photoreceptors in obligate xlRP carriers142. Although only five patients were 
examined in that study, each showed arrangements of healthy, unaffected cones 
and regions with abnormal cones distributed in irregular patterns. This prompted the 
authors to suggest that healthy cones expressed predominantly the wild type X-
allele and abnormal cones principally expressed the mutant allele i.e. skewed X-
inactivation occurred in a mosaic pattern across the retina in all five carriers with 
different mutations. Skewed X-inactivation is possibly the cause of the occasional 
affected carriers within xlRP families. However, this is unlikely to be the reason for 
semi-dominant families, unless the chromosome inactivation is consistently skewed 
in retinal cells by a genetic modifier in a chromosomal region co-segregating with 
the primary xlRP mutation136,144.  
Banin et al144 examined several potential explanations for the phenomenon of semi-
dominant xlRP pedigrees, and eliminated the following factors in phenotype severity 
in carriers: 1) it is not gene-specific as both RPGR and RP2 have been associated 
with both forms of xlRP (i.e. both dominantly- and recessively- manifesting); 2) it is 
not mutation-specific as the same mutation, on different chromosomal backgrounds, 
can cause both forms. The authors concluded that an additional modifier allele 
linked to RPGR, either in the gene promoter or in the chromosomal segment 
segregating with the causative mutation, may affect penetrance in female carriers. 
Additional evidence for genetic modifiers that affect disease severity is the report of 
discordant phenotypes observed between non-identical twin males with the same 
RPGR mutation20. 
The identification of the novel RP2 mutation in this large African family holds 





expression in xlRP carrier females. Improved understanding of genetic modifiers is 
key to providing more accurate prognosis for patients and measuring efficacy of 
potential treatments184. Of more immediate benefit is the molecular diagnosis of this 
family (mistakenly assumed to have adRP), finally allowing accurate recurrence risk 






4.3 Expanding the disease spectrum associated 
with AFG3L2 mutations 
 
The second significant finding which emerged from re-analysis of the ten unresolved 
families, utilising the updated set of IRD genes and multiple inheritance models, was 




4.3.1.1 WES analysis pipeline 
The 714 gene symbols included four genes not yet recorded on the RetNet 
database (personal communication with Prof. S. Daiger, The University of Texas 
HSC at Houston). The reasons these particular genes (RTN41P1, SLC19A2A, CO2 
and, importantly, AFG3L2) were being considered for RetNet inclusion were not 
disclosed. 
Candidate variants were prioritised using the scripts, criteria and analysis pipeline 
defined previously. However in order to improve the disease-risk prediction of the 
primary candidate, an additional, larger dataset namely the Beacon Network185 was 
accessed. This is a federated system (https://beacon-network.org/#/), whereby a 
meta-database is created through virtual connections between multiple autonomous 
databases. The Beacon Network can be queried simply for the presence or absence 
of a specific allele, using chromosome coordinates. The tiered-access approach 
circumvents patient/data privacy concerns by providing additional details only upon 
authorisation.  
 
4.3.1.2 Validation by cycle sequencing 
Primers were designed to confirm the mutation of interest, according to the criteria 
described (Chapter 4.2). Primers for validation in this particular study amplified a 
559bp portion of exon 9 [F: 5' AGCCCAAGTCACCCTTTACA 3'; R: 5' 
CCAGGGACTGGTGAGAGGT 3’] of the AFG3L2 mRNA NCBI Reference 





described in Chapter 4.2. The cycling conditions were as follows: 94°C – 3 minutes, 
30 cycles of {94°C – 30 seconds, 60°C – 30 seconds,  72°C – 40 seconds}, 72°C – 
7 minutes, on a Multigene thermocycler (Labnet International Inc., NJ, USA). A 
volume of 5µL PCR products was visualised using 2% weight/volume (w/v) agarose 
gels as described in Chapter 4.2.  
PCR products were subjected to enzymatic SAP/Exo purification and cycle 
sequencing was performed in a 20µL reaction as described (Chapter 4.2). 
Sequences were aligned to the reference sequence (NM_006796.2) using Bioedit 
Sequence Alignment editor v.7.1.3.0172. 
 
4.3.1.3 Clinical examination 
Members of family RPD 401 were ophthalmologically re-examined as the clinical 
information available was sparse at the outset of this research project, only noting 
signs of RP in several family members, with reduced penetrance in some. 
Furthermore, the reported phenotype associated with the primary candidate gene 
identified in this investigation was unusual. Thus, retinal examinations were 
performed by two ophthalmologists on multiple family members (n=5). Additional 
clinical information was collected from previous medical evaluations and the 
anecdotal family history taken during counselling sessions for recruitment. The 
previous medical examinations included computed tomography (CT) brain scan, 
and electroencephalogram (EEG), of two relatives respectively. ERG and OCT were 
not performed due to cost considerations. 
 
 4.3.2 Results 
A variant of interest, c.1144G>A; p.(Val382Ile), was identified in exon 9 of AFG3L2 
in the Sotho-Tswana family RPD 401.The pedigree displayed male-to-male disease 
transmission, therefore the family had been analysed using an ad inheritance 
model. The number of variants in this family, after each filtering step, are listed in 
Table 4.3.1, beginning with 2,002 IRD gene variants that were neither intergenic, 
intronic nor synonymous. The details pertaining to the five candidate variants that 























2,002 1,262 270 36 13 5 
 
Table 4.3.2 Summary of the five candidate variants in family RPD 401 
evaluated as putative causative mutations. 

























. . . 2 6 8 0 0 0 
AFG3L2: 
NM_006796       
c.1144G>A; 
p.(Val382Ile) 





1.41E-03 0.0018 rs150243168 0 0 0 9 7 16 
 
The CNGB1, EYS, and KIZ variants were excluded, as allele frequencies for these 
variants in the ExAC Browser171 (accessed 24 February 2016) were high, at 
79/120,638 alleles, 2,042/19,786 alleles, and 61/9,602 alleles respectively. These 
variants each vastly exceed the likely frequency threshold of true dominant, 
pathogenic RP mutations (1:100,000 individuals78).  
The PLK4 variant was not listed in the ExAC browser. However, this nucleotide 
position was multiallelic, and a G>A variant at the same genomic coordinate 





reference SNP ID rs773122147. This alternative allele (G>A) had a frequency of 
1/120,830 alleles in the ExAC browser171 (accessed 24 February 2016). PLK4 is 
associated with ar microcephaly, dwarfism, severe intellectual disability, and 
retinopathy186. This mode of inheritance conflicted with that observed in family 401. 
Furthermore, the PLK4 variant had a much lower predicted pathogenicity score than 
the AFG3L2 variant.  
The strongest candidate was c.1144G>A; p.(Val382Ile) in exon 9 of AFG3L2. This 
variant had the highest predicted pathogenicity score of the five putative mutations, 
with 14 of the 16 prediction tools reporting it as pathogenic, and an overall score of 
28. The c.1144G>A variant was not recorded in any of the datasets examined 
(accessed 24 February 2016), namely LOVD (www.lovd.nl/)168,  HGMD 
(www.hgmd.cf.ac.uk/), 1000 Genomes Data112 or African American NHLBI exome 
sequencing data170 in Ensembl release 8 (http://www.ensembl.org/)169, the ExAC 
Browser171, or AGVP data115. Furthermore, the only representation of this allele 
(chromosome 18: 12356713 C>T) in the Beacon Network185 (accessed 14 
September 2016) occurred in an in silico prediction database containing almost 
every possible single-nucleotide variant i.e. the variant was not present in any 
patient sample (personal communication with David Caplan of SolveBio Genomic 
Intelligence, https://www.solvebio.com/). This indicates that this novel variant is very 
rare, as expected for an ad IRD mutation. The variant was not detected in the 
remaining cohort of 56 individuals, and was in fact the only exonic AFG3L2 variant 
identified in the WES data (four 3’ UTR and three upstream variants were 
excluded). The heterozygous variant was subsequently confirmed via cycle 
sequencing (Figure 4.3.1) and initially appeared to track with disease in the family, 
occurring in individuals RPD 401.1DES and 401.3YVO, and absent in the five other 
family members tested. However, upon clinical evaluation, individual RPD 
401.1DES, who was included for WES under the assumption that she had RP, was 






Figure 4.3.1 (A) Pedigree of family RPD 401, showing the presence of the 
novel c.1144G>A variant in AFG3L2 in two family members Squares represent 
males, and circles, females. Shaded symbols indicate individuals affected with IRD: black 
represents RP, dark grey represents thyroid eye disease and light grey represents 
individuals with visual impairment that has not been clinically confirmed. Confirmed clinical 
diagnoses are listed. Identifier codes represent the individuals from whom biological material 
was available, and those selected for whole exome sequencing are noted with an asterisk. 
Segregation of the variant in the families is indicated as: M/+ (heterozygous variant) and +/+ 
(wild type alleles). (B) Sequencing electropherogram showing the heterozygous 






Table 4.3.3 Clinical information for the members of family 401 with ocular 
phenotypes 
DNA identifier Clinical description 
RPD 401.1DES Thyroid eye disease. No IRD or optic atrophy. CT scan 
performed in 2015 showed residual proptosis after bilateral 
retraction repairs. Optic nerve and visualised brain appear 
normal.  
RPD 401.3 YVO AOO 30 years. Diffuse RP. Hearing loss. Hypertension. 
EEG performed to determine whether she had a seizure in 
2013, was normal (no epileptiform activity).  
RPD 401.6PET AOO 18 years. Cavernous optic atrophy, due to low tension 
glaucoma or dominant optic atrophy. Visual acuity 6/60. 
Normal intra-ocular pressures and nerve fibre assessment. 
No maculopathy or RP-like features. Slight dysarthria, but 
no obvious ataxia or cerebellar dysfunction. 
RPD 401.7LER Keratoconus. No optic nerve or retinal pathology.  
“AOO” Age of Onset  
 
4.3.3 Discussion  
Given the benefit of hindsight due to the clinical re-evaluation, family RPD 401 
would perhaps not have been included in the WES cohort as there is no clear 
(single) IRD phenotype. Nevertheless, AFG3L2 is an interesting potential candidate 
gene for further investigation in this family, particularly as no causative mutation was 
identified in any other known IRD genes. AFG3L2 is ubiquitously expressed187 
including in the retina10,13. It is a pleiotropic gene in humans (Figure 4.3.2), with 
mutations causing a range of effects such as ad spinocerebellar ataxia type 28 
(SCA28)188,189 and dominant optic atrophy (DOA)56.  
The AFG3L2 protein is a mitochondrial metalloprotease. It contains a conserved 
adenosine triphosphate (ATP) binding site in a AAA domain187 (‘adenosine 
triphosphatases associated with diverse cellular activities’). AFG3L2 forms homo- 
(with itself) and hetero- (with paraplegin, encoded by SPG7) oligomeric proteases, 
known as m-AAA proteases in the inner mitochondrial membrane. These proteases 
assert protein quality control via chaperone activity, facilitating the correct assembly 
of the respiratory chain complexes190.  
Two AFG3L2 mouse models, a null mutant and a missense mutation carrier, both 
display severe neuromuscular defects due to impaired axonal development190. 
Respiratory chain complex enzymatic activity is impaired in the models, affecting 
mitochondrial metabolism and morphology of neuronal tissue (but without affecting 





The SCA28 phenotype in humans is characterised by slow disease progression, 
imbalance, gait and limb ataxia, dysarthria (slurred speech), eye movement 
abnormalities (nystagmus), ptosis (drooping eyelids) and ophthalmoparesis (weak 
extraocular muscles)188,191. It has been established that about 78% of SCA28 
patients have at least one of these ocular signs192. As is the case with mouse 
models, the mitochondrial abnormalities are restricted to neuronal tissue in 
humans189. The vast majority of SCA28 mutations occur in exons 15 and 16, 
affecting the proteolytic domain189,191,192, however one mutation has also been 
reported in exon 10, affecting the AAA domain189.  
 
Figure 4.3.2 Illustration showing the AFG3L2 exons above the protein 
domains they encode. The amino acid numbers involved in each domain are presented, 
and various mutations causing different phenotypes are given in different coloured text: 
spinocerebellar ataxia type 28 (black); progressive myoclonus epilepsy (pink); spastic ataxia 
neuropathy (green); dominant optic atrophy (blue); retinitis pigmentosa and thyroid eye 
disease in this study (red). Legend: MTS, mitochondrial targeting sequence; TM1/TM2, 
transmembrane domain 1 and 2. Image adapted from references56,189 
 
Two classes of AFG3L2 mutations have been proposed, which explain the dominant 
and recessive phenotypes observed: (1) dominant negative mutations which affect 
both homo- and hetero- complexes and are thus fully penetrant, and (2) 
haploinsufficient mutations, which are alleviated when oligomers are formed with 
wild type AFG3L2 or paraplegin thus demonstrating reduced penetrance. The 





specialised functions of the m-AAA proteases such as substrate recognition and/or 
chaperone function189. 
A homozygous mutation (p.Tyr616Cys) in exon 15 has been previously identified in 
siblings of a consanguineous family with a spastic ataxia neuropathy syndrome193. 
The siblings had an early onset phenotype with spastic gait, dystonia (abnormal 
muscle tone), dysarthria and progressive myoclonic epilepsy. The ocular signs 
included oculomotor apraxia (absence of controlled, purposeful eye movement) and 
ptosis. Cerebellar atrophy was also observed. This mutation, again, resides in the 
proteolytic domain. However, this mutation was functionally proven to be 
hypomorphic and did not result in complete loss-of-function (both proteolytic 
function and ATP’ase activity was retained)193. Moreover, in yeast studies the 
mutation affected the homo-oligomeric proteases and, to an even greater extent, the 
hetero-oligomeric complexes. The isoenzymes can function synergistically, partially 
substituting for each other. However with both complexes affected, functional m-
AAA protease levels were low. This resulted in a recessive phenotype, combining 
features of both AFG3L2 and paraplegin deficiencies. Two additional cases of 
homozygous mutations, proximate to p.Tyr616Cys, have been reported194. In these 
two apparently unrelated individuals, a homozygous p.(Met625Ile) mutation was 
identified as causing progressive myoclonic epilepsy194.  
Most recently, a novel AFG3L2 mutation was identified in a family with DOA56. DOA 
causes vision loss due to degeneration of the optic nerve, and can be associated 
with other symptoms like muscle weakness, ataxia and peripheral neuropathy. The 
most frequent associated symptom is neurosensory deafness. All identified DOA 
genes (OPA1, OPA3 and SPG7) encode mitochondrial membrane proteins, yet this 
was the first report linking AFG3L2 to the phenotype56. The causative mutation did 
not reside within the proteolytic domain, like most previously described mutations, 
but in the AAA domain (exon 11). The clinical description of the DOA family included 
reduced visual acuity, photophobia, colour vision impairment, and optic disc pallor. 
Importantly, a moderate to marked reduction in retinal nerve fibre thickness was 
observed. No other oculomotor or neuromuscular problems, ataxia or cerebellar 
atrophy were evident, although mild intellectual disability was reported56. The DOA 
gene, OPA1, is a substrate for AFG3L2 and it has been suggested that the 
p.(Arg468Cys) mutation in this family may disrupt the interaction, resulting in this 






To the best of our knowledge, the variant identified in this Sotho-Tswana African 
family is the first reported in exon 9 of AFG3L2. From the sparse clinical information 
it was initially inferred that the family was affected with adRP. However, upon 
clinical re-evaluation the two ‘mutation-positive’ individuals were diagnosed with RP 
with hearing loss, and thyroid eye disease, respectively. Whilst functional studies 
are required to ascertain whether this novel c.1144G>A; p.(Val382Ile) variant is 
pathogenic174, it affects an amino acid in the AAA domain189 that is conserved 
amongst homologues187. Indeed, p.Val382 exists in the highly conserved central 
pore loop motif F/YVG189. It has been suggested that this particular motif is essential 
for the recognition of substrates and ATP-depending movement of polypeptides into 
the proteolytic chamber189. The p.(Val382Ile) missense mutation may therefore 
affect the interaction between m-AAA proteases and their substrates.  
The combination of phenotypes in the p.(Val382Ile) carriers is very interesting. The 
ophthalmologist noted hearing loss (a commonly associated symptom of DOA), but 
no signs of ataxia in the patient with RP (RPD 401.3 YVO). There were no obvious 
neurological problems in the patient with thyroid eye disease (RPD 401.1DES), who 
had a CT scan showing normal brain and optic nerve.  
Thyroid eye disease, also known as Graves’ disease, is an autoimmune disorder 
characterised by proptosis (bulging eyes), eyelid retraction and oedema195. Graves’ 
ophthalmopathy mainly occurs in patients with hyperthyroidism due to Graves’ 
disease (which is systemic). There are, however, cases of Grave’s ophthalmopathy 
without Graves’ disease or hyperthyroidism195. Intriguingly, one of the Graves’ 
disease risk loci, RAC2 (an important immune response gene196), encodes a 
product which interacts with AFG3L2197. Thus, it would be interesting to perform 
additional investigations into whether genetic modifiers could influence the 
phenotype such that it resembles thyroid eye disease. Variants in RAC2, for 
example, may affect it’s interaction with the p.(Val382Ile) form of AFG3L2. There 
are 26 RAC2 variants in family RPD 401, seven of which occur in the individual with 
thyroid eye disease. Five of these variants are present in the thyroid eye disease 
case and absent in the individual with RP, or are homozygous in the thyroid eye 
disease case but heterozygous in the RP case. None of these five variants occur in 
coding regions, but they might affect important regulatory elements. 
Individual RPD 401.6PET, exhibiting cavernous optic atrophy, did not carry the 
AFG3L2 variant. The WES data was subsequently examined for variants in the 
DOA genes (OPA1, OPA3 and SPG7) in RPD 401.3 YVO only. This was performed 





DOA in the family. No rare exonic or splice variants of these genes were present in 
the RP patient. Moreover, the phenotype of individual RPD 401.6PET could not be 
distinguished between low tension glaucoma or DOA, suggesting his visual 
impairment could be coincidental. Indeed, his normal nerve fibre assessment is in 
contrast with the DOA family described previously in the literature56. Alternatively, 
the presence of dysarthria may imply genetic mosaicism, which may explain why 
the AFG3L2 variant was not detected in this patient’s buccal DNA sample.  
There is currently insufficient evidence to translate this family into “diagnostic” 
mode. Furthermore, the lack of a single, heritable phenotype complicates additional 
WES data analysis for this family. However, if further investigations prove the 
AFG3L2 variant to be functional it would expand the phenotypic spectrum 
associated with this gene to include the first case of RP. The question would then 
remain whether the RP phenotype is because the variant affects the m-AAA 
protease recognition of — or interaction with — a specific retinal substrate, or 
whether retinal-specific thresholds exist for certain substrates that are perhaps more 






Chapter 5. Analysis of exome data 




5.1 IDH3A identification, facilitated by analysis 
of the European Retinal Disease Consortium 
candidate genes list 
 
The genetic heterogeneity displayed by IRDs decreases the likelihood of identifying 
multiple families with different mutations in a novel gene, particularly within a single, 
small study cohort. The use of consortia, like the European Retinal Disease 
Consortium (ERDC, http://www.erdc.info/), is therefore valuable for researchers 
working on rare, heterogeneous diseases, allowing joint analysis efforts to take 
place in a collaborative manner. The ERDC is a consortium, comprising 15 
international research groups, which has published a list of novel IRD gene 
candidates on its website. For each of these genes, the likely causative variant(s) 
has been identified in a single family. In the present study, eight indigenous African 
families remained without molecular diagnosis after interrogation of all known IRD 
genes, and were subsequently analysed in a targeted approach for variants in the 




5.1.1.1 WES analysis pipeline 
The WES methodology and analysis strategy has been described in detail (Chapter 
4.2). After intergenic, intronic and synonymous variants were excluded, the genes of 
interest were extracted from the data. Although 26 genes were reported by the 





four (ACBD5, IFT140, PRPS1, and ZNF513) were not included in this enquiry, as 
they had already been incorporated in the preceding RetNet gene analysis 
(Appendix 4). The commands used to extract the genes of interest from the WES 
were (for n=26 and n=22 ERDC genes, respectively):  
> grep –w –f ERDC20160127.csv  NOintergenic_intronic_OR_synonymousDATA.csv > 
Filtered2016ERDCDATA.csv 
> grep –w –f ERDC20160127COMPACT.csv  
NOintergenic_intronic_OR_synonymousDATA.csv > 
COMPACTFiltered2016ERDCDATA.csv 
The WES data were separated into the eight families of interest using Microsoft 
Excel software. The prioritisation filters were applied to variants in each family, 
using the scripts, criteria and analysis pipeline described previously (Chapter 4.2).  
 
5.1.1.2 Validation by cycle sequencing 
Primers were designed to confirm the variant of interest, according to the criteria 
described in Chapter 4.2, and amplified a 330bp fragment spanning exon 5 [F: 5’ 
TTTCACAAGGTAGCCGAGGT 3’; R: 5’ GATGCACAGAAAGCAGTCCA 3’] and a 
494bp fragment spanning exon 10 [F: 5’ TTGTATTGCTGAGGAAAGATGG 3’; R: 5’ 
TGTCTATACATCAGTGCTGCTTAACTT 3’] of the IDH3A mRNA NCBI Reference 
Sequence, NM_005530.2 
PCR was performed under the standard conditions defined in Chapter 4.2. The 
cycling conditions were as follows: 94°C – 3 minutes, 30 cycles of {94°C – 30 
seconds, 60°C – 30 seconds,  72°C – 40 seconds} , 72°C – 7 minutes, on a 
Multigene thermocycler (Labnet International Inc., NJ, USA). A volume of 5µL PCR 
products was visualised using 2% weight/volume (w/v) agarose gels as described in 
Chapter 4.2.  
PCR products were subjected to enzymatic SAP/Exo purification and cycle 
sequencing was performed in a 20µL reaction containing 20pmols forward primer, 
as described (Chapter 4.2). Sequences were aligned to the reference sequence 






5.1.1.3 Longitudinal clinical evaluation 
The clinical records of the family of interest were evaluated, in order to describe the 
phenotype associated with a putative novel gene. The proband from the family had 
initially been evaluated and diagnosed in 2006. Both the proband and her affected 
sister were subsequently re-examined in 2012 by a single ophthalmologist. After 
molecular diagnosis in 2016, only one of these original patients was 
ophthalmologically re-examined, as the proband was deceased. This latest 
examination was performed by the same ophthalmologist who evaluated both 
siblings in 2012. Fundus photography and OCT were performed.   
 
5.1.2 Results 
In total, 2,685 variants were detected in the ERDC gene list (n=26 genes). However, 
only 362 variants were retained after the removal of all intergenic, intronic and 
synonymous variants (Appendix 4). Upon further elimination of the ACBD5, IFT140, 
PRPS1 and ZNF513 genes, 314 variants remained.  
The eight families of interest each had, on average, ~135 ERDC variants of which 
~65 had a MAF <0.1 and ~16 were exonic or splice variants (Table 5.1.1). Although 
multiple possible inheritance modes were applied per family, only two families 
carried variants that co-segregated with disease. These variants were both 
predicted to be pathogenic, and were rare in the larger WES cohort. Although 
SAMD11 has subsequently been confirmed as an IRD gene69, the SAMD11 
c.122G>A; p.(Arg41Gln) variant (SNP ID rs148711625) in family RPD 1001 was 
excluded upon manual appraisal due to a high MAF, with 54 G/A genotypes in 661 
African individuals in the 1000 Genomes data112,  132 G/A and four A/A genotypes 
in 2,180 African Americans in the NHLBI exome data170, 136 G/A and one A/A 
genotypes in 1,522 Africans in the ExAC data171, as well as 32 G/A and two A/A 






Table 5.1.1 Summary of variants in the ERDC candidate genes after 
prioritisation filters. The inheritance models applied for each family are listed in the co-













(rare  in 
WES  
cohort) 
RPX 54 159 79 19 0 (ad or xl) 0 0 
RPD 55 146 63 13 0 (ad or xl) 0 0 
RPD 94 116 55 11 0 (ad) 0 0 
RPR 624 131 60 17 0 (ar or xl) 0 0 
RPD 799 135 63 11 0 (ad) 0 0 
RPD 
1001 
149 79 19 1 (ad); 0 (xl) 1 SAMD11 
RPD 
1005 
132 67 21 0 (ar or xl) 0 0 
RPM 
1167 
111 54 15 2 (ar) 2 IDH3A 
 
Ultimately, a single family (RPM 1167, comprising three individuals) was identified 
as having putative mutations in an ERDC gene. Two heterozygous IDH3A variants 
were identified in affected sisters of Tsonga (maternal) and Ndebele (paternal) 
origin; a truncation mutation, c.463G>T; p.(Gly155*) in exon 5, and a missense 
mutation, c.946C>T; p.(Arg316Cys) in exon 10 (SNP ID rs770798851). Cycle 
sequencing validation in the siblings and their mother showed the mutations were in 






Figure 5.1.1 (A) Pedigree of family RPM 1167, showing co-segregation of two 
IDH3A mutations with disease. Squares represent males, and circles, females. Shaded 
symbols indicate individuals affected with IRD. Identifier codes show individuals from whom 
biological material was available, and those selected for whole exome sequencing are noted 
with an asterisk. Segregation of mutation(s) in the families is indicated as: M/+, 
heterozygous for mutant allele; +/+, homozygous for wild type allele. (B) Sequencing 
electropherograms of IDH3A exon 5 and exon 10 confirming the presence of 
each heterozygous mutation, indicated by an arrow.  
 
The truncation mutation is presumably novel, as it was not listed in the databases 
searched (accessed 4 March 2016). This mutation is predicted (using Mutalyzer 
v.2.0.21173) to truncate the 366 amino acid protein by 212 C-terminal amino acids, 
effectively reducing the product by half (Figure 5.1.2). The missense mutation was 
predicted to be pathogenic by 12/16 ANNOVAR software tools as well as the PON-
P2 online pathogenicity predictor (http://structure.bmc.lu.se/PON-P2/)198, and is 
exceedingly rare, present in only one of 121,410 alleles in the ExAC data171 (the 
heterozygous allele occurred in the ‘European non-Finnish’ population group). No 
further IDH3A exonic variants were identified in the WES data of the 16 families in 






  1  MAGPAWISKV SRLLGAFHNP KQVTRGFTGG VQTVTLIPGD GIGPEISAAV MKIFDAAKAP 
 61  IQWEERNVTA IQGPGGKWMI PSEAKESMDK NKMGLKGPLK TPIAAGHPSM NLLLRKTFDL 
121  YANVRPCVSI EGYKTPYTDV NIVTIRENTE GEYSGIEHVI VDGVVQSIKL ITEGASKRIA 
181  EFAFEYARNN HRSNVTAVHK ANIMRMSDGL FLQKCREVAE SCKDIKFNEM YLDTVCLNMV 
241  QDPSQFDVLV MPNLYGDILS DLCAGLIGGL GVTPSGNIGA NGVAIFESVH GTAPDIAGKD 
301  MANPTALLLS AVMMLRHMGL FDHAARIEAA CFATIKDGKS LTKDLGGNAK CSDFTEEICR 
361  RVKDLD* 
Figure 5.1.2 Predicted truncation of the IDH3A protein sequence due to the 
c.463G>T mutation. The sequence highlighted in red is absent when the protein is 
truncated, resulting in a predicted loss of 212 amino acids.  
 
In 2006, individual RPM 1167.1 (born in 1986) was clinically diagnosed with rapid 
progression of diffuse RP and macular coloboma (a hole/missing tissue in the 
macula). In 2007, that individual was referred for molecular testing for a diagnosis of 
MD. In 2010, a sample from RPM 1167.1 was tested using the ABCA4 Microarray91 
which at that stage tested for 558 mutations in the ABCA4 gene, however no 
mutation was identified. In 2012, individual RPM 1167.2 (born in 1989) was referred 
with a diagnosis of possible cone-rod dystrophy. Both sisters had an age of onset of 
~8 years, and in 2012 their diagnosis was re-evaluated to LCA as fundus 
examination showed severe mid peripheral bone spicule pigmentary changes, mild 
arteriolar narrowing, severe macular pigmentation, coloboma-like atrophy of the 
macula, and optic atrophy. Neither had nystagmus or other ocular associated 
diseases e.g. strabismus (abnormal eye alignment or “squint”), hypermetropia (long-
sightedness), keratoglobus (thinning and protrusion of the cornea) or cataract, nor 
any systemic associations. Their vision at that stage was limited to counting fingers 
at 1 meter. Therefore in 2013, a sample from RPM 1167.1 was tested using the 
LCA Microarray92, which at that stage tested for 780 mutations in 15 LCA-
associated genes, but again no mutation was identified. 
In 2016, after WES analysis identified IDH3A as the causative gene, RPM 1167.2 
was evaluated by the same ophthalmologist that evaluated both sisters in 2012 
(RPM 1167.1 was deceased by 2016). Fundus photographs showed peripheral 
bone-spicule pigmentary changes (Figure 5.1.3 A), peripheral and mid-peripheral 
pigmentary retinopathy, macular pigmentation with severe coloboma-like atrophy, 
mild arteriolar narrowing and mild optic atrophy. Fundus autofluorescence (Figure 
5.1.3 B) was strongly reduced within the macula, diffusely increasing in a broad ring 
around the macula, and fading towards the periphery. The OCT (Figure 5.1.3 C) 





lamellar disorganization (lamellar structures were visible but could not be identified). 
The clinical picture thus represented arRP with a macular coloboma-like atrophy, 
resembling LCA.  
 
 
Figure 5.1.3 Clinical findings in individual RPM 1167.2, who carries compound 
heterozygous mutations in IDH3A. Credit: Dr. G. Fischer. (A) Fundus photograph 
showing the peripheral bone-spicules (red arrows) and coloboma-like atrophy (white line); 
(B) The broad ring of reduced fundus autofluorescence (white lines) within the macula (M); 






Figure 5.1.3 (continued) (C) optical coherence tomography results, confirming the 
coloboma-like atrophy (arrows).  
 
5.1.3 Discussion  
Having excluded all known IRD genes, eight families were analysed for mutations in 
22 putative novel IRD genes proposed by the ERDC. As a result of this approach, 
one South African family was identified with compound heterozygous mutations in 
IDH3A.  
It is likely that the genes responsible for a large proportion of IRDs have already 
been identified, and therefore any novel causative gene will probably be a rare 
source of cases65. The rare nature of IRDs, the complexity of these disorders (i.e. 
the vast genetic and allelic heterogeneity), and the fact that 50–70% of cases can 
be attributed to known genes, further reduces the likelihood that multiple families will 
be identified with the same novel causative gene. However, the demonstration of 
several families with mutations attributed to a putative novel gene provides stronger 
evidence of causality than a single family. Thus, collaborations (like this one set out 
by the ERDC) are immensely constructive, and the sharing of these data amongst 





candidate gene list is an important asset, the utilisation of which was shown to be 
an effective approach in this investigation. This particular resource should be 
highlighted amongst researchers to foster global collaboration for gene discovery. 
The IDH3A gene was first cloned in humans in 1995199 and assigned to 
chromosome 15q25.1–q25.2  in 1996200. IDH3A is expressed in the retinal 
transcriptome10,13, and encodes isocitrate dehydrogenase 3 (NAD(+)) alpha. 
Isocitrate dehydrogenases (IDH) catalyse the oxidative decarboxylation of isocitrate 
to α-ketoglutarate200 in the tricarboxylic acid cycle (TCA). The TCA, also known as 
the Citric acid cycle, or Krebs cycle, is a series of reactions in the mitochondrial 
matrix whereby organic fuel molecules, e.g. glucose, are catabolised in the 
presence of oxygen to generate energy in the form of ATP.    
IDH enzymes belong to two subclasses, distinguished by whether they use the 
coenzyme nicotinamide adenine dinucleotide (NAD(+)) or nicotinamide adenine 
dinucleotide phosphate (NADP(+)) as an electron  acceptor (NCBI Gene Entry 
http://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=full_report&list_uids=3419). 
There are three NAD-IDH enzymes that localise to the mitochondrial matrix and 
catalyse the rate-limiting step of the TCA. Each isozyme is a tetramer, composed of 
two α-subunits, one β-subunit, and one γ-subunit200. IDH3A encodes the α-subunit 
of one isozyme of NAD-IDH.  
Loss of function mutations in the NAD-IDH β-subunit (IDH3B) causing two unrelated 
cases of RP were reported in 2008201. Besides the IRD, no phenotype associated 
with mitochondrial dysfunction (e.g. reduced muscle strength or cardiac problems) 
was observed. This was despite the fact that the measured NAD-IDH activity in 
homozygous cell lysates from the patients was less than ~5% of normal control 
activity. It was proposed that NADP-IDH adequately substitutes for the mutant NAD-
IDH in all tissues except the retina, and it was noted that retina is the only tissue 
where NADP-IDH expression levels do not exceed those of NAD-IDH.  The authors 
suggested that NADP-IDH may be the major enzyme responsible for this step of the 
TCA in tissues other than the retina, and concluded that NAD-IDH is essential for 
proper retinal functioning201.  
Visual phototransduction is an energy-demanding process. This, coupled with the 
photoreceptor OS renewal (described in Chapter 1), results in high metabolic 
activity in the retina. It was previously thought that the mitochondria housed in the 
photoreceptor IS supplied the energy required for these processes. However it has 





IDH, are catalytically active in the OS at comparable levels to those in the retinal 
mitochondria202. Furthermore, the same group previously detected IDH3A in OS 
discs203. Panfoli et al thus suggested that the OS, which lacks mitochondria, 
possesses functional mitochondrial machinery in the cytosol to meet the high 
demand for ATP202.  
Mutations in IDH3A may impair the metabolic processes, or result in oxidative stress 
intolerable to the photoreceptor, and thus cause apoptosis and consequent visual 
loss. Although animal models of IDH3A mutations are available, including 
commercially-available zebrafish ( https://zfin.org/ZDB-GENE-040426-1007 )  and 
mouse models (https://www.mousephenotype.org/data/genes/MGI:1915084 , 
http://www.informatics.jax.org/allele/summary?markerId=MGI:1915084 ), to the best 
of our knowledge, no associated phenotypes have been reported. Functional 
investigations of the molecular mechanisms leading to IDH3A-related IRD are thus 
planned with ERDC collaborators. Furthermore, the spectrum of IDH3A mutations 
and phenotypic data associated with seven mutation-positive individuals has been 
compiled with these colleagues for publication (manuscript accepted 3 March 2017, 
Ophthalmology, the journal of the American Academy of Ophthalmology). It appears 
that, even with this limited number of cases, some genotype-phenotype correlation 
exists; all subjects developed symptoms in the first decade of life. Furthermore, 
patients with missense mutations are diagnosed with typical arRP, while those with 
truncating mutations generally manifest with a more severe phenotype (including 
the coloboma-like lesions) although intrafamilial variation in disease expression was 
noted. The identification of genotype-phenotype correlations is valuable for 
‘personalised ophthalmology’. An accurate prediction of visual prognosis is 
important for patients and facilitates their decision-making204. Furthermore, the 
knowledge of genotype-phenotype correlations may be useful for clinicians, and can 
help inform disease management. Knowledge about disease progression is also 
beneficial in identifying patients for clinical trials, particularly in terms of their stage 
of disease and whether therapy will be beneficial, as well as evaluating treatment 
outcomes25.   
The identification of the compound heterozygous mutations in IDH3A has important 
implications for this local family. The clinical diagnosis of the two sisters in family 
RPM 1167 has been revised several times. Individual RPM 1167.1 was clinically 
diagnosed with diffuse RP, MD, and LCA in her lifetime. Similarly, RPM 1167.2 has 
been diagnosed, at different stages, with possible cone-rod dystrophy and LCA. It is 





follow-up provides an opportunity to observe the onset and evolution of the disorder 
with time. Nonetheless, this genetic finding now provides an unambiguous diagnosis 
(arRP) for the family, and permits carrier testing for relatives. Of broader 
significance, is the identification of a new arRP gene; IDH3A can now be added to 
IRD gene panels or interrogated using other NGS applications, for patients 
internationally, including in SA. Screening of patient samples is required to ascertain 
whether arRP is the only IRD associated with this gene. Moreover, the identification 
of additional IDH3A IRD cases will provide information regarding the incidence of 
mutations in this gene in various population groups, and thus the contribution of this 






5.2 Elimination of candidates, supplementary 
screening and pathway analysis 
 
For seven families, mutations in all known IRD genes and novel candidate genes on 
the ERDC list had been carefully excluded. Analysis was thus extended to evaluate 
the remaining exome data of these families. 
The WES data originally comprised a total of 286,546 exonic, non-synonymous 
variants as described previously (Appendix 4). Having eliminated the variants in 
RetNet genes (n=4,866) and ERDC genes (n=314) a total of 281,366 variants 
remained in the cohort of 56 samples. The seven unattributed families were 
extracted from this data for further analysis. A multitude of approaches were 
employed to characterise as many of these families as possible, therefore, in the 
interests of clarity, the methods are embedded with results in this section.  
 
5.2.1 Exome analysis in seven families 
The unattributed families comprised 26 individual samples that had been subjected 
to WES. The data (minus all genes interrogated in previous analyses, Chapters 4.2–
5.1) were separated into the seven families of interest using Microsoft Excel 
software. On average 115,148 variants were identified per family (Table 5.2.1). 
Prioritisation filters were applied to variants in each family separately, using the 
scripts, criteria and analysis pipeline previously described (Chapter 4.2). Co-
segregation analysis was performed using the apparent mode of inheritance and if 
male-to-male transmission was absent, an xl inheritance mode was used in 
addition. Hence five families were analysed using two different inheritance models. 
The scorep.pl script for scoring pathogenicity was used with the same baseline 
threshold of 6, corresponding to a minimum of three pathogenic predictions, in order 
to be less stringent so as to not exclude variants in error. As before, pathogenic 
variants were interrogated to remove those occurring frequently and randomly (i.e. 
without appropriate co-segregation with disease) in the larger cohort of 56 samples. 
However, an additional filtering step was included in this exome analysis to remove 
variants in the 2,157 genes on the “gene exclusion list”205. These genes (including 
pseudogenes and paralogues) have been identified by retrospective analysis of 





that such hypervariable genes are unlikely to be IRD candidates, and could thus be 
excluded.  
 
Table 5.2.1 Numbers of exomic candidate variants remaining in seven 
unresolved families, after each prioritisation filter. The inheritance models applied 
for each family are listed in the co-segregation column (ad, ar and/or xl).  













126,213 67,329 17,439 895 (ad) + 46 
(xl) = 941 
485 5 {0} 
RPD  
55 
116,704 61,878 16,836  495 (ad) + 8 
(xl) = 503 
267 30 {9}  
RPD  
94 
108,586 54,132 13,322 568 (ad) 221 48 {13} 
RPR 
624 
104,944 53,047 13,305 692 (ar) + 89 
(xl) = 781 
357 26 {8}  
RPD 
799 
114,883 59,994 15,674 1,278 (ad) 602 61 {26} 
RPD 
1001 
121,250 66,372 18,097 540 (ad) + 75 
(xl) = 615 
329 28 {11} 
RPD 
1005 
113,457 59,069 15,904 574 (ar) + 11 
(xl) = 585 
252 32 {2} 
 
In total, 230 candidate variants were detected in 190 distinct genes. Manual 
appraisal using extant knowledge for this large number of variants was impractical. 
Furthermore, prioritisation of candidates based on gene expression in the retina was 
unreliable, as different candidate genes were present in various retinome datasets. 
The 190 distinct genes were compared to published datasets using the Microsoft 
Excel software conditional formatting tool to highlight duplicates. It was established 
that 170 of the 190 candidate genes (89%) were listed in the Whitmore et al data13, 
generated by sequencing RNA from temporal, macular and nasal regions of the 
retina. In contrast, only 63 and 73 of the candidate genes (33–38%) were listed in 
the 13K and 15K retinome gene lists10, respectively. These 13K and 15K 
retinal/RPE gene lists were compiled by meta-analysis of retinal datasets. Retinal 
gene expression could therefore not be used to eliminate candidates with 
confidence.  
In order to ascertain whether mutations in the same gene could be causative in 
more than one family, the Microsoft Excel software conditional formatting tool was 
used to highlight candidate gene duplicates between families. Four candidate genes 





was different (Table 5.2.2). Each variant was evaluated for allele frequency in ExAC 
Browser171 (accessed 16 June 2016).  
 
Table 5.2.2 Summary of the four candidate genes from the residual exome 
data, with variants in multiple families. The inheritance models applied, that resulted 
in selection of these genes, are listed in the gene column (ad, ar and/or xl).  


















































For each variant listed on ExAC, the majority of alleles were reported in the African 
population group. The allele counts of each of the ATPAF2, NIN and DNAH17 
variants given in the ExAC browser exceeded the recommended frequency centred 
threshold of 1/100,000 for an ad IRD gene78. In addition, the annotations for the 
gene ‘NBPF8,NBPF9’ were incomplete, and the chromosomal coordinates spanning 
these variants in families RPR 624 and RPD 799 revealed a non-coding gene in the 
region in Ensembl (http://www.ensembl.org/)169. Thus, no coding candidate gene 
was found to be causative in multiple families i.e. each family could have mutations 
in a unique IRD gene.  
In the absence of alternative strategies, the family with the least candidate variants 
was interrogated further. Four candidate variants (identified using an ad inheritance 
model) in family RPX 54 were evaluated and ultimately eliminated based on allele 
frequency data in the ExAC data171 (accessed 9 June 2016). These four variants 





(326/120,044 alleles, including five homozygous Africans), C1orf131 rs34759016 
(189/121,396 alleles, including one homozygous African), and PDHX rs61752925 
(236/120,694 alleles, including two homozygous Africans). A fifth variant was 
confirmed by cycle sequencing to be an indel in LGALS13, 
c.230_240delinsATTTACACTAT; p.(Thr77_Asp79delinsAsnLeuHis). PCR and cycle 
sequencing were performed using primers which amplified a 390bp fragment 
spanning exon 3 of LGALS13 [F: 5’ GTGTGTGTCTGCGCAAGG 3’; R: 5’ 
CCAGGGGCAGGAGTAGTTAT 3’], as described in Chapter 4.2, with the exception 
that the PCR annealing temperature was 60°C and 20pmols forward primer were 
used for the sequencing reaction. The LGALS13 variant was predicted (using 
Mutalyzer v.2.0.21173) to affect three consecutive amino acids; Thr77, Thr78 and 
Asp79 (Figure 5.2.1). However, the amino acid variants namely p.(Thr77Asn); 
p.(Thr78Leu) and p.(Asp79His) have been previously reported to occur in a 
mutation hotspot in a South African study of preterm labour and pre-eclampsia (with 
no record of retinal disease), and were identified in 30 individuals206. This variant 
was therefore deemed unlikely to cause IRD.  
 
  1 MSSLPVPYKL PVSLSVGSCV IIKGTPIHSF INDPQLQVDF YTDMDEDSDI AFRFRVHFGN 
 61 HVVMNRREFG IWMLEETTDY VPFEDGKQFE LCIYVHYNEY EIKVNGIRIY GFVHRIPPSF 
121 VKMVQVSRDI SLTSVCVCN* 
------------------------------------------------------------------ 
  1 MSSLPVPYKL PVSLSVGSCV IIKGTPIHSF INDPQLQVDF YTDMDEDSDI AFRFRVHFGN 
 61 HVVMNRREFG IWMLEENLHY VPFEDGKQFE LCIYVHYNEY EIKVNGIRIY GFVHRIPPSF 
121 VKMVQVSRDI SLTSVCVCN* 
Figure 5.2.1 The predicted alteration of the LGALS13 protein sequence due to 
the c.230_240delinsATTTACACTAT variant. The wild type sequence (top) highlighted 
in red is altered by the variant in family RPX 54 (bottom).  
 
Thus, family RPX 54 concluded with no candidate variants at the end of the analysis 
pipeline, raising concern that the causative variant had been incorrectly eliminated, 
or not captured. All five eliminated variants in family RPX 54 (above) had been 
filtered using an ad inheritance model, highlighting the possibility that an xl gene 
could be associated with IRD in this family. However, no candidates passed the 
prioritisation filters when an xl inheritance model was used. This prompted 







5.2.2 Supplementary analysis of RPGR ORF15 
Two challenges were faced in the analysis of residual WES data towards identifying 
novel genes involved in IRDs in our cohort. Firstly, one family had no candidates at 
the end of the analysis pipeline. Secondly, large numbers of candidates were 
present in the six remaining families. It was essential that mutations in the known 
IRD genes be excluded, prior to interrogating multiple variants to implicate (and 
prove) novel IRD candidates. Given the lack of male-to-male disease transmission 
in 5/7 unresolved families, the primary xlRP gene, RPGR, required further 
consideration.  
The RPGR gene was identified as causing xlRP in 1996207,208. Four years later, an 
RPGR transcript with a novel 3’ terminal exon, known as exon ‘open reading frame 
15’ (ORF15), was characterised209. ORF15 was reported as a mutational hotspot, 
accounting for the majority of xlRP cases studied. Multiple isoforms of RPGR exist, 
and the isoform containing ORF15 is the predominant transcript expressed in the 
retina209. ORF15 includes exon 15 and a portion of intron 15, and is comprised of a 
highly repetitive, low complexity, purine rich sequence. The nature of this sequence 
has been postulated to be responsible for the region’s high mutability, possibly by 
adopting unusual structural conformations, thereby reducing the replication 
fidelity209. Additionally, this genomic sequence generates technical challenges in 
molecular investigations.  
It has recently been shown that RPGR ORF15 is difficult to capture using NGS 
approaches due to the highly repetitive sequence therein, exceeding 1Kb in 
length210. Huang et al showed that ORF15 was insufficiently captured during NGS, 
causing false negative results. They therefore proposed that a complementary 
approach be taken in the molecular diagnosis of IRDs, with additional sequencing of 
targets like RPGR ORF15 which evade capture-based technologies210.  
It was evident that intron 15 (which forms part of ORF15) was not captured 
sufficiently in our WES data, when the .bam files of affected males from unresolved 
families were viewed using Integrative Genomics Viewer 
(https://www.broadinstitute.org/igv/) (Figure 5.2.2). Subsequently, data from affected 
males of each of the five unresolved potential xl families were interrogated to 
ascertain whether this genomic region was shared between relatives. Affected 





could potentially represent a family harbouring an RPGR ORF15 mutation that was 
not captured or covered by WES. 
 
 
Figure 5.2.2 A screenshot of the Integrative Genome Viewer profiles of .bam 
files in this study, showing the coverage across the RPGR gene. Grey peaks and 
corresponding blocks beneath them indicate covered regions. RPGR ORF15 includes exon 
15 (blue, bottom panel) and a portion of intron 15 which has not been captured.  
 
All variants on the X chromosome were extracted from the WES data (including 
intergenic, intronic, synonymous, upstream and downstream, ncRNA and UTR 
variants), using the following command on a PC running the UBUNTU LINUX 
operating system: 






A total of 39,480 X chromosome variants were identified in the total cohort. The 
129,158 bp region spanning the RPGR gene was then extracted, from chromosomal 
co-ordinates 38,080,739 to 38,209,897, and encompassed 64 variants. Affected 
males from the families of interest were manually inspected to determine whether 
the same ‘haplotype’ occurred in relatives, as determined by the presence of 
identical variants spanning a portion of the region. A single affected male from 
family RPD 55 had been subjected to WES, therefore no intra-familial comparison 
could be performed. The results of the five unresolved potential xl families are 
presented in Table 5.2.3.  
 
Table 5.2.3 Results of analysis of the genomic region encompassing RPGR in 
unresolved families with possible X-linked disease inheritance.  






variants shared by 
related males  
Size of the genomic 
region shared by 
related males (bp) 
RPX 54 3 29 41,320 
RPD 55 1 N/A N/A 
RPR 624 2 20 28,464 
RPD 1001 2 15 16,211 
RPD 1005 2 None None 
 
Only one family, RPD 1005, did not exhibit a shared genomic region around RPGR. 
The affected males in this family differed at 15 positions between chromosomal co-
ordinates 38,128,811 and 38,156,677. The family was therefore unlikely to carry an 
ORF15 mutation. However, the haplotype analysis indicated that ORF15 mutations 
could indeed be present in three unresolved families. Interestingly, the two affected 
males in family RPD 1001 had a stretch of variants in common with three affected 
males in family RPX 54, indicating this genomic region could be identical by 
descent. The final family had a single affected male subjected to WES therefore the 
possibility of an ORF15 mutation could not be excluded. 
The ORF15 region was therefore sequenced in an affected proband from each of 
four families (RPX 54, RPD 55, RPR 624 and RPD 1001). Due to the technical 
challenges of conventionally (i.e. Sanger) sequencing the region, this 
supplementary analysis was performed commercially (Asper Ophthalmics). Two 
mutations were identified in three families and no mutation was identified in the 





individuals from families RPX 54 and RPD 1001 each carried an identical mutation, 
namely c.2790_2791delGG; p.(Glu931Glyfs*147). The individual from family RPR 
624 carried a different mutation, namely c.2964_2965delGG; p.(Glu989Glyfs*89). 
The individual selected from family RPX 54 for ORF15 sequencing had previously 
been tested using the Asper xlRP microarray. In 2010, the xlRP microarray 
screened for 182 specific mutations in RP2 and RPGR, excluding the ORF15 
region. The c.2790_2791delGG mutation was therefore not detected at that time.    
Both mutations c.2790_2791delGG and c.2964_2965delGG were listed in LOVD 
(www.lovd.nl/)168, with variant numbers RPGR_00175 and RPGR_00314 
respectively, and each mutation had been previously associated with xlRP211,212. No 
population MAF data was presented for either mutation in Ensembl release 8 
(Ensembl transcript ENST00000378505.6, http://www.ensembl.org/)169 or the ExAC 
Browser171 (both accessed 31 October 2016). Using the corresponding mRNA NCBI 
Reference Sequence NM_001034853.1 in Mutalyzer v.2.0.21173, it was predicted 
that both deletions truncate the protein by 76 amino acids, although the frameshift 
length differs between them (Figure 5.2.3).    
The analysis of RPGR ORF15 to supplement the WES data thus resulted in 
identification of the probable causal mutation in three additional families (Figure 
5.2.4 A–C, presented on the three successive pages after Figure 5.2.3), thus 






   1  MREPEELMPD SGAVFTFGKS KFAENNPGKF WFKNDVPVHL SCGDEHSAVV TGNNKLYMFG 
  61  SNNWGQLGLG SKSAISKPTC VKALKPEKVK LAACGRNHTL VSTEGGNVYA TGGNNEGQLG 
 121  LGDTEERNTF HVISFFTSEH KIKQLSAGSN TSAALTEDGR LFMWGDNSEG QIGLKNVSNV 
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 301  SCGENHTALI TDIGLMYTFG DGRHGKLGLG LENFTNHFIP TLCSNFLRFI VKLVACGGCH 
 361  MVVFAAPHRG VAKEIEFDEI NDTCLSVATF LPYSSLTSGN VLQRTLSARM RRRERERSPD 
 421  SFSMRRTLPP IEGTLGLSAC FLPNSVFPRC SERNLQESVL SEQDLMQPEE PDYLLDEMTK 
 481  EAEIDNSSTV ESLGETTDIL NMTHIMSLNS NEKSLKLSPV QKQKKQQTIG ELTQDTALTE 
 541  NDDSDEYEEM SEMKEGKACK QHVSQGIFMT QPATTIEAFS DEEVEIPEEK EGAEDSKGNG 
 601  IEEQEVEANE ENVKVHGGRK EKTEILSDDL TDKAEVSEGK AKSVGEAEDG PEGRGDGTCE 
 661  EGSSGAEHWQ DEEREKGEKD KGRGEMERPG EGEKELAEKE EWKKRDGEEQ EQKEREQGHQ 
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1021  GRGGGRGGRR GGRRGRGRRG GRRRKGKGGG RRRKQEEQRR GGGRRGEVSG DRRRRE* 
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Figure 5.2.3 Mutalyzer protein predictions indicating the different amino acid 
frameshift lengths, but identical stop codon positions, generated by the 
c.2790_2791delGG; p.(Glu931Glyfs*147) (top) and c.2964_2965delGG; 
p.(Glu989Glyfs*89) (bottom) mutations in RPGR ORF15. The amino acid 
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Figure 5.2.4 Pedigrees of three families with RPGR ORF15 mutations. Squares represent males, and circles, females. Shaded symbols indicate 
individuals affected with IRD, and a question mark highlights subjects for whom the clinical status is unknown. Identifier codes show individuals from whom 
biological material is available, and those selected for WES are noted with an asterisk. The individuals indicated with an arrow were subjected to RPGR 
ORF15 sequencing; these persons in families RPD 54 (A) and RPD 1001 (B) each carry the c.2790_2791delGG mutation, whilst the individual in family RPR 






Family RPD 54 is large, and comprises what were originally deposited as three 
Xhosa nuclear families in the registry, and subsequently found to be related (as 
indicated in Table 2.3). Although RPD 1001 is also a Xhosa family, it appears 
unrelated to RPD 54, which is supported by the fact that these two families identify 
with different tribes/clans within the Xhosa ethnolinguistic group (self-reported by 
family members). The ethnolinguistic group of family RPR 624 was unknown. 
Clinical information was sparse for members of the three families. Within family 
RPD 54, affected males RPD 334.5MKH, RPX 54.3RON, and RPX 54.7LUM had a 
reported age of onset of three years, two years, and eight years, respectively, whilst 
RPX 54.8MZO was simply diagnosed with diffuse RP.  Within family RPD 1001, 
RPD 1001.2MLA also had diffuse RP, and RPD 1001.4BON had an age of onset of 
14 years. In the third family, RPR 624.3NTO was reported to have had diffuse RP 
from six years of age. He experienced a rapid deterioration of his vision until the age 
of 18 years, after which the disease was stable. By the age of 30 years his visual 
acuity was 20/200, bilaterally. Clinical detail was not available for any affected 
females in the pedigrees.  
 
5.2.3 Functional enrichment and pathway analysis of 144 
candidate genes 
Families RPD 55, RPD 94, RPD 799 and RPD 1005 remained unresolved 
(Appendix 5), and hence were enriched for novel gene discovery, with a total of 171 
candidate variants in 144 unique genes (Table 5.2.1). Of the 171 variants, 50 had 
no SNP ID and could perhaps be analysed in the first instance, however SNP IDs 
have been assigned to pathogenic mutations in population databases24,174,213 hence 
this approach could result in rejection of a true candidate.  
The 144 genes were compared to retinome datasets using the Microsoft Excel 
software conditional formatting tool to highlight duplicates. It was established that 
128 genes are expressed in the retina, according to the Whitmore et al data13 
whereas only 51 and 58 genes are listed in the 13K and 15K retinome gene lists10, 
respectively. A core set of 47 genes are listed in all three datasets, however 
restricting analysis to these genes could also have resulted in the exclusion of a true 
candidate.  
The most inclusive strategy for identification of novel IRD genes would be 





and inefficient approach. Therefore, in order to guide the future research, functional 
enrichment analysis was performed for all 144 genes using the WEB-based GEne 
SeT AnaLysis Toolkit (WebGestalt214,215 http://www.webgestalt.org/, accessed 9 
November 2016). WebGestalt organises and visualises gene sets by user-selected 
attributes, and reports categories within the input list that are significantly enriched 
compared to a reference gene set214. The organism of interest and input gene 
identifier types were specified as ‘Homo sapiens’ and ‘gene symbols’, respectively. 
The genes not initially recognised by the software were replaced with gene aliases 
until ultimately all but one (GOLGA8M) could be unambiguously mapped to Entrez 
genes. The reference gene set selected was the Homo sapiens genome (i.e. the 
entire Entrez gene list), and the remaining default selections were used, namely 
hypergeometric statistical method and Benjamini & Hochberg (BH) multiple test 
adjustment214. In order to provide a functional overview of the 143 input genes, the 
10 most enriched categories were chosen as output, rather than specifying a 
significance level215. The minimum number of genes per category was set to 1. The 
attributes selected for enrichment analysis were: disease, phenotype, pathways and 
gene ontology.  
No diseases pertinent to this study were enriched in the 143 genes. The top 10 
enriched disease categories included Brenner tumour of ovary, carcinoma, breast 
diseases, breast neoplasms, skin diseases, Alzheimers disease, and very-long-
chain acyl-coenzyme A dehydrogenase deficiency. Similarly, some of the enriched 
phenotypes were seemingly unrelated to this investigation, e.g. female 
hypogonadism and elevated alpha-fetoprotein. However some enriched phenotypes 
may be relevant for candidate prioritisation, namely (i) morphological abnormalities 
of the central nervous system, such as abnormal cortical gyration (n=4 genes) and 
microcephaly (n=9 genes); and (ii) abnormalities of cell physiology (n=5 genes) 
including carnitine metabolism and fatty-acid anion metabolism.  
For pathway enrichment analysis, three collections were selected within 
WebGestalt, namely KEGG pathways, Pathway Commons and WikiPathways. The 






Table 5.2.4 Summary of results of the WebGestalt pathway analysis, using the 
KEGG, Pathway Commons and WikiPathways collections. The top 10 enriched 
categories of genes are listed, together with the number of genes in each category.  
KEGG pathways Pathway Commons 
pathways 
Wikipathways 







LKB1 signalling events 
(n=13) 






Mitochondrial LC-fatty acid 
beta-oxidation (n=2) 










Ovarian infertility genes 
(n=2) 
Adherens junction (n=2) Glypican pathway 
(n=14) 
Synaptic vesicle pathway 
(n=2) 
Gastric acid secretion 
(n=2) 
Arf6 signalling events 
(n=13) 
Thyroxine (thyroid 





ErbB signalling pathway 
(n=2) 
Fatty acid metabolism 
(n=2) 
GMCSF-mediated 
signalling events (n=13) 
Fatty acid beta oxidation 
(n=2) 
Melanoma (n=2) Signalling events 
mediated by hepatocyte 
growth factor receptor 
(c-Met) (n=13) 
miRNAs involved in DNA 
damage response (n=1) 
 
None of the enriched pathways are connected to IRDs in an obvious way, however 
the 13 identical genes within the various signalling categories (Pathway Commons) 
may be of interest. Again, interpretation of these data is complicated by the 
heterogeneity of known IRD genes. Lastly, Gene Ontology (GO) enrichment 
analysis was performed in WebGestalt, yielding enriched categories of biological 
processes, molecular functions, and cellular components. The most applicable 
biological processes were: calcium-dependent cell-cell adhesion (n=3 genes), 
localization of cell (15 genes), centrosome-templated microtubule nucleation (n=1 
gene) and positive regulation of small GTPase mediated signal transduction (n=3 
genes). The most relevant molecular functions were: voltage-gated cation channel 
activity (n=4 genes) and protein tyrosine kinase activator activity (n=2 genes). The 
most pertinent enriched cellular components were the axoneme (n=4 genes), and 
cell projection (n=20 genes). Since it is not known whether the putative four novel 





together) these WebGestalt results should be interpreted with caution, and should 
not be used to eliminate candidates. Instead, enriched categories should 
complement future analysis, by providing additional information which may aid in the 
prioritisation of candidate genes. 
Finally, in order to ascertain whether any of the candidates interact directly with 
known IRD genes, RPGeNet v1.0216 (https://compgen.bio.ub.edu/RPGeNet/, 
accessed 11 November 2016) was used. RPGeNet is a searchable, web-based, 
RP-specific network, which integrates the gene and protein interaction data of 110 
RP/LCA genes. This ‘interactome database’ was searched for the most direct 
interactions of the 144 candidate genes, i.e. the distance to other nodes was set to 
1, and the interaction level to 0. These skeleton network settings were required for 
searching such a large number of candidate genes. Since ubiquitously expressed 
genes are implicated in IRD, the ‘absolute’ gene expression option (i.e level of 
expression in the retina) was selected, rather than the ‘relative’ option (i.e 
expression fold-change in retina versus the average expression in all tissues) for 
colour coding of results. When 144 genes were input simultaneously, only two direct 
interactions were identified: the candidate ATM interacts with the syndromic gene 
PANK2, and the candidate MPDZ interacts with CRB1 (Figure 5.2.5).  
In order to confirm the results, the 144 genes were input as smaller batches of 10. 
The same results were obtained (i.e. ATM and MPDZ were the only candidates 
interacting with known IRD genes) however six batches (i.e 60 genes) gave an error 
output. Furthermore, the same error was obtained for single genes in those batches, 
indicating that the candidate gene input names were not recognised, or the genes 
have no interactions at the specified interaction level. It should be noted that the 110 
RP/LCA gene “seeds” in RPGeNet do not represent a comprehensive list of all IRD 
genes. Furthermore, the application does not permit easy export of the results. 
Nevertheless, this is a useful tool for candidate prioritisation in the field of IRD 






Figure 5.2.5 Screenshots of the RPGeNet analysis output, showing the 
interaction of two candidates, ATM (A) and MPDZ (B) with known IRD genes. 
The results are portrayed as follows: gene expression is represented by the colour of the 
inner circle, with black representing null expression, and shades of yellow to green to blue 
as retinal expression level increases. RP/LCA “seed” genes e.g. CRB1 and PANK2, are 
highlighted by a violet border (squares indicate syndromic genes); orange borders represent 
genes with no interaction in RPGeNet; a gray border shows the gene interactions at level 0 
(skeleton network).  
  
5.2.4 Discussion 
At the end of this investigation, three families were identified with mutations in 
RPGR, and four (out of the original 16) families remain without a genetic diagnosis.  
Family RPX 54 concluded with no candidate variants after the analysis pipeline, 
highlighting a limitation in the WES approach. RPGR, a major IRD gene, is not 
captured adequately by this methodology due to the nature of its sequence 
(particularly in the ORF15 region). The mutation hotpot, ORF15, was found to be 
omitted in our data. This originally gave rise to a false-negative result for mutations 





Supplementary sequencing of this region identified two RPGR ORF15 mutations in 
three indigenous African families, an important finding in this study. Although the 
WES cohort was limited, and one family should likely be discounted due to a lack of 
clear IRD (RPD 401), this nevertheless indicates that ORF15 mutations account for 
as much as 3/15 (20%) of the indigenous African IRD cohort. Furthermore, when 
the RP2 mutation is included, 4/15 (~27%) of the families subjected to WES are, in 
fact, attributed to mutations in the xlRP genes. This relatively large fraction could be 
artifactually skewed, as technical challenges have largely prevented analysis of the 
ORF15 region, despite previous efforts in the Division of Human Genetics at UCT. 
However, the identification of the same c.2790_2791delGG; p.(Glu931Glyfs*147) 
mutation, on a shared haplotype, in two unrelated Xhosa families (albeit from 
different tribes/clans) implies that a founder effect may exist in SA, which could 
contribute to the burden of IRD disease.  
Both of the identified ORF15 mutations can be classified as pathogenic according to 
recently published guidelines174, as they: (i) are predicted null variants in a gene in 
which loss of function is a known mechanism of disease, (ii) probably result in a 
reduction of protein length, (iii) have been previously reported as pathogenic, (iv) 
occur in a known mutation hotspot, and (v) are absent from control databases. 
Nevertheless, variant co-segregation with disease should be confirmed in all 
available samples, in order to properly convert these three families into diagnostic 
mode in the translational programme. It is therefore recommended, for both 
research and diagnostic purposes, that an effort is made to overcome the technical 
challenges and perform RPGR ORF15 screening in local southern African 
populations.  
Understanding the challenges and limitations of NGS is essential for informed 
analysis and interpretation of research results, and drawing accurate conclusions 
from the findings217.  Awareness about which genes have been inadequately 
interrogated is important, particularly when negative results are obtained. In this 
particular instance, there was an initial misconception that RPGR could be excluded 
in the cohort, as no mutations were identified in the coding regions of this gene. The 
observation that ORF15 was insufficiently covered, was a crucial lesson in this 
study.  
The targeted capture NGS diagnostic reports issued by the Manchester Centre for 
Genomic Medicine (received through the UCT IRD translational research 
programme) specify that ORF15 has not been included in that analysis. Indeed, 





IRDs39,42,50,60. However, an approach has recently been put forward which permits 
NGS-based analysis of this region218. It was suggested that high-fidelity PCR of a 
2.1Kb region encompassing ORF15, followed by fragmentation and indexing of the 
PCR products and subsequent NGS, greatly improves the coverage of this region. 
The authors reported that 31% of cases which previously tested negative through 
various approaches (including targeted capture NGS and WES), were found with 
pathogenic ORF15 mutations using this technique218. It is therefore anticipated that 
the high-fidelity PCR step can be employed, and ORF15 thereby integrated into the 
design of IRD targeted capture NGS panels. However, should resource limitations 
prevent the implementation of IRD capture panels in SA, traditional sequencing 
technologies should be considered. Sanger sequencing of the ORF15 region 
requires particular PCR reagents and multiple reverse primers (personal 
communication with Dr SJ Bowne, The University of Texas HSC at Houston).  
Ultimately, mutations were identified in all but four families in the WES study cohort. 
For these four families, there remains the possibility that their causative gene is 
novel. However, the vast number of WES variants in each family, due to the genetic 
diversity of the indigenous African populations, resulted in a “bottleneck” in the 
identification of novel IRD candidate genes. This was further exacerbated by the 
marked complexity of the known molecular causes of IRDs, which limited the ability 
to efficiently exclude genes based on their tissue expression or biological function. It 
would appear that the most effective strategy moving forward would be evaluation of 
each of the candidate genes, in each family. To this end, prioritisation software such 
as ToppGene219 or ENDEAVOUR220 could be used to rank the genes containing the 
30 candidate variants in family RPD 55, 48 variants in RPD 94, 61 variants in RPD 
799 and 32 variants in RPD 1005, in turn. These tools require the user to submit a 
training set of genes (for example, all known RP genes or IRD genes), together with 
the list of candidate genes to be prioritised. The candidates are ultimately ranked 
according to their similarity to the training genes, based on specific functional 
annotations/attributes which are selected by the user. In addition, supporting 
evidence may be gained by classifying all the candidate variants of this study, 
based on their pathogenicity scores. Finally, these gene- and variant- level data 
should be interrogated in combination with the information obtained from 







Chapter 6. Discussion 
 
The considerable clinical and genetic heterogeneity displayed by IRDs confounds 
our understanding of the aetiology and pathophysiology of these conditions. 
Compelling clinical utility accompanies a genetic diagnosis, and major 
advancements have been made in gene-based therapeutic strategies. However, the 
molecular basis of IRDs in indigenous southern Africans has remained largely 
unexplored, due to challenges within the SA context, leading to recruitment bias and 
the use of testing strategies that had been constructed upon internationally-reported 
molecular findings in patients of European descent.  
The goal of the current investigation was to delineate the molecular basis of disease 
in the indigenous African population group, in a novel approach towards studying 
genetic contributions to IRDs. As part of this endeavour, NGS technology (namely 
WES) was applied to identify IRD mutations. This advanced genomic technology 
has significantly impacted the characterisation of Mendelian diseases, especially 
IRDs. It was anticipated that the examination of these heterogeneous disorders in 
such a genetically diverse population group (which has historically been 
underrepresented in genomic studies), would be challenging. Nonetheless, an 
additional aim of this study was to provide direct benefit to local families by 
developing diagnostic assays in order to facilitate their translation towards a 
molecular genetic service. Furthermore, the information gathered from this research 
would contribute towards the understanding of IRDs in SA.  
 
6.1 Summary of main results 
The general strategies and approaches employed in this research, and the results 
obtained, are summarised in Figure 6.1.  
In this study, mutations were identified in a novel IRD gene, IDH3A, which had not 
previously been linked to human retinal disease. In addition, pathologically relevant 






Figure 6.1 An illustration summarising the research strategy and the principal 
findings of this investigation. The general approaches are indicated in grey, stages of 
WES analysis are shown in dark blue hexagons, and screening strategies in light blue. The 
major findings obtained using each strategy are bulleted, with the number of resolved 
families highlighted in red (identified by WES) or green (identified by cascade screening).  
 
Overall, thirteen different causative mutations were identified in ten distinct IRD 
genes as a result of this investigation. Single mutations (homozygous in ar cases 
and heterozygous/hemizygous in ad/xl cases) were identified in all genes except 
ABCA4 and IDH3A, which each carried compound heterozygous mutations (i.e. in 
trans), and RPGR ORF15 which carried two different mutations. Importantly, as a 
result of this research project, 48 affected individuals, from 19 distinct families, 
acquired a new genetic diagnosis (Figure 6.2A and B).  
The strategy to use WES technology was extremely successful, as 11/15 (~73%) 
families in this cohort were resolved and the novel IRD gene (IDH3A) was identified 
in this portion of the project. This excludes the family in which a variant of interest, 
but unclear significance, was identified in AFG3L2. This particular family was not 





segregating within the family upon subsequent clinical re-evaluation. The AFG3L2 
variant is therefore not included in the calculations presented in this section.   
 
 
Figure 6.2(A) Map of South Africa illustrating the distribution of all affected 
individuals with IRD mutations identified during this study. Causative genes are 
represented in different colours, defined on the bottom of each map. The individual with the 
RPGR ORF15, c.2964_2965delGG mutation is differentiated from the two individuals with 
the RPGR ORF15 c.2790_2791delGG mutation, with an asterisk. Credit: Sr. G. Benefeld, 






Figure 6.2(B) Map of South Africa illustrating the distribution of distinct 
families with IRD mutations identified during this study. Causative genes are 
represented in different colours, defined on the bottom of each map. A single proband from 
each family is shown, to highlight identical mutations (in PDE6B, CERKL, MYO7A and 
RPGR ORF15) identified in unrelated families. The individual with the RPGR ORF15, 
c.2964_2965delGG mutation is differentiated from the two unrelated individuals with the 
RPGR ORF15 c.2790_2791delGG mutation, with an asterisk. Credit: Sr. G. Benefeld, 
Division of Human Genetics, University of Cape Town. 
 
Diagnostic assays were designed to: (a) facilitate rapid, sensitive and accurate 
testing for family members in the translational research programme, and (b) 
determine allele frequencies, and hence identify potential common mutations 
contributing to the burden of disease in SA. These assays, utilising either restriction 
enzyme digests or TaqMan technology, were designed to screen for eight of the 
mutations in larger cohorts of cases (an additional 137 or 193 unrelated, indigenous 
African IRD probands). Eight of the 19 families were diagnosed via this cascade 
screening, with their IRD attributed to the MYO7A, PDE6B or CERKL mutations. 
However, neither of the two ABCA4 mutations, nor the RHO, PRPF3 or PRPF31 
mutation was detected in any additional families. This observation raised the 
question of whether such cascade screening for any given mutation, simply by 





effective method (or an efficient use of resources). Thus, due to time constraints 
and cost considerations, and in order to channel research efforts optimally, assays 
were not designed to screen for the remaining five causative mutations in larger 
case cohorts.  
Although screening assays were not specifically designed for the remaining five 
mutations, a majority (11/13) of mutations were validated by cycle sequencing, 
therefore these sequencing experiments have been optimised for any future 
diagnostic tests requested by relatives. The exceptions are the two RPGR ORF15 
mutations, where the repetitive, low complexity nucleotide sequence presents 
significant technical challenges to any PCR-based analysis. It has been suggested 
that Sanger sequencing validation of NGS variants with robust quality scores may 
be unnecessary, because it limits the high-throughput nature of NGS technology221. 
Beck et al have questioned the utility of this practice, particularly since they found 
17 NGS variants that were incorrectly called by a single round of Sanger 
sequencing in their study. However, cycle sequencing remains the gold-standard, 
serving the dual purpose of validation and the co-segregation analysis of variants, to 
establish pathogenicity. In this study, cycle sequencing was performed since many 
of the mutations detected were novel, and required confirmation of co-segregation 






6.2 Research perspectives and implications of 
findings 
 
6.2.1 Genetic basis of IRDs in Africans 
The findings of this ‘pilot’ study have made a significant impact towards elucidating 
the genetic landscape of IRD among the indigenous African populations of SA. At 
the time this project was initiated in 2014, 271 families (19%) in the IRD registry at 
UCT were of indigenous African ethic origin. Only 20 of these families (n=20/271, 
~7%) were in diagnostic mode, having had their full complement of pathogenic 
mutations identified (Table 2.1). The causative genes in these previously diagnosed 
families were identified by reviewing the registry. These 10 causative genes were: 
ABCA4 (n=4 families diagnosed), BBS10 (n=5), MYO7A (n=2), RHO (n=3); CDH23, 
CRB1, PCDH15, RP2, TOPORS, and USH2A (n=1 family diagnosed with each 
gene).  
The present study identified additional mutations in ABCA4, RP2 and RHO in the 
local population, and implicated six IRD genes for the first time in indigenous 
Africans (PRPF3, PRPF31, CERKL, PDE6B, IDH3A and RPGR). This project has 
therefore almost doubled the number of indigenous African families with a molecular 
diagnosis in the UCT IRD registry, from 20 to 39 families. 
Only one founder mutation had previously been associated with an IRD phenotype 
in this population group, BBS10 c.728_731delAAGA, which causes BBS118. Founder 
mutations are important as: (i) the presence of numerous patients with the same 
causative mutation can facilitate research into the penetrance and genetic modifiers 
of disease, (ii) these mutations may be a major cause of disease, thus targeted 
testing along population lineages may be an efficient diagnostic strategy, and (iii) 
the presence of a founder mutation in different populations may be an indication of 
relatedness (i.e. the sharing of an identical segment of DNA, by descent)120. The 
research efforts of this study have revealed another founder mutation associated 
with syndromic IRD, namely MYO7A c.6377delC, which accounts for a large 
proportion (43%) of the USH cases in SA. Intriguingly, this USH founder mutation 
occurs in indigenous Africans of different ethnolinguistic groups, reflecting 





screening of this mutation is a cost-effective enhancement to the diagnostic service 
in the country,  
The c.6377delC MYO7A mutation had been reported previously222, as had the 
PDE6B c.1860delC mutation223 and two RPGR mutations, c.2790_2791delGG and 
c.2964_2965delGG211,212, identified during this study. The remaining nine IRD 
mutations (~70%) were novel, explaining the low detection rate of Asper 
microarrays (testing ‘Eurocentric’ mutations) when applied to this group of patients. 
NGS approaches have detected novel IRD mutations to differing degrees in various 
population groups. Novel IRD mutations comprise ~30–60% of those identified in 
the UK and European populations32,40,42,44,60,224, and 60% in the USA, including the 
Hispanic population41,225. In contrast, 67% and 76% of IRD mutations are novel in 
Chinese46 and Thai47 populations, respectively. Hence, the value of studying 
different populations (i.e. divergent from USA, UK and European populations) is 
clear, particularly for cataloguing novel IRD mutations and for understanding IRD in 
humans of all ethnic origins. 
In 2016, Ellingford et al reported that, when the Manchester NGS panel of 105 IRD 
genes was applied to patients referred from institutions worldwide, 52% of identified 
mutations were not reported in databases39. This large, international cohort (n=537 
individuals) provides a useful resource for comparison with our study, although the 
indigenous African WES cohort is small (n=16 families) and the majority of families 
in the UCT registry have not been comprehensively screened. The findings 
presented immediately hereunder should thus be extrapolated with caution.  
The summary of the Manchester group’s results revealed that, although 402 
causative IRD mutations had been identified, overall the most common variant was 
CERKL c.375C>G; p.(Cys125Trp)39. This particular CERKL mutation was not 
identified in the African cohort, however the proximal mutation c.365T>G; 
p.(Leu122Arg) was identified in four unrelated homozygous probands (4/19 families, 
21% of families characterised in this present study; 4/39 families, 10% of all 
characterised indigenous African families to date). Other findings also support the 
emerging picture of a dissimilar IRD mutation profile in indigenous Africans. It was 
reported that, within a single clinical category, the most frequent IRD-related genes 
identified using the Manchester panel were EYS for ar cone-rod dystrophy/RP and 
RHO for ad cone-rod dystrophy/RP39. In South Africa, it appears that (as well as the 
previously reported BBS mutation), mutations in MYO7A, ABCA4 and RHO are the 
most frequent in causing USH (six families; four identified by screening in this 





by this WES study and four already in the registry) and adRP (four families; one 
characterised by this WES study and three already in the registry), respectively. In 
Manchester, the most common mutations are missense variants (n=137/311, 44%), 
followed by nonsense variants (n=76/311, 24%) and frameshift insertion/deletion 
events (54/311, 17%). In contrast, in the 39 indigenous South African families 
resolved to date, 46% of mutations are missense (n=19/41 mutations), and a 
comparable proportion i.e. 41% of mutations (n=17/41 mutations) are frameshift 
insertion/deletion events, whilst 10% (n=4/41) mutations are nonsense variants. 
These figures are likely to have been impacted by the frameshift insertion/deletion 
mutations in BBS10, MYO7A and PDE6B, which each occur in several families.  
It was interesting that four families in the WES cohort (n=4/15; 26%) were attributed 
to mutations in the known xl genes, RP2 and RPGR. Technical challenges have 
largely prevented analysis of the ORF15 region in the Division of Human Genetics 
at UCT, therefore this high percentage may be artefactual. Nevertheless, with 
affected females manifesting in 3/4 families (RPD 54, RPD 1001, and RP 583), an xl 
mode of inheritance was not initially expected. Also surprising, was the identification 
of two unrelated Xhosa families (from different clans/tribes) with the same 
c.2790_2791delGG mutation, on a shared haplotype spanning RPGR ORF15. This 
suggests that this particular mutation may occur frequently in the local population 
therefore, in this particular case, cascade screening of a larger cohort may be 
warranted. 
The WES data generated by this project provided additional information of general 
interest. A total of 1,816,031 variants were detected in 56 individuals. The 
description of these variants is presented in Table 6.1.  
 
Table 6.1 Categories of ~1.8M variants identified in the exome sequencing 
data of 56 indigenous Africans. 
Category Number Percentage of total (%) 
Intergenic 759,459 41.82 
Intronic (including ncRNA) 710,303 39.11 
3’ UTR/5’ UTR 148,210 8.16 
Exonic 129,631 7.14 
ncRNA (excluding intronic ncRNA) 33,418 1.84 
Upstream/downstream 33,660 1.85 






Approximately 7.2% of all genetic variation detected in the African exomes occurred 
within gene exons and splice regions. Detailed examination of the genetic variation 
in each of these 56 exomes, and comparison with the exomes of individuals from 
other population groups exceeded the scope of this study. Furthermore, to the best 
of our knowledge, most genomic studies in Africans involve genome-wide 
genotyping105,109,111,116,226,227, NGS analysis in African populations which are different 
from those in our study228–230, or very low coverage (4x) whole genome sequencing 
in relevant population groups115. The only publication reporting exome data from a 
“Bantu-speaking” individual, namely Archbishop Emeritus Desmond Tutu104, which 
might be compared with the 56 exomes, focussed on SNPs. However, it is noted 
that the number of filtered (high priority) exome variants in the present research 
cohort exceeds that reported by Weisschuh et al in 201660. In a largely European 
cohort, their WES analysis pipeline identified 100–150 variants per dominant family 
that were rare, potentially pathogenic and shared by two family members, thereby 
making the prioritisation of novel IRD candidate genes challenging60. In the present 
South African study, the five dominant families unresolved after the examination of 
IRD genes and ERDC genes, had on average 380 such variants (Table 5.2.1), more 
than two fold the reported figure. A minor number of xl variants are included in this 
number, however more relatives were included per family which reduced the 
number of variants co-segregating with disease.  
Notwithstanding genomic diversity impeding the identification of further novel IRD 
genes, this study has several important implications for all the families which have 
been resolved. Members of these families can request genetic testing in order to 
confirm a clinical diagnosis, or determine carrier status. In addition, predictive 
testing and reproductive options231 may be possible. Importantly, these patients may 
now be eligible for participation in gene-based therapy clinical trials 
(https://clinicaltrials.gov/ct2/home)25,232, which is generally impossible in the absence 
of a genetic diagnosis. Of particular relevance are the lentiviral vector constructs 
being tested in humans to replace MYO7A and ABCA4, namely USHstat 
(ClinicalTrials.gov identifier NCT01505062)233, and Stargen  (ClinicalTrials.gov 
identifier NCT01367444)234, respectively. Preclinical studies have also shown 
success for RPGR177,235 and RP2184 gene replacement, therefore human clinical 
trials are anticipated. In the aforementioned cases, haploinsufficiency is generally 
the cause of IRD and supplementation of the wild type gene ameliorates disease 
progression. However, for dominant negative mutations or toxic gain-of-function 





silencing, and many such suppression and replacement approaches are being 
investigated232,236,237. It should be noted that there are currently many additional 
treatments for IRDs being investigated, which are not gene-specific, for instance 
stem-cell transplants238, and optogenetic sensory replacement to confer light 
sensitivity to other cells in the photoreceptor-deprived retina239.  
 
6.2.2 Genotype – phenotype observations 
Several interesting genotype-phenotype associations were noted during this 
investigation. For example, 60% of the MYO7A cases were clinically diagnosed with 
Type 2 USH, a less severe form of disease than the Type 1 USH which this gene is 
usually associated with.  
The phenotypes associated with RHO, PRPF3, PRPF31 (i.e. adRP) and ABCA4 
(i.e. MD) were as expected. However, observations were made regarding the 
phenotypes of the patients in our cohort with PDE6B and CERKL mutations. The 
mutations in each of these genes were initially identified through WES analysis, and 
subsequently detected in additional probands by TaqMan screening. The CERKL 
c.365T>G mutation was ultimately identified in four homozygous probands with 
different IRD phenotypes (i.e. two arRP, one sporadic RP, and one sporadic STGD). 
This particular variant was also identified in the heterozygous state in one proband 
with RP, whose mother apparently had vision problems (however no biological 
material or clinical data was available for the mother). CERKL is reportedly 
associated with ar forms of cone dystrophy, cone-rod dystrophy and RP (RetNet, 
https://sph.uth.edu/retnet/). It was thus somewhat surprising that an identical 
mutation resulted in distinct phenotypes in the various South African patients. The 
varying clinical diagnoses in the homozygous probands may be attributed to 
modifier effects or different stages of disease at the time of diagnosis. In the 
heterozygous case several possible explanations exist: (1) the CERKL mutation 
may be co-incidental with a mutation in a different (ad) gene; (2) a second 
heterozygous mutation exists in CERKL, and different compound heterozygous 
mutations within CERKL have resulted in the successive generations manifesting 
with disease; or (3) the observation regarding the mother’s vision is misleading and 
she does not suffer from IRD. Overall, the PDE6B mutation was identified in two 
homozygous probands (with arRP) and four heterozygous probands (i.e. two 
sporadic RP cases, one arRP case, and one individual with an apparent adRP 





CSNB and arRP240. CSNB is phenotypically similar to early stage arRP, as rod 
photoreceptor dysfunction causes nightblindness; however, rod apoptosis does not 
occur in CSNB as with arRP. The mutations resulting in arRP are thus presumed to 
be due to a complete loss of enzyme activity, causing elevated cGMP levels and 
subsequent rod photoreceptor apoptosis. Conversely, mutations producing the 
CSNB phenotype result in constitutive activation of PDE6 and consequently rod 
photoreceptor desensitisation240. No mutations in PDE6B have been associated with 
adRP, to date241. Hence, the proband with an apparent dominant family history is 
probably carrying the heterozygous mutation coincidentally as it appears to be 
relatively frequent in the affected indigenous Africans (n=8/418 alleles; 1.9%). The 
remaining three heterozygous mutation carriers (2 sporadic RP; 1 arRP) might 
harbour a mutation in the alternate allele of the gene.  
It was remarkable that three of the four families with mutations in xl genes did not 
display a conventional xl inheritance pattern in their pedigrees, but contained 
affected females. This is a well-known phenomenon with RPGR mutations, however 
to the best of our knowledge only one other family with semi-dominant RP due to an 
RP2 mutation has been reported143. Many individuals in the South African family 
with an RP2 mutation had cataracts, and most of the affected females (n=4/5) who 
were clinically examined did not match the Grover et al classification for manifesting 
female carriers140. 
The phenotype associated with the novel IRD gene, IDH3A, appears to be 
correlated to genotype, in so far as patients with arRP and coloboma-like atrophy of 
the macula carried a null variant, whereas patients with missense variants present 
with classic arRP (manuscript accepted 3 March 2017, Ophthalmology, the journal 
of the American Academy of Ophthalmology). However, intrafamilial phenotypic 
variability has been noted. Furthermore, the first occurrence of a recessive mutation 
in the IDH3A gene was reported very recently242, and was associated with severe 
encephalopathy in an infant of North-African-Jewish ancestry. The clinical 
manifestations of the child included retinitis pigmentosa and bilateral optic atrophy, 
amongst other nervous system defects. To the best of our knowledge the seven 
patients (four families) identified via the ERDC collaboration and this infant with 
encephalopathy represent the first cases of human disease linked to IDH3A. 
Identification of additional cases with recessive IDH3A mutations may provide more 
information surrounding the phenotype(s) associated with this gene.  
Finally, the identification of a missense variant in AFG3L2, in a mother with RP and 





did not display segregation of a clear, single, Mendelian IRD. Functional studies are 
required to assess whether this variant is pathological. If shown to cause disease, 
this would extend the phenotypic spectrum associated with this gene. Mutations in 
AFG3L2 have previously been linked with SCA28, progressive myoclonus epilepsy; 
spastic ataxia neuropathy and DOA, but not with RP or thyroid eye disease.  
In conclusion, we hypothesise that IRD phenotypes observed in the indigenous 
Africans, with their vastly different genetic and environmental landscape may, in 
some cases, be distinct from those described in mostly Caucasian patients in the 
literature. 
 
6.2.3 Genetic screening approaches in indigenous Africans  
During the course of this investigation, Van Huet et al reported a low efficacy of the 
Asper Ophthalmics (http://www.asperbio.com/asper-ophthalmics) arRP APEX 
microarray in a European cohort243, confirming the premise of our study. The 
microarray solved only ~9% of a large cohort of 250 European probands with arRP, 
corresponding to the detection rates of 7% Caucasians and 13% indigenous 
Africans in SA (although the local cohort was smaller, Table 2.2) using the same 
array. They ascribed this low efficacy to several reasons, which would equally 
explain the overall poor yield of this technology in indigenous African samples, 
namely: (1) The microarrays test only for specific sets of reported mutations, which 
have primarily been identified in patients of European ancestry; (2) the microarrays 
are not comprehensive, as they are not updated frequently and do not contain rare 
mutations and genes; (3) the clinical and genetic heterogeneity of IRDs mean that 
an inappropriate microarray might be selected for use in a given proband; and (4) 
older versions of microarrays contained benign variants, thereby reducing their 
capacity243. In this analysis, WES (and supplementary RPGR ORF screening) 
solved 73% of the indigenous African families with IRDs, a vast improvement over 
our previous success rate of 13% using arrays, thereby confirming the superiority of 
NGS approaches. 
Prior reports indicated that known IRD genes account for only 50–70% of diagnosed 
cases24.  Since the genomic portraits of global populations differ significantly from 
each other, the contribution of known IRD genes to the burden of disease in 
indigenous Africans was previously unknown, hence WES was the method of 
choice for this study. It was established that 10/15 (~67%) of the local cases were 





and one family was characterised with a novel IRD gene. Considering RPGR ORF 
15 is not captured in targeted panels, it is likely that 7/15 (~47%) of the South 
African families would have been identified, had they been screened using a panel-
based approach, with targeted enrichment of known IRD genes. This is only slightly 
lower than the 51–57% panel diagnostic rate published by several groups in the last 
year39,50,51. 
In their review of the Manchester panel, Ellingford et al reported a trend that ‘newly 
identified genes are becoming increasingly rarer causes’ of IRD, with 79% of 
diagnosed cases attributed to genes discovered between 1995 and 200439. They 
suggested that more extensive analysis of known IRD genes, for example for deep-
intronic or copy number variants, might further impact the diagnostic yield. The use 
of targeted IRD panels rather than WES has also been advocated by Consugar et 
al50. In a direct, empiric, comparison of panel vs WES for four samples, they 
reported that WES was ~10% less sensitive, due to less efficient coverage of key 
genomic positions. They thus indicated that probe design in panels was improved, 
compared to the probes used in commercial exome capture kits, resulting in 
increased and more uniform coverage. Other advantages of panels were described, 
namely: (1) reduced turnaround time, (2) increased probability of a meaningful 
result, and (3) reduced possibility of incidental findings50. Souzeau et al have 
recently presented the ethical considerations surrounding the return of incidental 
findings in ophthalmic genetic research244, and in terms of practicalities, important 
points were raised. Notably, most research laboratories are not accredited nor 
equipped to report incidental findings, as “researchers often have a lack of expertise 
for results or conditions that are outside of their scope of research” and “the 
requirements for the return of incidental findings….put an unsustainable burden on 
the research enterprise”244.  
Although WES has significant advantages over panels in a pure research arena, 
and allows re-analysis of data as novel genes are reported, the filtering of large 
amounts of this data in order to isolate a causative mutation remains the primary 
challenge. This challenge in the current study in particular, was exacerbated with 
the indigenous African samples. Both targeted IRD panels and WES can detect 
novel mutations in reported genes, as well as mutations in unexpected IRD genes245 
(outside of the known genotype-phenotype relationships). Therefore, perhaps a two-
tiered approach, as suggested by Carrigan et al51 should be employed for 
indigenous African IRD sufferers in the translational research programme in SA. If 





number of families requiring WES by as much as 50%. However, the design of such 
panels requires careful consideration, whether to include deep intronic mutations 
known to cause IRDs39,50, and whether to include syndromic genes, as hypomorphic 
mutations of these genes could result in a milder phenotype of IRD without extra-
ocular symptoms41. In addition, targeted enrichment probes would still not capture 
GC rich sequences with repetitive elements like RPGR ORF1550, and this region, in 
particular, would require supplementary analysis218 in SA.  
 
6.3 Study limitations  
The small size of the WES cohort (n=16 families) was constrained by the selection 
criteria that were applied. A larger cohort would have been preferable for evaluating 
the WES findings and extrapolating these results as putative trends in the molecular 
basis of indigenous African IRDs. 
It is also important to note that there are several reasons true causative mutations 
could have been missed during WES analysis, which may be relevant to the four 
unresolved families that remain.  
Beginning with the laboratory experiment, WES kits do not actually capture all the 
exons of all known genes and are biased against GC rich regions27. Although 92–
95% of exons are captured27, several known IRD genes have been reported with 
low coverage of particular exons due to the sequence GC content, for example 
IMPDH1 exon 1, PEX7 exon 1, PITPNM3 exon 1, FLVCR1 exon 1, RP9 exon 1, 
CHM exon 542, and RPGR ORF15210.  There are particular types of mutations which 
are not detected by WES, such as deep intronic mutations, for example CEP290 
c.2991+1655A>G, a frequent cause of LCA246–248. In addition, during the alignment 
stage of WES, if an indel occurs, the entire read is discarded as it does not align to 
the human reference sequence, thus large genomic alterations are not detected 
using this technique249,250. For example, a 356bp Alu repeat insertion in the MAK 
gene (associated with RP) is missed by variant callers and detection of this 
recurrent mutation  requires analysis of raw sequence reads250. Approximately 7% 
of mutations listed in HGMD are large indels, repeats or complex rearrangements250.  
It is known that deletions of PRPF31 are responsible for ~3% of adRP, and ABCA4 
and RPGR deletions have also been identified175. Furthermore, in 2016, Khateb et 
al performed manual coverage analysis of IRD gene exons captured by WES, and 
determined that 10% of IRD cases had large homozygous or hemizygous 





many as seven consecutive genes on the X chromosome. The finding that copy 
number variants (CNVs) contribute significantly to the missing heritability of IRDs 
was supported by Bujakowska et al, who identified large deletions of IRD genes in 
18% of the cases that were not solved by NGS approaches, ~7% of IRD cases 
overall, and further identifying 35 known IRD genes may be prone to non-allelic 
homologous recombination thus representing CNV hotspots252. 
True mutations may also have been eliminated during almost any stage of the WES 
candidate prioritisation pipeline. In extracting certain sets of genes, e.g. known IRD 
genes, from WES data the possibility of gene aliases in either dataset is 
problematic, as relevant data may not have been retrieved. Pathogenicity prediction 
thresholds may also have been too stringent. The identification of low MAF variants 
may also introduce errors; during initiation of their bioinformatics pipeline, Crowgey 
et al noted that, for several alleles, the hg19 human reference genome used for 
alignment actually contained the minor allele253. This is an issue, particularly with 
understudied populations, as the true minor allele is filtered out because it is 
reported “in the 96–100% range rather than the expected 0–4%”253. Variant 
prioritisation based on cosegregation might fail if: (1) the incorrect inheritance 
pattern is assumed, (2) genetic mosaicism results in an allelic imbalance249,253, or (3) 
digenic inheritance is the cause of disease254. It is therefore possible that mutations 
in reported IRD genes are in fact, causal in the four remaining families.  
 
6.4 Future research 
This research project has identified several avenues for future exploration. Primarily, 
there are four families outstanding, which should be analysed further. This may 
involve prioritisation tools such as TOPPGENE, as described in Chapter 5.2. 
Though reported IRD genes display a wide range of functions, about 15% of IRD 
genes (the largest category) are those involved in photoreceptor ciliary 
functioning7,65,255, therefore these genes might be considered first, within the four 
families.  
Alternatively, approaches could be taken to either screen for known indels, like the 
Alu repeat in MAK250, or to attempt to leverage the WES data to detect CNVs. The 
latter may be challenging; several tools have been developed for CNV detection in 
WES data, (e.g. ExomeCNV, CoNIFER, cnvOffSeq, ExomeDepth, and CEQer), 
however, Khateb et al relied on a manual approach to detect CNVs, as many tools 





in numerous false-positives. Furthermore, read depth aberrations from different 
WES batches suggests that larger numbers of (unrelated) samples, or larger batch 
sizes should be used for CNV analysis256, and the 16 families of this study may be 
insufficient. Thus, a better approach might be to generate array-based comparative 
genomic hybridisation (array CGH) data for the four families, to combine with the 
existing WES data. Van Cauwenbergh and colleagues in Belgium, for example, 
have recently designed a customised array CGH platform, arrEYE, for CNV analysis 
of IRD genes257.  
There are several additional findings from this study which may form the basis of 
new research investigations. RPGR ORF15 warrants screening, using either 
traditional or NGS approaches, in IRD patients of all ethnic origins in SA and this 
should not be limited to families with an obvious xl inheritance pattern. Also related 
to xlRP, the WES data from the semi-dominant family with an RP2 mutation may be 
interrogated to identify disease modifiers to explain the disease manifestation in 
females. These modifiers may segregate with the RP2 mutation in this family, given 
the number of affected females observed. Hence, all variants on the X chromosome 
in the affected males could be analysed, extending outwards (5’ and 3’ directions) 
from the c.704C>A; p.(S235*) mutation. The modifiers may affect CpG islands, or 
genes interacting with RP2, to effect a consistently skewed X-inactivation in retinal 
cells.  
Functional analysis of AFG3L2 is recommended, to ascertain whether the variant 
identified in this study is pathogenic. This variant may affect the interaction of this 
m-AAA protease with a retinal substrate, or it could be a mild mutation which only 
meets retinal-specific thresholds for disease (i.e. is not pathological in other 
tissues).  
Finally, the novel IRD gene, IDH3A, should be screened in large cohorts of patients 
(not restricted to SA) to determine the contribution towards disease, therefore the 
gene should be included in IRD targeted capture panels. Understanding the 






6.5 Conclusion and recommendations  
In conclusion, this study has provided new insights into the genetic profile of IRDs in 
the South African population. Whilst common causative mutations do occur in 
indigenous Africans, in general each family harbours unique mutations. It is thus 
recommended that APEX microarrays should no longer be used to characterise the 
mutations causing IRD in these patients. The majority of causative mutations in this 
population group are novel, and therefore are not detected using this technique. 
Since most mutations do occur in reported IRD genes, resources should instead be 
directed towards NGS approaches, either WES or targeted capture panels, which 
are likely to identify approximately 50% of local cases. Additional cases will almost 
certainly be diagnosed if supplementary RPGR screening is performed. 
Furthermore, cascade screening of specific mutations should only be implemented 
in indigenous African case cohorts if at least two unrelated probands are identified 
with an identical mutation; although founder mutations can contribute significantly to 
IRDs, screening for a given mutation by virtue of the fact it was detected in a single 
patient, is inefficient.  
An important lesson learnt from this study, which is applicable to IRD researchers 
globally, is that with all NGS analysis the xl genes should be considered, regardless 
of the perceived mode of inheritance in a family.  
The strategies employed, and outcomes of this work, have significant implications 
for stakeholders in Africa. Specifically, these findings are important to those initiating 
IRD research (or diagnostic services) in other African countries. Furthermore this 
approach may be useful to those interested in examining other heritable disabilities 
on the continent.  
Finally, the importance of including African populations in genomic research cannot 
be overstated. Research in Africa has its’ challenges, including lack of resources, 
logistical obstacles and language/geographic barriers. However, unless this bias is 
addressed, and diverse genomes are better represented in medical studies, 
inequalities in precision medicine and human health will remain unaddressed. 
Mutation- and gene- discoveries in diverse populations may lead to improved 
understanding of disease mechanisms and novel therapeutics. African populations, 
and African scientists, play an important role in this endeavour, and the body of 
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REQUEST FOR MOLECULAR STUDIES FORM 
 
GENETICS OF RETINAL DEGENERATIVE DISORDERS 
DIVISION OF HUMAN GENETICS, WERNHER & BEIT NORTH  
FACULTY OF HEALTH SCIENCES, UNIVERSITY OF CAPE TOWN, OBSERVATORY, 7925 




SURNAME:   ___________________________    NAME: ________________________________ 
               















TEL: …………………...    FAX: …………………… E-mail ……………………………………………. 
 
REFERRAL SOURCE 
PLEASE NOTE: A confirmation of diagnosis (COD) form is required to accompany all samples. 
This separate form needs to be completed by an Ophthalmologist and can be faxed separately.  
 
NAME OF REFERRING DOCTOR: ______________ REFERRING FACILITY:________________ 
 




REASON FOR REFERRAL  (CLINICAL DIAGNOSIS) 
 
AFFECTED -           AT RISK -           CARRIER -           SPOUSE -        UNAFFECTED -  
 
RETINITIS   PIGMENTOSA   USHER SYNDROME            DOMINANT INHERITANCE     
STARGARDT DISEASE         MACULAR DYSTROPHY       RECESSIVE INHERITANCE       
ARMD – WET                         ARMD – DRY                       X-LINKED INHERITANCE       
OTHER DISORDER: AGE OF ONSET: ISOLATED CASE                      
DIAGNOSIS AGE: 
 
FAMILY HISTORY INFORMATION 
ADDITIONAL FAMILY HISTORY __________________________      
 
ADDITIONAL DISORDERS (APPARENT OR PREVIOUSLY TREATED): 
______________________ 
RELEVANT CLINICAL DETAILS: _______________________________________________________ 
 
PHYSICAL DISABILITY-      INTELLECTUAL DISABILITY-       DEAFNESS -      IMPAIRED VISION -         
NIGHT BLINDNESS -   AGE OF ONSET: ___________     OTHER:  ____________________________         




PEDIGREE/ FAMILY TREE (If more extensive, please use a separate page) 
 
Maternal Ethnicity/ Genetic Origin:______________ 






Have samples from this patient been sent to a DNA lab before? Yes -    No -    Don't Know - .   
 




Have samples from other family members previously been sent to a DNA lab for genetic 
ophthalmic disease testing?  Yes -       No -       Unsure - .  
 
If “Yes”: Name of lab:_____________________________Mutation identified:_________________ 
 
 
RETINA SA MEMBERSHIP 
 
This is not a requirement, but is necessary information to assist us with our database.  
 
Are you currently a Retina SA member?    Yes -       No -                                       
 








ABCA4 Quick 7 -                             “Asper Chip” -  Specify_________________  
 





For Laboratory use only: DNA number: ___________________  Vol.Blood:__________ (ml)            
 












SPECIMEN TUBES REQUIRED: 2x 4ml Plastic purple top tubes (containing EDTA)  
NAME AND DATE OF BIRTH TO BE ON EACH TUBE 
BLOODS ARE TO BE KEPT REFRIGERATED.  SPECIMENS ARE TO BE CAREFULLY 
PACKAGED AND TRANSPORTED IN A POLYSTYRENE COOLBOX WITH AN ICE BRICK.  DO 
NOT FREEZE. 
BLOODS ARE CODED ON ARRIVAL IN THE LABORATORY ACCORDING TO FAMILY NAME 
WHEN AVAILABLE, RESULTS ARE GIVEN TO PARTICIPANTS ACCORDING TO AN 
ESTABLISHED PROTOCOL 
   
CONSENT FORM REQUIRED FOR DNA ANALYSIS AND STORAGE 
GENETICS OF RETINAL DEGENERATIVE DISORDERS 
 
PLEASE DELETE DETAILS THAT ARE NOT APPLICABLE: 
 
1.    I, ______________________________________, request that an attempt be made using genetic 
material to assess the probability that, I / my child / my unborn child, might have inherited a disease-causing 
mutation in the gene for: (Name of Disorder): 
 
2.   I understand that the genetic material for analysis is to be obtained from:  
blood cells / skin sample  / other (specify)  
 
3.   I request that no portion of the sample be stored for later use.                    (MARK IF APPLICABLE) 
  
OR I request that a portion of the sample be stored indefinitely for:(DELETE WHERE NOT APPLICABLE)      
 (a) Possible re-analysis 
 (b) Analysis for the benefit of members of my immediate family 
 (c) Research purposes, subject to the approval of the University of Cape Town Human Research Ethics 
Committee, provided that any information from such research will remain confidential   
 
4.   Regarding the results of any current and future analysis carried out on this sample of stored biological 
material: only meaningful results that have clear diagnostic implications will be made known to me, via my 
doctor, in accordance with the relevant protocol, if and when available. In addition, I authorise that these 
results may be made known to: (DELETE WHERE NOT APPLICABLE) 
 
      Doctor/Family member/Friend: ______________________________________________ 
 
5.   I authorise / do not authorise my doctor(s) to provide relevant clinical details to the Division of Human 
Genetics, UCT.                                                                                      
 
6.   I have been informed that:  
 There are risks and benefits associated with genetic analysis and storage of biological material and 
these have been explained to me.  
 The analysis procedure is specific to the genetic condition related to the visual impairment 
mentioned above and cannot determine the complete genetic makeup of an individual.  
 The genetics laboratory is under an obligation to respect medical confidentiality. 
 Although samples are stored in the Division of Human Genetics, collaborations with international 
facilities may require the samples and clinical information to be shared. In these cases, all samples 
will be de-identified and given a unique code, and full patient confidentiality will be maintained.  
 Genetic analysis may not be informative for some families or family members. 
 Even under the best conditions, current technology of this type is not perfect and could lead to 
incorrect results. 
       Where biological material is used for research purposes, there may be no direct benefit to me. 
 
7.  I understand that I may withdraw my consent for any aspect of the above at any time without this 
affecting my future medical care. 
 
ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME AND ALL THE QUESTIONS I HAD WERE 
ANSWERED BY: _____________________________________IN A LANGUAGE THAT I UNDERSTAND.          
 
DATE   _______  /_____  /____                           PLACE:  ______________________________________      
            






CONFIRMATION OF DIAGNOSIS 
To be completed by the eye specialist – PLEASE PRINT CLEARLY 
Name of Patient:  
 




Gender: M F Ethnic Group Asian Black Coloured Indian White 
 
In my opinion the patient has one of the following conditions: 
RETINITIS PIGMENTOSA Diffuse Form  
Sectoral (regional) form  
USHER SYNDROME 
(RP & congenital hearing loss) 
Type I – profound deafness  
Type II – severe deafness  
MACULAR DEGENERATION Age-related MD - Wet  
 - Dry  
Best Disease  
Cone & Rod Dystrophy  
Sorsby Fundus Dystrophy  
Pattern Dystrophy  
Stargardt Disease  
Fundus Flavimaculatus  
 
Other retinal disorder (specify):  
 
 
MODE OF INHERITANCE 
Dominant  Recessive  
X-
Linked 





Age of onset:  years 
 
Progression of disease:  
 
Other clinical features:  
 
Tests performed: ERG  
Visual 
Acuity 










Other family members affected:  
 
Name of Doctor:  Signature:  
 
Date: Y Y Y Y – M M – D D Tel. (      ) Fax (      ) 
 
PLEASE RETURN THE COMPLETED FORM TO: 
Prof Jacquie Greenberg (jacquie.greenberg@uct.ac.za / fax: 021 650-2010) 
Division of Human Genetics 
Level 3, Wernher and Beit North 
Institute of Infectious Disease and 
Molecular Medicine 
Faculty of Health Sciences 
University of Cape Town 
Observatory, 7925 
South Africa 
Tel: +27 21 406 6297 





Appendix 3. Screenshots of the UCT Human Genetics 






















Appendix 4. Flow diagram summarising WES analysis  
 
 
The summaries of variants (black) were obtained by using the ‘grep’ or ‘file grep’ 
commands, using keywords or gene lists respectively, to extract particular variants 
from the DATA.csv file  
Variant filtering (blue) was done by sequentially using the ‘inverse grep’ command 
to exclude types of variants. Thereafter, the “file grep” command was used to 
extract RetNet IRD and ERDC genes (red and orange) for analysis. The ‘inverse file 
grep’ command was used to exclude the RetNet IRD and ERDC variants, thereby 







Appendix 5. Pedigrees of four unresolved families 
 
 
Squares represent males, and circles, females. Shaded symbols indicate individuals 
affected with IRD. A question mark highlights subjects for whom the clinical status is 
unknown. Individuals selected for WES are noted with an asterisk.  
 
 


















Family RPD 94 
 
